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ABSTRACT 
CARNOSINE METABOLISM AND FUNCTION IN THE THOROUGHBRED HORSE 
Murk Dunnett 
Thoroughbred horseracing involves high-intensity exercise characterized by the production and 
accumulation of hydrogen (H+) ions within the skeletal muscles. Without a system for 
maintaining acid-base balance the consequential accumulation of H+ ions within the working 
muscles would produce a rapid decline in intra-cellular pH with a concomitant impairment of the 
contractile process. Carnosine (ß-alanyl-L-histidine, pKa 6.83) occurs at high concentration in 
equine muscle where it functions as an effective H+ ion buffer at physiological pH. 
High-performance liquid chromatography analytical methods were developed for carnosine and 
used to investigate its distribution and metabolism in equine fluids and tissues, with emphasis on 
type 1, IIA and IIB muscle fibres. Foals and yearlings had significantly lower plasma carnosine 
concentrations than older horses. Plasma carnosine concentration showed little change during 
normal feeding and high-intensity exercise, however, episodes of equine exertional 
rhabdomyolysis produced large increases. Carnosine concentrations in tissues, such as the heart, 
liver and intestine were 10 to 100-fold lower than in skeletal muscle. Carnosine displayed a 
heterogeneous distribution within skeletal muscle. Its concentration in type IIA and 1113 fibres 
was approximately 5-fold higher than in type I fibres. 
Extensive, partly anaerobic training produced a 2-fold increase in the carnosine concentration in 
type IIA fibres, and an increase, although non-significant, in type I and IIB fibres. Thirty days of 
dietary ß-alanine and histidine supplementation produced an adaptive increase in ß-alanine and 
histidine bioavailability, and significant increases in the carnosine concentration in type IIA and 
IIB fibres. 
A greater skeletal muscle carnosine concentration via training and/or ß-alanine and histidine 
supplementation would produce a corresponding increase in H+ ion buffering capacity, which 
may reduce the rate of metabolic acidosis during high-intensity exercise, and possibly delay the 
subsequent onset of localized muscle fatigue. 
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CHAPTER 1 
GENERAL INTRODUCTION AND A REVIEW OF THE LITERATURE ON CARNOSINE 
1.1 GENERAL INTRODUCTION 
1.1.1 The historical and contemporary role of the horse in society 
Of the many animal species domesticated during the evolution of human civilization the horse 
has probably made the greatest contribution to Man's social development. The versatility of this 
species in terms of strength, speed, endurance and amenability to training has resulted in its use 
in many areas of human endeavour such as. hunting, transport, agriculture, warfare and sport. 
The decline in the use of the horse as a working animal has been accompanied by a 
corresponding increase in equine sporting activities both commercially and for leisure purposes. 
Equine sporting activities are probably as old as the overall relationship between man and horse, 
and most likely originated from the practise of skills necessary for the survival of the individual 
and the community. The number of equine sports throughout the World is considerable and 
reflects the diversity of cultures in which the horse is found. Some equine sports include; flat- 
racing, steeplechasing (including hurdling and point-to-point racing), harness racing (including 
trotting and pacing), endurance racing, three-day eventing, show jumping, dressage, carriage 
driving, fox and stag hunting, polo and vaulting. World-wide sporting activities are dominated 
both in terms of numbers of animals involved and numbers of events staged by track-based 
racing which mostly comprises flat-racing, steeplechasing and harness racing. 
1.1.2 An outline of thoroughbred racing and breeding 
The breeding and racing of thoroughbred horses is a vast commercial enterprise both nationally 
and internationally. Recent figures estimate that there are some 50,000 thoroughbred horses in 
the USA, and 3,500 in France. In Britain alone horse racing and breeding is a multi-billion 
pound industry. In the tax year 1993/94 the leviable betting turnover alone was estimated at 
£4,441 million (HBLB 1993/94). During the 1994 British racing season, including both flat and 
jump racing, there were 11,202 Thoroughbreds in training owned by 8,778 (monthly average) 
active owners from a registered total of 18,888. In addition there were 559 licensed trainers and a 
further 286 permit-holding trainers, 743 professional jockeys and 748 amateurs, and 5,908 other 
racing stable employees (Jockey-Club 1994). The majority of these horses contributed to a total 
2 
of 7,089 races in 1,102 fixtures at 60 racecourses resulting in 71,217 runners competing for total 
prize money of £54.8 million (BHB 1994). In 1994 there were 11,594 foals bred for the 
purposes of racing, from 22,072 registered mares and 1,061 active stallions in Britain and Ireland 
(Jockey-Club 1994). Other major centres for Thoroughbred breeding and racing include Ireland, 
Australia, Japan, South Africa, Dubai and Hong Kong. 
Thoroughbred flat-race horses are required to exercise over distances ranging from 5- 20 
furlongs (1000 - 4000 m) for approximately I-5 min. Average speeds for a5 furlong race can 
often reach 18 m s-1 and maximum speeds attained during racing over this distance can approach 
22 m s-1. Thoroughbred steeplechasers race over longer distances of 16 - 36 furlongs (3200 - 
7200 m). Although average speeds are lower the horses are required to negotiate between 6-9 
hurdles or fences per mile. Both forms of racing provide a severe test of horses strength, speed 
and stamina. 
1.1.3 Metabolic acidosis and intra-cellular hydrogen ion buffering during exercise 
Production and accumulation of large quantities of lactic acid, and lesser amounts of pyruvic, 
malic and other acids, occurs in the working skeletal muscles during periods of high-intensity 
exercise as a consequence anaerobic glycolysis. At physiological pH carboxylic acids dissociate 
into carboxylate anions (i. e. lactate) and hydrogen (H+) ions. It has been reported that during 
fatiguing exercise that lactic acid production is responsible for 94% of the total H+ ion load in 
human skeletal muscle (Hultman and Sahlin 1980). Lactate concentrations in the equine middle 
gluteal muscle in excess of 200 mmol kg-1 dry weight (DW) following both racing (Valberg 
1987) and repeated bouts of maximal treadmill exercise (Snow et al. 1985) have been observed. 
However, following both single and repeated bouts of maximal exercise, lactate concentrations in 
the middle gluteal muscle of the horse of 150 mmol kg-1 DW are more common (Harris et al. 
1989; Harris et al. 1987). Such a muscle lactate concentration is representative of a H+ ion 
production of 150 000 jmmol kg-' DW which would theoretically cause a fall in the intra-cellular 
pH to a value of 1.0 - 2.0. In practice however, a reduction in intra-cellular pH from a resting 
value of 7.1 to a post-exercise value of 6.5 represents an increase in H+ ion concentration of only 
3 
0.71 limol kg-' DW (Marlin and Harris 1991). Although a proportion of the H+ ions produced 
will be exported from the skeletal muscle to the blood there remains a strong correlation (r = 
0.97) between muscle pH and the lactate and pyruvate concentration (Harris et u!. 1989). and 
hence the majority of the H+ ions produced can be accounted for through buffering within the 
muscle. 
Mammalian skeletal muscle is reliant upon several different buffering mechanisms which operate 
in concert to regulate intra-cellular pH homeostasis. Overall or total intra-cellular H+ ion 
buffering ( ßml0j ) in skeletal muscle can be considered to have three major components: 
physico-chemical buffering, metabolic buffering and dynamic buffering. The physico-chemical 
component can be further divided into two components. First, intrinsic buffers which include; 
the weak acid-base moieties associated with proteins, the histidine and 3-methylhistidine 
residues of actin and myosin, the imidazole dipeptides carnosine, anserine and balenine, and free 
histidine. Second, extrinsic buffers, such as bicarbonate. The metabolic buffering component 
comprises the dephosphorylation of ATP to IMP, NH4+ and inorganic phosphate, 
dephosphorylation of phosphocreatine, and NH4+ ion production during amino acid catabolism. 
The dynamic buffering component regulates the intra-cellular H+ ion concentration via 
transmembrane H+ ion flux, for example from the cytosol to the blood plasma. 
The imidazole dipeptides can account for a significant proportion of the intra-cellular physico- 
chemical buffering (Abe et at. 1985), although the exact proportion is highly variable between 
species (Okuma and Abe 1992). 
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1.2 REVIEW OF THE LITERATURE ON CARNOSINE 
1.2.1 Discovery and chemical structures of carnosine and related compounds 
The imidazole dipeptide carnosine (ß-alanyl-L-histidine) is a polar, water soluble, small 
molecular weight compound (MW 226.2) which exists in the zwitterionic form at pH 7.0 (Figure 
1.1). The molecule possesses three ionizable groups, a terminal amino group (pKa 9.66), a 
carboxylate group (pK, 2.77) and an imidazole ring (p& 6.83) (Tanokura et at. 1976). 
Carnosine also possesses a chiral carbon atom and hence can exist as both the L- or the D- 
isomer. The L-isomer is the naturally occurring form of the compound. 
Carnosine (ß-alanyl-L-histidine) was first isolated from Liebig's meat extract (Gulewitsch and 
Amiradzhibi 1900a; Gulewitsch and Amiradzhibi 1900b). Five years later, a German biochemist 
isolated a nitrogenous organic compound from the same source which was named ignotine 
(Kutscher 1905). Subsequent comparative analysis established that carnosine and ignotine were 
identical (Gulewitsch 1906/7). Gulewitsch established the dipeptide nature of carnosine by 
demonstrating that it was hydrolysed to histidine (Gulewitsch 1906/7) and ß-alanine (Gulewitsch 
1911). The structure of carnosine was confirmed following its chemical synthesis (Barger and 
Tutin 1918; Baumen and Ingvaldsen 1918). Naturally occurring methylated analogues of 
carnosine were soon discovered. Anserine (ß-alanyl-L-l-methylhistidine) was first isolated from 
skeletal muscle of the chicken and goose (Ackermann et al. 1929; Tolkachevskaya 1929) and its 
structure was confirmed following its chemical synthesis (Behrens and du-Vigneaud 1937). 
Balenine, also known as ophidine (ß-alanyl-L-3-methylhistidine), was discovered in skeletal 
muscle of the Cobra (Imamura 1934), however, for many years it was thought to be ß-alanyl-L- 
2-methylhistidine. The correct chemical structure for this dipeptide was later established using 
nuclear magnetic resonance spectroscopy (Wolff et at. 1968). Homocarnosine (y-aminobutyryl- 
L-histidine), a dipeptide analogue of carnosine in which the ß-alanine residue is replaced by y- 
aminobutyric acid , was discovered in bovine brain (Pisano et al. 1961). N-a-acetyl-L-carnosine, 
a carnosine derivative in which one of the hydrogen atoms of the terminal amine group replaced 
by an acetyl group, was discovered in the central nervous system (CNS) and skeletal muscle of 
5 
Figure 1.1 Empirical formula and chemical structure of carnosine. (* Denotes the chiral 
centre). 

Table 1.1 Discovery of carnosine and related compounds. Adapted from Boldyrev and 
Severin (1990) 
u c 
ý. aý 
aý 
r1 
0 
i/D 
E 
z 
z 
0 r- E 
0 U 
CD 0 
Ný 
O" N LC 
V) k0 
M C> J 
.ý. i ZZ IN 
Ü vý 
CCv 1ý) 
ß 
2 
`ý yy 'C7 "L7 
.UC 
. '. 
C 
m cCC _G 
UOO 
ÖUNDQ tiC 113 0 C7 F" Q C. OQ Z UD ri 
ý_ ZZ 
eccUU '° 
2 
aý eý ra 
äcU 
id u u2 0 
V C7 ÜmZZ Ü 
v 
C 
i_ J- 
C_ C 
. 22 
tiro vy .CA .ý 
CC CCS Cý 
C Cý CCS C 
zS LS ý3 35 ýa ca is 
c2 m c2 >- zzz c2 
0 
GyÜC 
o00ä UCEE 
CU cLG 
Cm0CC 
C_ UU .CC 
Ü 
Ü<m0Z<<<Ü 
Figure 1.2 Empirical formulae, chemical structures and molecular weights of histidine and 
other imidazole dipeptides. 
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the frog (Sobue et a!. 1975). These and other carnosine related imidazole dipeptides which have 
since been discovered are listed in Table 1.1. The empirical formulae, chemical structures and 
MW of histidine and some imidazole dipeptides are shown in Figure 1.2. 
1.2.2 Occurrence and distribution of carnosine and related compounds in nature 
Carnosine distribution in non-vertebrate species 
Carnosine and related compounds have a wide though heterogeneous phylogenetic distribution. 
To date the occurrence of the imidazole dipeptides has been investigated in more than 80 species. 
The literature appears to contain no reports of the presence of carnosine in the tissues of either 
plants or micro-organisms, although histidine is present in both plant and animal proteins. ß- 
alanine is reported to be present at low concentrations in some plants, such as green coffee beans 
(2.7 - 5.7 mg k(Y-t DW or 0.03 - 0.06 mmol kg-' DW) (Arnold et u!. 1994) and the cycad Stangeria 
eriopus (not quantified) (Osborne et al. 1994). Green coffee beans also contain free 1- 
methylhistidine (< 50 mg kg-' DW or 0.3 mmol kb 1 DW), 3-methylhistidine (25.0 - 43.2 mg kg-' 
DW or 0.16 - 0.28 mmol kg-' DW) and y-aminobutyric acid (not quantified) (Arnold et al. 1994). 
Carnosine is found in some arthropods such as, the lavae of the blowfly (not quantified) 
(Bodnaryk and Levenbrook 1968). Carnosine (and anserine) have been detected in some species 
of molluscs and crustaceans (Luckton and Olcott 1958), although they are reported to be absent 
in several others (Suyama et at. 1970). Some species of molluscs and crustaceans and many 
fish, however, appear to possess much greater amounts of the amino acid precursors of 
dipeptides, histidine and ß-alanine, rather than the dipeptides themselves (Luckton and Olcott 
1958). More recently a previously unknown imidazole dipeptide, carcinine (ß-alanylhistamine), 
was detected in the CNS and muscle of the crustacean Carcinus maenas (Arnould and Frentz 
1975a; Arnould and Frentz 1975b) and later in other crustacea (Arnould 1986). The typical 
concentrations of the imidazole dipeptides in the tissues of these species are shown in Table 1.2. 
9 
Table 1.2 Mean concentrations of carnosine and related compounds in the muscle tissue of 
invertebrates. 
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Curnosine distribution in tissues 
Skeletal muscles of vertebrates contain very high concentrations of carnosine and other 
imidazole dipeptides. often in excess of 50 mmol kg DW. Early investigations by (Wood 1957) 
and (Davey 1960a), using colourimetric and ion-exchange assays, tentatively suggested the 
presence of carnosine in rat stomach but did not detect the peptide in other tissues, including 
heart, kidney and liver, nor in the heart of horses. Subsequent improvements in analytical 
techniques have shown that low millimolar concentrations of carnosine and the other imidazole 
dipeptides occur principally in heart and tissues of the CNS and gastro-intestinal tract (GIT) of 
several species including the rat, rabbit, guinea pig, frog, mouse, pigeon, chick and man. 
However, the distribution between different tissues of a given species and between species is 
highly variable. 
Sobue et al. (1975) reported carnosine concentrations in rabbit heart, liver and kidney of 618, 
441 and 39 nmol g-1 WW (2.47,1.76 and 0.16 mmol kg-' DW), respectively. Similar values in 
cardiac muscle were reported by O'Dowd et a!. (1988) in rat, guinea pig and frog. The retina of 
pigeons and chickens contain 0.08 - 0.26 ppmol g-1 WW (0.32 - 1.04 mmol kg-1 DW) of carnosine 
and anserine concentrations of 1.4 - 5.2 µmol g-' WW (5.6 - 20.9 mmol kg-1 DW) (Margolis and 
Grillo 1984). In contrast, camosine was almost invariably absent from mammalian (including 
human) retina, however, homocarnosine was present at concentrations of 0.05 - 0.10 µmol g1 
WW (0.2 - 0.4 mmol kg-1 DW). Retinal carnosine concentrations were highest in the frog (6.4 
mmol kg-' DW). Both carnosine and anserine were found at low concentrations in other regions 
of the avian CNS including chicken cerebellum, cerebral hemispheres and optic lobes (Margolis 
and Grillo 1984). Within the CNS of vertebrates studied, including the hamster, pig, dog, rabbit 
and rat, the highest concentrations of carnosine are localized within the olfactory bulb and 
epithelium (Ferriero and Margolis 1975; Neidle and Kandera 1974). The carnosine 
concentration in mouse olfactory bulb was 0.9 - 2.2 nmol mg-1 WW (3.6 - 8.8 mmol kg-' DW) 
(Ferriero and Margolis 1975; Neidle and Kandera 1974; Wideman et al. 1978), and in the Geko a 
concentration of up to 3.9 ; imol g-1 WW (15.6 mmol kg-1 DW) was reported (Margolis 1981). In 
other regions of the mammalian CNS, such as the cerebellum, cerebrum and brain stem, 
homocarnosine, with tissue concentrations up to 52.4limol 100 g-' WW (2.1 mmol kg' DW), is 
the major imidazole dipeptide present (Abraham et al. 1962). In human brain homocarnosine 
concentration was 2 to 4-fold higher in white matter than in grey matter (Abraham et a!. 1962). 
Flancbaum et at. (1990) reported the most comprehensive study of carnosine concentrations in 
tissues other than skeletal muscle when investigating a possible relationship between carnosine 
and histamine concentrations in the rat, mouse, guinea pig and man (see section 1.2.4 Histamine 
synthesis in response to shock and wound healing). These mean values of carnosine 
concentrations and those determined by other investigators are given in Table 1.3. 
The total concentration of the acetylated forms of the imidazole dipeptides, N-a-acetylcarnosine, 
N-a-acetylanserine and N-a-acetylhomocarnosine, in cardiac muscle and tissues of the CNS 
(other than olfactory bulb) exceeds the concentrations of the non-acetylated forms. The 
estimated total concentration of the acetylated imidazole dipeptides in cardiac muscle is greater 
than 10 mmol kg-' ww (40 mmol kg-' DW) (O'Dowd et al. 1988). 
12 
Table 1.3 Mean carnosine concentrations in tissues of the rat, mouse, guinea pig and man. 
Adapted from Flancbaum et al. (1990). 
13 
Tissue Mean ± SD carnosine concentration (mmol kg-' DW) 
Rat Mouse Guinea pig Man 
Heart 0.44 ± 0.06 0.19±0.06 0.31 ± 0.07 0.19 ± 0.02 
Kidney 0.29 ± 0.05 0.43 ± 0.09 0.16 ± 0.07 1.08 
Stomach 0.19 ± 0.03 0.24±0.14 0.08 ± 0.02 0.22±0.10 
Liver 0.19±0.03 0.16±0.08 0.15 ± 0.04 - 
Spleen 0.14 ± 0.03 0.25 ± 0.07 0.14 ± 0.04 - 
Lung 0.21 ± 0.10 0.39 ± 0.13 0.06 ± 0.03 - 
Ileum 0.11 ± 0.03 0.27 ± 0.06 0.15 ± 0.06 - 
Hypothalamus 0.07 ± 0.01 0.46 ± 0.07 0.05 ± 0.02 - 
Pituitary 0.25 ± 0.06 - 0.03 ± 0.02 - 
Olfactory bulb. 0.20 ± 0.09 0.55 ± 0.09 0.09 ± 0.04 - 
Jejunum - - - 0.31 ± 0.10 
= Only one sample. 
Table adapted from Flancbaum et al. (1990) 
Carno. sine in vertebrate skeletal muscle 
The concentrations of imidazole dipeptides found in vertebrate skeletal muscle are highly 
variable between species (Carnegie et al. 1983; Crush 1970; Plowman and Close 1988). Skeletal 
muscle of the Little Piked Whale contains the highest reported concentration of imidazole 
dipeptides with a total concentration of 2153 mg % or approximately 380 mmol kg' DW of 
which balenine contributed 350 mmol kg-t DW (Suyama et al. 1970). Either carnosine, anserine 
or balenine, or a combination of these, occur at high concentrations in the skeletal muscle of 
almost all of the vertebrate species studied. The particular dipeptide, or combination of 
dipeptides present and their intra-muscular concentrations are extremely variable. From the very 
large number of species studied to date it is apparent that great similarities exist between the 
dipeptide ratios in individual species within the same zoological class. In general anserine 
predominates over carnosine in birds, balenine predominates over carnosine in reptiles and 
aquatic mammals whereas greater amounts of carnosine than anserine occur in many land based 
mammals. Balenine is absent from almost all land mammals (Crush 1970). The carnosine : 
anserine : balenine ratios in the skeletal muscles of different species have been studied in an 
attempt to establish a simple diagnostic test for the identification of the composition of consumer 
meat products (Carnegie et al. 1983; Plowman and Close 1988). Some examples of the 
concentrations of carnosine and related compounds in the skeletal muscles of different species 
are given in Table 1.4. 
The incidence of a single dipeptide occurring in isolation in the skeletal muscle of a given 
species is comparatively rare. Carnosine alone appears to be present in only humans (Christman 
1976) and equine skeletal muscle (Bump et al. 1989; Davey 1960a; Harris et al. 1990; Marlin et 
at. 1989). Christman (1976) reported carnosine concentrations in human psoas muscle in the 
ranee 1.0 - 7.7 ymlol ä-1 WW (4.0 - 30.8 mmol kg't DW). Anserine was not detected. These 
results have been confirmed by several subsequent investigations (Harris et at. 1990; Mannion et 
al. 1992; Parkhouse et at. 1985). The carnosine and anserine concentrations in human skeletal 
muscle in contrast to values from two other competitive athletic species, the greyhound and 
camel, are given in Table 1.5. 
14 
Table 1.4 Mean concentrations of carnosine and related compounds in the skeletal muscle of 
vertebrates. 
15 
e) 
u_ 
äý 
L 
U 
3 
0 
oD 
.: L 
O 
C 
O 
L 
Qý 
U 
= O 
U 
+1 
C 
cC 
U 
2 
aý 
U 
:2 
CL V) 
Cl) 
Cl) 
U 
aý c 
aý 
ca m 
c y 
Q% 
i.. 
aý c 
0 E 
U 
o 
.0 
00 C\ 
00 Cý 
/. ... ... i. 
00 00 00 
ýc - -: ý 
ö. ý -Z? c ö c 
ct: 
Cn> i' O Cv 
öA op EEE Op EE 
, 3 °-ý .C cvý C& ýýý333ý3ccm 
O ti 
O0 
;nL 
=& LLL 
= Cl. O O= OCC 
U3rý r--U U C uuE: E: : Ua 
In In 
4_ +1 F1 
OD (`! O O ', -D DDDýDDOMýn00 ZZ 0\ N --Z ZZZZZZM--000OO 
ýD -: N OOOýMO 
M ýD Ö vý O cri O 
+I 
_1_ 
+1 +1 +1 . +1 +1 +I +1 
OOMMM Nlý 1: \OOIO-q -7 
McVÖ0 
OOO ýr- 
NMt1ý0 0ý 
N 
z 
00 MO0 N[ß\000 
cc 00 -- rr l-t-(3ý06 
^ -+ N . -. 
+1 
. 
+1 
_- . ý. 
+1 +1 +I +I +I +I +I r 00 r- 00 r- 'It 'T N0 It It 
N- M Q ^ý fgWCO \Ökn W MC) 
' 
1 I 
d 
LL mo. 
O00 
"L 
0 
ý 
i 
R iýr Qr G. 1I 1I 
UZzzZZZZzZ 
. 14-0 Cü 
0 
0 
ZL 
V ÖC "9 O'D 14 C 
0 
G ue y A' 1; 
QC 
Ä 
Ud: 0C4 E-U- CD :G E-v) 
s . .0 oil 
N: G3TrýaG1Lý 
U, 
R Cl. y, E 
'ý Cc o 2 
ti 
c 
E 
L 
r. + 
O 
Z 
ai 
E 
rA 
a) ÖA 
-d 
Ü 
CL 
O 
z 
II 
z 
V 
v 
V 
0 
z 
Ca 
z 
Table 1.5 Mean muscle carnosine and anserine concentrations in the skeletal muscles of 
man, greyhound and camel. 
16 
Species Muscle Concentration (mmol kg-' DW) Reference 
Carnosine Anserine 
Man Vastus lateralis 16.0 ± 7.2 ND Harris et al. (1990) 
Quadriceps femoris 20.0 ± 4.7 ND Mannion et al. (1992) 
Quadriceps femoris 21.8 ± 4.1 ND Mannion et al. (1995) 
Greyhound Various muscles # 33.0 ± 19.1 48.6 ± 18.4 Harris er at. (1990) 
Camel Gluteus medius 28.7 ± 14.9 36.9 ± 12.4 Dunnett and Harris (1995c) 
ND = Not detected. 
$= semitendonosis, biceps femoris, triceps, deltoid and longissimus dorsii. 
The horse has been shown to possess one of the highest skeletal muscle imidazole dipeptide 
concentrations recorded amongst land based species. Early measurements of the carnosine 
concentration in equine skeletal muscle by Zapp and Wilson (1938) reported carnosine 
concentrations of 463.436 and 161 mg/100 g WW (approximately 81.9.77.1 and 28.5 mmol kg-' 
DW) in the gluteus medius, gastrocnemius and coleus muscles, respectively. Anserine 
concentrations of 17 - 48 mö/100g WW (2.8 - 8.0 mmol kam' DW) were also reported, however 
this later finding has not been supported by subsequent work. A carnosine concentration of 25.5 
jimol g-t WW (102.0 mmol kg-' DW) was detected in equine longissimus dorsi muscle (Davey 
1960a). Slightly higher concentrations of between 108 and 134 mmol kg-' DW have been 
reported more recently by several investigators (Bump et al. 1990; Harris et al. 1990; Marlin et 
a!. 1989; Miller-Graber et al. 1990; Sewell et al. 1992). Furthermore, some differences in the 
skeletal muscle carnosine concentrations between various breeds of horses has been indicated. 
American Quarterhorses were shown to have higher concentrations than thoroughbred horses, 
which in turn had higher concentrations than standardbred horses (Bump et al. 1989; Bump et al. 
1990). Carnosine concentrations in the middle gluteal muscle of Quarterhorses, Thoroughbreds 
and Standardbreds are given in Table 1.6. 
Sub-cellular distribution of carnosine in skeletal muscle 
It probable that carnosine exists predominantly in the free state in equine skeletal muscle with 
less than 10% present in a bound form (Bock 1958). A subsequent investigation which 
compared the dialysis rates of carnosine from aqueous standard solutions and fresh homogenates 
of frog skeletal muscle concurred with the earlier findings in equine muscle (Bock and Langley 
1960). Evidence from the analysis of fractionated homogenates of rat gastrocnemius muscle 
indicates that 99.5% of the total imidazole dipeptide content is contained within the 15000g 
supernatant phase with only 0.3% present in the washed mitochondria and no detectable amounts 
of imidazole dipeptides in the residue. This suggests that the imidazole dipeptides are cytosolic 
in origin. Following intra-peritoneal administration of histidine-C'4 or ß-alanine-C 1-t to chicks 
and subsequent isolation of radio-labelled imidazole dipeptides, it was found that 99% of the 
radioactivity was present in the supernatant, I% of the radioactivity was in the myofibrils and 
17 
Table 1.6 Mean muscle carnosine concentrations in different breeds of horses. 
18 
Breed Muscle Carnosine 
mmol kg-' DW 
Reference 
Thoroughbred Gluteus medius 108.6 ± 15.2 Marlin et al. (1989) 
Gluteus medius 108.3 ± 15.9 Harris et al. (1990) 
Gluteus medius 125.3 ± 11.6 Bump et al. (1990) 
Gluteus medius 133.6 ± 20.7 Miller-Graber et al. (1990) 
Gluteus medius 125.0 ± 26.0 Sewell et al. (1992) 
Gluteus medius 107.8 ± 12.9 Dunnett and Harris (1995b) 
Standardbred Gluteus medius 110.6 ± 2.4 Bump et al. (1990) 
Quarterhorse Gluteus medius 156.8 ± 7.1 Bump et al. (1990) 
Glutius medius 159.1 ± 11.8 Bump et al. (1989) 
less than 0.1% was present in mitochondria and microsomes Minnick *et al. 1963). Similarly, 
Harding and O'Fallon (1979) have reported that approximately 70% of the carnosine found in 
mouse olfactory bulb and epithelium was localized within the cytosol. 
Effect of training and exercise on muscle carnosine content 
Seven weeks of sub-maximal training resulted in a small but non-significant decrease in the 
carnosine concentration in equine middle gluteal muscle (Bump et al. 1989). Mean muscle 
carnosine concentrations, as described earlier, are higher in human subjects trained for high- 
intensity exercise such as sprinting and rowing in contrast to untrained individuals or those 
trained for sustained exercise of lower intensity, such as marathon running (Parkhouse et al. 
1985). However, the higher muscle carnosine values evident in sprinters and rowers may well 
arise from a genetic predisposition rather than a training effect. 
Bump et al. (1989) reported a significant reduction (p < 0.05) in the carnosine concentration in 
equine middle gluteal muscle from a pre-exercise value of approximately 140 mmol kg-1 DW to a 
value of 112 mmol k; -' DW immediately following a sub-maximal exercise bout which resulted 
in a mean peak blood lactate concentration of 9.7 mM. However, this finding was refuted in a 
later study by Harris et a!. (1992) in which the carnosine concentration in the middle gluteal 
muscle of the thoroughbred horse was unchanged from the pre-exercise value immediately 
following 4x 700 m bouts of near maximal exercise which resulted in a mean peak blood lactate 
concentration of 26.8 mM. The changes previously reported by Bump et at. (1989) probably 
arose as a result of the use of wet tissue and could be attributed to an exercise induced increase in 
the blood content of muscle samples (Harris et al. 1992). No significant change in the muscle 
carnosine concentration of the gluteus medius of thoroughbred horses was found during fatiguing 
exercise (Miller-Graber et a!. 1990). 
1.2.3 Skeletal muscle carnosine and hydrogen ion buffering 
Carnosine is an organic base. The imino nitrogen atom of the imidazole ring of carnosine and 
anserine have p& values of 6.83 and 7.04, respectively, and are capable of accepting (binding) 
19 
Ht ions (Tanokura et u!. 1976). Compounds with a capacity for buffering H+ ions function most 
effectively when the pH of the environment is within one pH unit of the pK, value. Carnosine 
will buffer most effectively between pH 5.83 and 7.83 and is therefore able to function as an 
efficient H+ ion buffer over the physiological pH range. The H+ ion buffering role of carnosine 
(and anserine) in skeletal muscle was first proposed as a significant component of the total intra- 
cellular physico-chemical muscle buffering capacity (ß, n) by Bate-Smith (1938). This 
hypothesis was supported by the discovery that the pK1 values for carnosine and anserine were 
approximately 6.9 and 7.1, respectively (Bate-Smith 1938, Deutsch and Eggleton 1938). It was 
calculated that carnosine accounted for 20 - 25% of the post-rigour buffering in equine muscle 
between pH 5.5 and 7.5. Furthermore, it was estimated that it may have contributed 
approximately 40% of the total in pre-rigour muscle. Davey (1960a) reached a similar 
conclusion that carnosine and anserine accounted for the major proportion (up to 40%) of the 
total buffering of extracts of pre- and post-rigour muscle in several species between pH 7.5 and 
6.5 . The hypothesis that carnosine 
functioned as a H+ buffer in vivo was strengthened by the 
work of Severin et at. (1963) which demonstrated that electrically stimulated frog sartorius 
muscle immersed in Ringer's solution supplemented with carnosine or anserine (4 - 12 mm), in 
contrast to an almost identical muscle immersed in Ringer's solution only, showed a greater 
amplitude of contraction and a longer time to fatigue. In addition the accumulation of lactate 
was reportedly lower in the carnosine or anserine perfused muscle cited in (Severin et at. 1963). 
Whitaker and Louw (1984) reported similar findings when frog gastrocnemius muscle 'in situ' 
was electrically stimulated via the ipsilateral sciatic nerve (proximal blood and nerve supply was 
intact) whilst perfused with either Ringer's solution or Ringer's including 20 mM carnosine or 
histidine. In the presence of histidine or carnosine, the time to exhaustion was significantly 
longer (p < 0.01), and lactate accumulation and K+ ion efflux from the muscle were reduced but 
not significantly. They concluded that fatigue was reduced in the presence of histidine or 
carnosine, with histidine having a superior effect . 
As early as 1938 it was reported that carnosine concentrations in skeletal muscle appeared to be 
higher in so-called 'white muscle' rather than 'red muscle' (Zapp and Wilson 1938). However, 
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(Davey 1960a) cautioned against a general acceptance of this across species after observing that 
although many red muscles which had a high myoglobin content had a low concentration of 
carnosine and anserine, the very red longissimus muscle of dolphins and whales contained very 
high dipeptide concentrations. A closer and inverse correlation appeared to exist between the 
oxidative capacity of the muscle, as indicated by its succinate dehydrogenase activity, and the 
carnosine and anserine content (Davey 1960a). Tamaki et al. (1976) dissected out both red and 
white muscle tissue from gastrocnemius, adductor magnus and latissimus dorsi muscles in rats. 
He found anserine contents in white muscle tissue of 12 - 17 ytmol ä-t WW (48 - 68 mmol kg -I 
DW) in contrast to values of 1-2 jimol g-' wW (4 -8 mmol kg-' DW) in red muscle. Carnosine 
concentrations in white muscles were approximately two-fold higher than in red muscle (Tamaki 
et al. 1976). Similar findings were described by Suzuki et at. (1987b) who reported that the 
anserine content of tuna white muscle was higher than that of dark muscle. Turnisky and Long 
(1990) determined carnosine and anserine concentration in rat soleus and gastrocnemius muscles. 
Carnosine and anserine concentrations in gastrocnemius muscle (58% fast-twitch glycolytic 
fibres, 37% fast-twitch oxidative-glycolytic fibres) were 7.91 and 5.17 mmol 1-I intra-cellular 
water (ICw), respectively, in contrast to values of 3.65 and 2.27 mmol 1-1 ICW, respectively in 
coleus muscle (> 80% slow-twitch oxidative fibres) (Turnisky and Long 1990). 
A low but significant correlation (p<0.05) was evident between muscle carnosine concentration 
and ßm (r = 0.69), and between muscle carnosine concentration and the percentage of fast- 
twitch fibres present (r = 0.46) in human vastus lateralis muscle from untrained subjects and 
sprint, rowing and marathon trained subjects (Parkhouse et at. 1985). However, Mannion et al. 
(1995) reported that there was only a moderate non-significant correlation between carnosine (r = 
0.43, p>0.05) or ßm (r = 0.42, p>0.05) and percentage type II fibre area in the quadriceps 
femoris muscle of non-specifically trained subjects. 
A similar investigation of gluteus medius muscle from Quarterhorses, Thoroughbreds and 
Standardbreds established a low but significant (p<0.05) correlation between carnosine 
concentration and fast-twitch glycolytic fibre percentage (r = 0.53) and a low significant (p< 
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0.05) negative correlation between carnosine and slow-twitch oxidative fibre percentage (r = 
-0.51) (Bump et al. 1989). In a comparison of ßm and total imidazole dipeptide concentration 
(carnosine + anserine) in skeletal muscle of Thoroughbreds, Greyhounds and humans, the higher 
ßm of equine and canine muscle of 117.7 and 105.2 limol H+ kg-' DW respectively, in contrast 
to the human ßm of 79.5 Fimol H+ kg-' DW, was explained by the much greater concentration of 
the imidazole dipeptides in the former. Mean imidazole dipeptide concentrations in equine, 
canine and human muscle were 108.3,81.6 and 16.0 mmol kg-' DW. Subtraction of the specific 
buffering capacity arising from the imidazole dipeptides from ßm resulted in almost identical 
residual values in equine, canine and human muscle of 81.8,79.1 and 74.2 iimol H+ kg-1 DW, 
respectively. Therefore, the differences in ßm between the three species appeared to arise 
predominantly from the differences in imidazole dipeptide contents (Harris et al. 1990). Similar 
results have been reported in several other species including, tuna, whale, pig and chicken, where 
differences in ßm between species and muscles were mainly accounted for by differences in the 
concentrations of histidine and the imidazole dipeptides (Abe et al. 1985; Okuma and Abe 1992). 
Histidine and imidazole dipeptides were found to be major buffering constituents in these species 
accounting for 12 to 39% of ßm (Okuma and Abe 1992). 
Multiple linear regression analysis has been used to estimate the carnosine concentrations and 
ßm of type I, IIA and lIB fibres from mixed muscle samples of the gluteus medius at post 
mortem of the untrained thoroughbred horses and one pony (Table 1.7A). Carnosine showed a 
strong significant (p < 0.001) correlation with ßm in mixed muscle samples (r = 0.76) and a 
significant ( p< 0.001) correlation with percentage type II fibre section area (r = 0.78). ßm was 
also significantly (p<0.01) correlated with percentage type 11 fibre section area (r = 0.60). 
Carnosine concentrations in type I, IIA and IIB fibres were estimated to be 21,86 and 116 mmol 
kä-1 DW, respectively (Sewell et al. 1990). Comparative estimates of carnosine concentrations 
and ßm by multiple linear regression analysis were later made in two-year-old Thoroughbreds 
actively engaged in training and racing (Table 1.7B). Carnosine concentrations were higher in 
these horses and were estimated to be 54,85 and 180 mmol kg-' DW in type 1, IIA and IIB fibres, 
respectively (Sewell et al. 1992). 
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Table 1.7 A Multiple linear regression analysis estimates of the carnosine concentration and 
ßm of type I, IIA and 1113 muscle fibres from untrained thoroughbred horses. 
Adapted from Sewell et al. (1990). 
Table 1.7 B Multiple linear regression analysis estimates of the carnosine concentration and 
ßm of type 1, IIA and IIB muscle fibres from two-year-old thoroughbred horses 
engaged in training and racing. 
Adapted from Sewell et al. (1992). 
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A 
Fibre type I IIA IIB SEM 
Carnosine (mmol kg-1 DW) 21 86 116 16 
Bin (mmol H+ kg-i DW, pH 7.1 - 6.5) 78 98 109 9 
ßmcarnosine 7 29 38 
ßmnon-camosine 71 69 71 
SEM = Standard error of the mean. 
B 
Fibre type I IIA IIB SEM 
Carnosine (mmol kg-' DW) 54 85 180 15 
ßm (mmol H+ kg-I DW, pH 7.1 - 6.5) 88 98 130 9 
ßmcarnosine 18 28 60 
ß'n 
non-carnos i ne 70 70 70 
SEM = Standard error of the mean. 
1.2.4 Other functions of carnosine 
Antioxidant activit\' 
The highest rates of oxidative metabolism in mammalian tissues are found in skeletal muscle and 
brain. Oxygen utilization in skeletal muscle is greatly increased during exercise and hence there 
is an increased potential for tissue damage via the generation of oxygen based free radicals and 
other reactive species (oxidative stress). It has been proposed that at the cellular level carnosine, 
and other imidazole dipeptides, may function as endogenous antioxidants which protect 
macromolecules, including DNA, RNA, proteins and membrane lipids, from oxidative stress 
induced damage caused by reactive oxygen species, such as singlet oxygen, hydroxyl radicals 
('OH), superoxide radicals (O2-'), hydrogen peroxide (H202) and hypochlorite (-OCl) (Boldyrev 
et al. 1988; Dahl et al. 1988; Dupin et at. 1984; Kohen et al. 1988). As a result of in vitro 
studies utilizing physiological concentrations of carnosine, several different mechanisms have 
been suggested by which carnosine may function as an antioxidant including free radical 
scavenging, chelation of divalent metal ions (Brown 1981; Kohen et at. 1988) and elimination of 
pre-formed lipid peroxidation products (Esterbauer et al. 1986). 
Carnosine and anserine were reported to attenuate in vitro Fe2+ / ascorbate induced lipid 
peroxidation in rabbit sarcoplasmic reticulum membranes (Boldyrev et at. 1989; Boldyrev et at. 
1988) and rat serum lipids (Chasovnikova et al. 1990) both by chelation of Fe2+ ions and by 
removal of pre-formed peroxidation products. A suppression of stress induced brain and serum 
lipid peroxidation in rats, following carnosine administration, has also been reported (Gulyaeva 
et at. 1989). Other studies however, have cast doubt on the ability of carnosine to significantly 
inhibit Fe2+ catalysed lipid peroxidation when it was shown that carnosine can interfere with the 
TBA assay used which can cause an overestimation of the degree of inhibition (Aruoma et al. 
1989; Salim-Hanna et al. 1991). Furthermore, the ability of carnosine to effectively chelate Fe2+ 
ions has recently been refuted following nuclear magnetic resonance (NMR) studies which have 
shown that carnosine does not form a complex with iron (Decker et at. 1992). Carnosine is able 
to form chelates with Cu2+ ions and has been shown to be effective in preventing both Cu2+ 
catalyzed hydroxylation (Kohen et at. 1988) and oxidation of deoxyguanosine (Decker et at. 
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1992). Individually, physiological concentrations of carnosine, anserine and homocarnosine 
have been reported to be capable of scavenging 'OH radicals but not 02-', H202 and -OC1 
(Aruoma et at. 1989), although (MacFarlane et al. 1991) have suggested that mixtures of 
carnosine, anserine, homocarnosine and 1-methylhistidine function synergistically to inhibit 
oxidation by O2-' in vitro . Carnosine has also 
been shown to be effective at quenching singlet 
oxygen (Shvachko et at. 1990). Conversely, in the presence of Cue carnosine is reported to 
promote the formation of O2-' but also to catalyse its conversion to H2O2 (Hartman and Hartman 
1992). It appears therefore, that carnosine can behave as an antioxidant towards some specific 
reactive oxygen species, but does not function as a broad-spectrum antioxidant. 
It has been proposed that the putative antioxidant properties of carnosine, anserine and balenine 
may protect skeletal muscle tissue from free radical induced damage during oxidative stress 
(Kohen et at. 1988). This hypothesis may in part be supported by the presence of an estimated 
21 - 54 mmol kg -1 DW of carnosine in equine type I muscle fibres (Sewell et al. 1990; Sewell et 
al. 1992), as they have a high oxidative capacity but negligible glycolytic capacity, minimal H+ 
production and hence very low buffering requirement. 
Regulation of muscle phosphorvlase activity 
Carnosine has been shown to activate rabbit muscle phosphorylase a and h in vitro in the 
presence of AMP (Johnson et al. 1982). Phosphorylase a was also activated in the absence of 
AMP. The maximal degree of activation (approximately 100%) occurred at a carnosine 
concentration of 50 mM with a greater activation evident for phosphorylase h. Anserine 
activated both phosphorylase a and h to a lesser extent than carnosine, eliciting a maximal effect 
(approximately 40%) at 30 - 40 mM. However, anserine inhibits phosphorylase h at 
concentrations above 30 mM. The relationship between dipeptide concentration and relative 
phosphorylase activity displayed a biphasic relationship; increasing dipeptide concentrations 
beyond 50 mM for carnosine and 30 mM for anserine progressively reduced the relative 
activity. The inclusion of allosteric inhibitors including ATP and D-glucose in the assay medium 
attenuated but did not eliminate the activation effect of carnosine on phosphorylase a and h. 
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Some slight anserine induced activation of phosphorylase remained in the presence of allosteric 
inhibitors. Histidine inhibited a and h forms of the enzyme. ß-alanine inhibited the a form and 
marginally activated phosphorylase h. 1-Methylhistidine slightly increased the activity of both 
forms of phosphorylase (Johnson et at. 1982). The activation of rabbit muscle phosphorylase a 
and b by carnosine and anserine was later replicated and contrasted with their effect on potato 
and yeast phosphorylase. Both carnosine and anserine inhibited the activity of potato and yeast 
phosphorylase at equivalent concentrations to those employed in the muscle enzyme assays. The 
dipeptides affected the enzyme Vmar values rather than the &. I values for the substrates. It was 
surmised from kinetic data that both carnosine and anserine compete for the same binding site(s) 
on muscle phosphorylase. Furthermore, the contrast in the effects of the dipeptides between the 
muscle enzyme and those from the potato and yeast sources may be indicative of specific 
imidazole dipeptide binding sites on muscle phosphorylase (Johnson and Aldstadt 1984). 
Myosin ATPase activation 
Carnosine (2 - 10 mM) was reported to elicit a 30 - 60% activation of the in vitro hydrolysis of 
ATP in the presence of glycerinated rabbit skeletal muscle myofibrils at an ATP concentration of 
5 mM (Yun and Parker 1965). In a later study in vitro, both carnosine and anserine were shown 
to promote ATP hydrolysis at physiological concentrations mediated by either myosin or 
glycerinated myofibrils in the presence of K+, Mg2+ and Ca2+ ions. Myosin ATPase activity of 
homogenized myofibrils was increased by 100% in the presence of 20 mM carnosine. Anserine 
produced greater activation than carnosine under the same conditions (Avena and Bowen 1969). 
Parker and Ring (1970) showed that carnosine had no effect on the myosin ATPase activity of 
invertebrate muscle and concluded that camosine induced activation is confined to those muscles 
which naturally contain high concentrations of the imidazole dipeptides. 
Histamine synthesis in response to shock and wound healing 
Histamine induced vasodilation and its central role in the mediation of cardiovascular function 
and circulatory shock has been recognised for many years. More recently feline endotoxic and 
canine hemorrhagic shock have been associated with increases in plasma and tissue histamine 
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concentrations (Nagy et al. 1986: Parratt et al. 1986). Nagy offered no explanation for the 
source of the increased amount of histamine, however. Parratt observed an increase in histidine 
decarboxylase activity and postulated that greater histamine concentrations arose from increased 
histamine biosynthesis in non-mast cell sources. 
Histamine is believed to be involved in the biochemical processes of wound healing, although 
the precise mechanism by which this occurs is unclear (Kahlson and Zenderfeldt 1972). 
Histamine production, stimulated by the administration of the mast-cell degranulation activator 
compound 48/80, enhances the healing response (Fitzpatrick and Fisher 1982b). Intra-peritoneal 
injections of carnosine have also been reported to restore at site wound breaking strength and 
collagen deposition in histidine deficient rats (Fitzpatrick and Fisher 1982a). Additionally, post- 
wounding reduction of tissue carnosine concentration was prevented by the intra-peritoneal 
administration of either histidine or histamine at the time of injury (Fitzpatrick and Fisher 
1982b). On the basis of these results it was proposed that a possible metabolic inter-relationship 
between carnosine, histidine and histamine exists and that this provides a non-mast cell reservoir 
of histamine, via carnosine hydrolysis to histidine and subsequent decarboxylation, available 
which is available during periods of increased demand. This hypothesis was investigated in the 
rat by artificially stimulating mast-cell histamine release by administering compound 48/80. 
This procedure caused a rapid increase in muscle histamine concentration and histidine 
decarboxylase activity, which was followed by a sustained increase in carnosinase activity and a 
reduction in muscle carnosine concentration at 24 h post administration (Greene et al. 1984). 
The involvement of carnosine in the biosynthesis of histamine and the subsequent effects on the 
wound healing processes was supported by the later work of Nagai et al. (1986) who 
demonstrated that in rats treated with hydrocortisone to suppress wound healing, subsequent 
treatment with carnosine lead to improved skin tensile strength at the incision site in contrast to 
controls. Similar effects were produced with the co-administration of histidine and ß-alanine but 
not with ß-alanine alone. Increases in both histidine decarboxylase activity and histamine 
content were found at the wound site following carnosine administration. No significant change 
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in carnosinase activity was found. It was proposed that the improvement in wound healing was 
partially attributable to the vasodilatory action of histamine which improved effusion from the 
wound site during the initial inflammation and also that free ß-alanine arising from carnosine 
degradation was utilized for collagen synthesis (Nagai et u!. 1986). The antioxidative properties 
of carnosine have also been used to explain the apparent efficacy of carnosine in promoting 
wound healing. Silaeva et al. (1990) reported that the topical application of carnosine to 
experimentally induced wounds in rats reduced the accumulation of lipid peroxidation products 
with conjugated diene and ketodiene groups and thiobarbituric acid-active products, in contrast 
to saline treated controls. The time to complete epithelization of the wounds was reduced in the 
carnosine treatment group in contrast to controls (Silaeva et al. 1990). 
Possible correlations between the distributions of carnosine, histidine, histamine and 3- 
methylhistidine in different tissues of the rat, mouse, guinea pig and man have been investigated 
an higher concentrations of carnosine were often though not exclusively found in those tissues 
which had higher levels of histamine (Flancbaum et al. 1990). 
Vasoconstriction 
Carnosine was shown to exhibit stereospecific depressor action following intra-venous 
administration in anaesthetized cats (du-Vigneaud and Behrens 1939; du-Vigneaud and Hunt 
1936). Melville et al. (1990) have reproduced this finding but also showed a pressor response in 
anaesthetized and pithed rats. Furthermore, they reported that carnosine exhibited both a- 
adrenoreceptor agonist and antagonist properties in isolated rabbit saphenous vein (Melville et al. 
1990). More, recently it has been reported from in vitro studies that carnosine chelated with 
Zn2+ ions exhibits sustained vasoconstrictor activity in isolated rabbit saphenous vein and artery. 
Carnosine concentrations of up to 10 mM were necessary to induce contraction in the absence of 
Zn2+ ions, however, in the presence of 1014M Zn2+ contracture was greatly potentiated, and the 
concentration of carnosine needed to elicit half of the maximum effect was reduced from 1.4 mM 
to 15 yM. The presence of zinc alone did not induce contraction. Certain zinc containing 
metalloproteins, such as angiotensin and Cu-Zn superoxide dismutase are significant in vascular 
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function and it was postulated that carnosine may potentiate the effects of these proteins by 
competitively binding zinc ions (O'Dowd et al. 1995). 
Neurotransmitter or neurornodulator 
There has been a steady accumulation of evidence which suggests that carnosine functions as 
either a neurotransmitter or neuromodulator in the olfactory bulb and epithelium of many 
vertebrates. It has been shown that carnosine is present in the primary olfactory pathway of the 
mouse and more specifically to be compartmentalized within the olfactory receptor neurons 
(Margolis 1974). Carnosine occurs at relatively high concentration in mouse olfactory bulb, 0.9 - 
2.2 nmol mg-1 WW (3.6 - 8.8 mmol kg-' DW), although these values are much lower than those 
associated with most mammalian skeletal muscles (Ferriero and Margolis 1975; Neidle and 
Kandera 1974; Wideman et at. 1978). It was also established that camosine is synthesised in situ 
by carnosine synthetase (Harding and Marshall 1976; Horinishi et at. 1978; Ng and Marshall 
1978) and that the carnosine synthetase activities in mouse olfactory bulb and epithelium were 
92 and 495 pmol mb protein h-1, respectively, in comparison with a skeletal muscle carnosine 
synthetase activity of 37 pmol mg-1 protein h-t (Harding and Marshall 1976). Carnosine appears 
to be transported into regions of the olfactory bulb which contain the olfactory nerve axons and 
terminals (Burd et al. 1980). Carnosine is reported to be catabolised to its precursor amino acids 
by carnosinase within the olfactory pathway (Harding and Marshall 1976). Carnosinase activity 
within the epithelium, almost 15000 pmol mg-1 protein h-1, was only exceeded by its activity in 
the kidney (Harding and Marshall 1976). The suggestion that specific carnosine receptors are 
present in the olfactory pathway was supported by evidence showing that membrane fractions of 
olfactory bulbs displayed reversible, saturable and stereospecific camosine binding (Hirsch et al. 
1978; Hirsch and Margolis 1979). In vitro experiments have shown carnosine to be released 
from olfactory bulb synaptosomes by two processes, the first of which was gradual, spontaneous 
and non-reliant upon depolarization. The rate of this release was increased two-fold on the 
addition of 1 mM carnosine. The second mechanism was calcium-dependent and depolarization 
sensitive (Rochel and Margolis 1982). These results were considered to be consistent with the 
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proposed function of carnosine as a neurotransmitter in the olfactory pathway of the mouse 
(Rochel and Margolis 1982). 
The presence of carnosine in other regions of the CNS including the retina of mammals has also 
been described (Margolis 1980; Margolis and Grillo 1984). The existence of anserine in the 
CNS and retina of birds has been reported (Fisher et al. 1977; Margolis and Grillo 1984). The 
cellular distributions of carnosine and anserine in the CNS of vertebrates have been investigated 
by the use of imidazole dipeptide specific antisera for immunocytochemical localization. In the 
rat, carnosine immunoreactivity was restricted to neurons, their axons and synaptic terminations 
in the glomerular layer of the olfactory bulb within the olfactory pathway, and non-olfactory 
carnosine distribution was confined to astrocytes and cerebellar Bergmann glia. In avian CNS 
widespread anserine immunoreactivity appeared to be solely associated with glial cells (Biffo et 
al. 1990). The presence of carnosine within the receptor neurons of human olfactory mucosa 
was also observed using immunohistochemical techniques (Sakai et al. 1990). 
Activation of muscle calpains 
It has been proposed that calpains, a group of calcium activated proteinases present in many 
types of eukaryotic cells, are involved in the degradation of contractile proteins (Dayton et at. 
1976). Calpain I and calpain II exhibit maximum activity at micromolar and millimolar Ca2+ 
concentrations, respectively (Birkhold and Sams 1994; Murachi 1985; Suzuki et at. 1987a). It 
was recognised that calpain activity could be regulated by endogenous antagonists and agonists 
of Ca2+ ion binding such as calpastatin, a protein inhibitor of calpain, (Takano et at. 1986) and 
isovalerylcarnitine, an activator of human neutrophil calpain (Pontremoli et at. 1987). The high 
intra-cellular concentrations of carnosine and anserine in skeletal muscle prompted Johnson and 
Hammer (1989) to investigate a possible regulatory role for these and their constituent amino 
acids on the activity of calpain II isolated from hamster and chicken smooth muscle . During in 
vitro studies they found that 80 mM concentrations of carnosine and anserine increased the 
activity of chicken and hamster muscle calpain II by approximately 20 - 30% at a Ca2+ ion 
concentration of 2.5 mM. 1-Methylhistidine increased the activity of chicken calpain II by about 
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the same amount and doubled the activity of hamster calpain II. The activation effects of these 
compounds were markedly attenuated at a Ca2T ion concentration of 5 Futil. Calpain 11 activities 
were only 10 - 40% of those at 2.5 mA'! Ca=*. It was also found that anserine and 1- 
methylhistidine reduced the inhibitory action of calpastatin on calpain 11, whereas carnosine 
increased inhibition. Johnson and Hammer (1989) concluded that carnosine. anserine and I- 
methylhistidine were not potent calpain II activators but that synergistically they may influence 
the interaction between calpain II and calpastatin. However, this effect is likely to be negligible 
in vivo where both imidazole dipeptide and Ca2+ ion concentrations are much lower than the in 
vitro concentrations used. 
In vitro studies have indicated that calpain II significantly reduces the activity of carnosine 
synthetase by as much as 60% at a calpain to tissue protein w/w ratio of 0.15 and that probably 
arises from extensive proteolysis of carnosine synthetase by calpain. It was proposed that such 
an effect might cause a reduction in muscle camosine concentration in vivo and that this may 
explain reports of reduced muscle carnosine concentrations as a result of ageing, hypertension, 
muscular dystrophy and denervation (Johnson and Hammer 1994). 
1.2.5 Carnosine metabolism 
Biosynthesis and carnosine svnthetase 
Early experimental work involving the use of intact animals and isolated tissue slices provided 
evidence to support the direct biosynthesis of carnosine from histidine and ß-alanine. Studies 
involving cell free extracts of chick skeletal muscle demonstrated the existence of an enzyme of 
broad specificity that catalyses not only the synthesis of carnosine, but also anserine, 
homocarnosine and several other dipeptides (Kalyanker and Meister 1959; Winnick and Winnick 
1959). Similar enzyme regulated synthesis was evident in vivo and in vitro in frog brain 
(Yockey and Marshall 1969). Carnosine synthetase, or homocarnosine-carnosine synthetase, 
was subsequently isolated from rat brain, partially purified and characterized (Skaper et al. 
1973). Carnosine synthetase (EC 6.3.2.11) which is cytosolic in origin (Ng and Marshall 1978) 
appears to be a dimer of MW 250,000, with a very high histidine content of 141 per 1000 
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residues (Rosario et al. 1981). The enzyme has an optimum activity at pH 7.4 and a requirement 
for ATP and Mgt (Skaper et at. 1973). The apparent K\j for histidine was approximately 16 
y1f (Horinishi et al. 1978), whereas that for ß-alanine was 1.0 - 1.8 mA'! (Kish et at. 1978: Ng 
and Marshall 1978). The enzyme is also responsible for the synthesis of homocarnosine in the 
CNS and has a KAI for y-aminobutyric acid of approximately 8.8 mm (Kish et al. 1978). It does 
not catalyse the synthesis of anserine from ß-alanine and 1-methylhistidine, rather anserine is 
formed via methylation of carnosine (Bauer and Schultz 1994). Carnosine synthetase is inhibited 
by several ß-alanine analogues, but most effectively by 3-aminopropanesulphonic acid (Seely 
and Marshall 1982). Carnosine synthetase activities were measured in the 100000 g supernatant 
fractions of heart, brain, liver and muscle of rat, mouse, chick and frog and were found to be 
generally highest in skeletal muscle (chick pectoral muscle; 21.4 nmol g-1 h-1 ) and lowest in 
liver (rat liver 0.1 nmol D-1 h-' ) (Ng and Marshall 1976a). A similar distribution of activities 
between tissues was found in all four species studied. High levels of carnosine synthetase 
activity have also been observed in chick erythrocytes (Ng and Marshall 1976b) and olfactory 
bulbs (Ng and Marshall 1978). 
Intra-muscular carnosine biosynthesis has been demonstrated in vivo by the administration of 
radio-labelled precursor amino acids. Watanabe and Konosu (1979) demonstrated that following 
the intra-muscular injection of t-}C-histidine in the eel, the radio-label was incorporated 
exclusively into carnosine within the muscle. Similar results using 14C-histidine and '4C-ß - 
alanine were obtained in tuna (Abe et at. 1986), trout (Abe and Hochachka 1987) and rats 
(Tamaki et al. 1980). Furthermore, a greater rate of incorporation of the radio-label into trout 
muscle carnosine was observed following the administration of 14C-ß-alanine rather than 14C- 
histidine, suggesting that ß-alanine availability may be a limiting factor in carnosine biosynthesis 
(Abe and Hochachka 1987). This is supported by data from Tamaki et at. (1980) which showed 
a two-fold increase in the incorporation of 14C-histidine into carnosine following pre- 
administration of non-radioactive ß-alanine. 
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Figure 1.3 Metabolic pathways of imidazole dipeptide biosynthesis and degradation. 
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Factors influencing biosynthesis and muscle content 
The results from several studies in various species indicate that substrate availability, including 
dietary availability, may be a limiting factor to the regulation of carnosine biosynthesis and 
accumulation in vertebrate skeletal muscle. Reduced skeletal muscle carnosine concentrations 
were found in several species. including adult rats (Fuller et al. 1947; Quinn and Fisher 1977), 
eels (Abe and Ohmama 1987), salmon (Luckton and Olcott 1958) and adult roosters (Leveille et 
al. 1960), maintained on histidine-free or histidine deficient diets. Dietary histidine deficiency 
causes a more rapid decline in skeletal muscle carnosine concentration in young animals, such as 
chicks (Ousterhout 1960; Ousterhout and Luckton 1960) and rats (Barbaro et al. 1978). 
Conversely, supplementation of the diet with histidine increases in the skeletal muscle camosine 
concentration once the histidine requirements for optimum growth have been fulfilled (Robbins 
et al. 1977). Rats fed a diet supplemented with histidine at a level of 5% w/w showed a two-fold 
greater carnosine concentration in the gastrocnemius muscle in contrast to rats on a control diet 
with a histidine content of 0.76% w/w (Tamaki et al. 1977). Dietary histidine supplementation 
over two weeks in the mature Quarterhorse, at 0.4% w/w in one study and up to 0.56% w/w 
twice per day in a further study, produced small but statistically non-significant increases in the 
carnosine concentration of the middle gluteal muscle (Powell et al. 1991; Miller-Graber and 
Seyers 1993). 
No investigations of the influence of dietary ß-alanine supplementation on muscle carnosine 
content appear to have made. However, twice-daily intra-peritoneal injections of very large 
doses of ß-alanine (22 mmol kg-' BW, 2000 mg kg-1 BW) in adult mice over a5 day period 
produced a ten-fold increase in skeletal muscle carnosine concentration in contrast to controls 
(Margolis et al. 1985). 
Increasing age appears to result in an initial increase in skeletal muscle imidazole dipeptide 
concentration during maturation and a subsequent decrease during senescence. The mean muscle 
imidazole dipeptide concentrations in rat longissimus dorsi increased from 2.49 to 2.99 ytmol g-1 
WW from age 3 to 12 months followed by a reduction to 1.94 µmol g-' WW at 27 months. The 
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overall trend was due to changes in the anserine concentration as carnosine showed a continued 
decline from 3- 27 months. Similar results were evident in the quadriceps femoris (Johnson and 
Hammer 1992). A similar trend appeared to evolve in human muscle with increasing age from 
the analysis of 32 muscle samples from subjects aged between 3 months and 80 years. Muscle 
carnosine concentrations in the younger age croup (3 months to 3 years) were 1.5 - 2.5 pmol --I 
ww in contrast to values in the teenage group of 4.9 - 8.3 ymol a-1 WW. Subjects in the older 
age group had carnosine values (1.0 - 1.5 jrmol g-' \W) lower than the younger group. 
However, the lower carnosine contents in the older age group were in patients undergoing 
extended immobilization following hip fracture (Christman 1976). 
In experimental rats unilateral ischemic denervation of gastrocnemius muscle caused a 
significant decline (p < 0.01) in the carnosine concentration over a period of three weeks and a 
slight but non-significant increase in the anserine concentration (Tamaki et at. 1976). Carnosine 
and anserine concentrations in denervated and intact muscles are given in Table 1.8. Turnisky 
and Long (1990) reported no effect of denervation on the anserine contents of rat soleus and 
plantaris muscle, a non-significant decrease in the carnosine content of these two muscles, but a 
significant increase in the muscle concentrations of carnosine (p<0.05) and anserine (p< 
0.005) in the gastrocnemius muscle. However, these muscles were analysed only three days after 
denervation, in contrast to three weeks after in the study of Tamaki et al. (1976). 
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Table 1.8 Carnosine and anserine concentrations in denervated and intact rat gastrocnemius 
muscle. Adapted from Tamaki et al. (1976). 
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Treatment Weeks post-treatment Mean concentration ± SEM 
(mmol kg-' Dw) 
Carnosine Anserine 
Non treated rats 0 22.3 ± 3.9 10.2 ± 2.7 
3 28.9±0.9 18.2±2.7 
Treated rats 
Intact side 1 29.6 ± 1.6 12.1 ± 0.9 
2 24.7± 1.1 1.0.8±2.0 
3 24.4±3.9 15.8± 1.6 
Denervated side 1 17.0 ± 3.8-, ' 15.7 ± 2.9 
2 5.9 ± 0.8-! 15.3 ± 2.1 
3 3.6±0.71 " 18.5± 1.9 
SEM = Standard error of the mean. 
1- =p<0.05 compared to intact side. 
ft =p<0.01 compared to intact side. 
Intestinal absorption and transport mechanisms 
Experimental evidence has been provided for the existence of peptide specific transport 
mechanisms within the brush border membranes of the small intestine (Craft et al. 1968; 
Matthews 1975). Following absorption, carnosine, like many other peptides, was thought to be 
hydrolysed in the cytoplasm of the intestinal epithelium prior to transfer of the resulting amino 
acids into the portal blood. Carnosine administration to human subjects by ingestion orjejunal 
perfusion resulted in a rapid increase in circulatory concentrations of histidine and ß-alanine, but 
no appearance of carnosine in the blood (Asatoor et al. 1970; Cook 1976). Carnosine and 
anserine were absorbed intact from rat intestine both in vitro and in vivo (Hama et al. 1976). 
Large increases in rat blood carnosine and anserine concentrations occurred two hours after 
forced feeding of large doses (up to 4500 mä kä 1 BW) of the imidazole dipeptides (Hama et al. 
1976). This finding was later reproduced although it was suggested that part of the orally 
administered carnosine was hydrolysed to histidine and ß-alanine in the small intestine (Tamaki 
et al. 1985). However, more recent investigations have supported the hypothesis that a 
significant proportion of the intact peptides are transported into the circulation (Gardner and 
Wood 1989). Plasma carnosine (81.8,44.4 and 4.6 yIM) was detected in one subject 30,60 and 
90 min after administration of 4g of carnosine in both isotonic and hypertonic test solutions 
containing lactulose, when sample collection and processing were performed at 4°C (Gardner et 
al. 1991). 
In vitro studies provided evidence for the active transport of carnosine by hamster jejunum 
(Matthews et at. 1974). Nutzenadel and Scriver (1976) reported active transport of carnosine by 
a high KtiI system (5 - 10 mM) in rat intestine which discriminated it from ß-alanine, a-amino 
acids and other dipeptides, and that intra-cellular hydrolysis prevented concentrative uptake 
despite the extent of hydrolysis being 10% only in eneterocytes. Carnosine transport in rabbit 
intestinal brush-border membrane vesicles was optimized by an inward proton gradient with an 
external pH of 5.5 - 6.0 against a fixed internal pH of 7.5 (Ganapathy and Leibach 1983). In 
vitro carnosine transport in rabbit kidney and mouse and guinea pig intestine conformed to 
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Michaelis-Menten kinetics, and has been shown to be a carrier mediated Na+-independent 
process (Ganapathy and Leibach 1983; Himuki 1985; Rajendran et al. 1984). 
Catabolism and carnosinase 
Historically the investigation of enzyme catalysed hydrolysis of carnosine has been confused by 
the existence of at least two different forms of the enzyme and complicated by differences in the 
behaviour of each form in tissues from different species. (Hanson and Smith 1949) reported the 
existence in pig kidney of 'carnosinase', a specific enzyme responsible for catalysing the 
hydrolysis of the peptide bond in carnosine to yield its constituent amino acids, histidine and ß- 
alanine. The enzyme was activated by the presence of Mn2+ ions. Carnosinase activity was 
detected in several tissues including kidney, liver and spleen of both pigs and rats, and a partially 
purified form of the enzyme was isolated from pig kidney and shown to be a metallo-protein 
activated by Mn2+ and Zn2+ ions (Rosenberg 1960; Wood 1957) Subsequently, two 
electrophoretically different forms of carnosinase were isolated from human liver, kidney and 
spleen. At pH 8.0 both exhibited the same substrate specificity and were approximately the same 
size (MW 90000) (Murphey et al. 1972). The existence of two carnosine-splitting enzymes was 
also described in hog kidney (Lenney 1976; Wolos et al. 1978). One of these two enzymes was 
later described as 'homocarnosinase' (Lenney et al. 1977). A Mn2+ - independent carnosinase 
and a Mn2+ - dependent carnosinase were isolated from mouse kidney (Margolis et al. 1979; 
Margolis et at. 1983). Rat brain was also shown to contain two carnosine hydrolysing enzymes; 
carnosinase and ß-Ala-Arg hydrolase (Kunze et at. 1986). Studies in mouse olfactory tissues and 
rat liver to establish the subcellular distribution of carnosinase have indicated that the majority of 
the activity is localized in the cytoplasm (Harding and Marshall 1976; Kalra et al. 1988). Human 
tissue carnosinase (MW 90000) was isolated from kidney and characterized as a metallo-cysteine 
dipeptidase. The enzyme showed optimum activity at pH 9.5, had a pf of 5.6, and a K. \ 
(carnosine) of 10 mM. It was activated by dithiothreitol (DTT) and p -hydroxymercuribenzoate 
(p HMB), was present in all tissues studied and had a wider specificity than hog kidney 
carnosinase. The enzyme appeared to be identical to prolinase, a non-specific peptidase (Lenney 
et al. 1985). 
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With more detailed analysis of the properties of hog kidney carnosinase Lenney (1990) 
attempted to rationalize characterization and nomenclature of carnosinase. He confirmed the 
presence of two dipeptidases in hog kidney capable of hydrolysing carnosine. He concluded that 
one was identical to the classical "carnosinase" described originally by (Hanson and Smith 
1949), that it also fulfilled the requirements previously ascribed to "homocamosinase" and "Mn2+ 
- independent carnosinase", and proposed that it be regarded as carnosinase. The second 
dipeptidase was functionally equivalent to "human tissue carnosinase", "Mn2+ - dependent 
carnosinase" and "ß-Ala-Arg hydrolase", and that it be considered a non-specific dipeptidase. 
Both carnosinase and non-specific dipeptidase were cytosolic (Lenney 1990). 
The abnormal appearance of camosine in the serum of two juvenile patients suffering from 
neurological disease and mental retardation prompted Perry et at. (1968) to investigate possible 
carnosinase activity in serum from these patients and in normal healthy subjects. The use of a 
previously published assay for tissue carnosinase activity indicated a mean enzyme activity of 
0.71 and 1.22 yemol ml-' h-' in children and adults, respectively (Perry et at. 1968). Serum 
carnosinase from humans has been isolated (Lenney et al. 1982). A glycoprotein with a sub-unit 
MW of 75000 and a p1 of 4.4, it was found to be structurally and functionally distinct from both 
carnosinase (tissue) and non-specific dipeptidase. Activities of serum carnosinase in tissues were 
measured and were proportional to the amount of trapped blood present. Brain however, 
contained 9 times more activity than could be accounted for by trapped blood (Jackson et at. 
1991). It had previously been shown that CSF contained relatively high activities of serum 
carnosinase (Lenney et al. 1983). It was therefore proposed that serum carnosinase is 
synthesized in brain and transported to the blood via the CSF rather than through the blood-brain 
barrier. Serum carnosinase activity was also found in six higher primates but not in twelve non- 
primate mammals except for Golden hamster (Jackson et at. 1991). A comparison of the 
properties of carnosinase, non-specific dipeptidase and serum carnosinase is given in Table 1.9. 
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Table 1.9 Properties of rationalized carnosinase, non-specific dipeptidase and serum 
carnosinase. Adapted from Lenney (1990). 
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The primary metabolites of carnosine, ß-alanine and histidine, can be further metabolized. The 
deamination of ß-alanine to malonate semialdehyde is catalyzed by ß-alanine-a-ketoglutarate 
transaminase. Histidine can be further metabolized as shown in Figure 1.4. 
Excretion 
Normal urinary excretion of carnosine in humans is relatively high in the neonate but decreases 
during the first four years. Older children and adults excrete less than 4% of the amount excreted 
by young children. This urinary excretion pattern appears to be attributable to changes in serum 
carnosinase activity (Roesel et al. 1986). 
Detection of ophidine (balenine) carnosine and anserine in human urine following meals 
comprising whale meat, other meats and tuna, respectively, has been reported (Abe et at. 1993; 
Undrum et at. 1982). Large amounts of carnosine were detected in the urine of fasted human 
subjects up to 3-5h after oral administration of 4ä (approximately 18 mmol) of carnosine in 
both isotonic and hypertonic test solutions containing lactulose. As much as 14% of the dose 
was recovered in the urine during the subsequent 5 h. Urinary excretion of carnosine was lower 
following administration in hypertonic solution. Urinary excretion of carnosine was significantly 
correlated to plasma carnosinase activity (p < 0.005, r= -0.815) (Gardner et al. 1991). 
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Figure 1.4 Metabolic pathways of histidine catabolism. 
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1.2.6 Disorders of carnosine metabolism 
H1'perß-aIaninemia 
Hyper-ß-alaninemia and ß-aminoaciduria associated with somnolence and seizures was reported 
and was postulated to arise from a deficiency in the activity of ß-alanine-a-ketoglutarate 
transaminase . Increased ß-alanine concentrations in brain, liver, kidney and skeletal muscle and 
large increases in the concentration of carnosine in the brain and muscles, but not in the liver and 
kidneys were found. Deltoid and abdominal muscle carnosine concentrations, relative to leucine, 
were 45.0 and 36.1 pmol g-1 WW (approximately 180.0 and 144.4 mmol kg-1 DW), respectively, 
in contrast to a control subject where concentrations in the same muscles were 6.84 and 6.62 
j mol g-' WW (approximately 27.4 and 26.5 mmol kä-1 DW), respectively. These data suggested 
that increased substrate availability is the probable cause of the increased muscle carnosine 
content (Scriver et al. 1966). 
Carnosinemia 
Carnosinemia associated with carnosinuria, progressive neurologic disease, severe mental 
deficiency and myoclonic seizures was reported after excessive urinary excretion of carnosine 
was encountered in two juvenile patients (Perry et at. 1967). Carnosine was detected in fasting 
plasma from one patient after a normal diet (8 µM) and persisted for at least 72 h after the 
imposition of a meat-free diet (4 pM ). Relatively large amounts of carnosine were excreted in 
the urine of both subjects (0.97 and 0.25 pmol mg-1 creatinine) 72 h after the imposition of the 
meat-free diet. Carnosine was not detected in fasting plasma from 120 healthy control subjects. 
A metabolic challenge imposed on both subjects by the administration of a chicken breast diet 
resulted in an increased excretion of carnosine and the appearance of large quantities of anserine 
(2.27 and 8.59 ymol mg-I creatinine) in the urine. A greatly elevated carnosine concentration 
(45.3 pM) and the presence of large quantities of anserine (102 pM) were also detected in the 
plasma of the patient which had previously exhibited carnosinemia. Neither patient excreted 1- 
methylhistidine, the normal urinary metabolite of anserine. Carnosine loading tests were 
performed on both individuals by oral administration at 5 mg kg-' body weight (BW) (22 ptmol 
kg-i BW). At 4h post administration 15% of the dose had been excreted by the patient exhibiting 
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both carnosinemia and carnosinuria and 9% by the patient displaying only carnosinuria. The 
same dose given to a normal healthy subject resulted in the excretion of only 0.4% of the dose 
within 4 h. Perry et al. (1967) proposed the carnosinemia and carnosinuria occurred as a result 
of impaired degradation of imidazole dipeptides arising from a genetically derived deficiency in 
carnosinase activity. 
The significance of plasma carnosinase activity in the aetiology of carnosinemia in these two 
patients was later investigated by Perry et al. (1968). Plasma carnosinase activities in the two 
patients were very low, 0.02 ± 0.02 and 0.04 Fimol ml-i h-', with the lower activity present in the 
patient displaying both carnosinuria and carnosinemia. In contrast, the activities in normal 
healthy adults and children were 1.21 ± 0.52 and 0.71 ± 0.31 pimol ml-I h-', respectively. 
Significant tissue carnosinase activity was found in post mortem extracts of liver, kidney and 
heart of one patient (Perry et al. 1968). 
Similar findings to these were later reported, for a family in which two boys with progressive 
neurological disorders and their physically and mentally normal sister exhibited carnosinuria, by 
Murphey et at. (1973). Carnosinemia was evident in both boys with serum carnosine 
concentrations of 200 - 300 yiM , but not in the sister. Carnosinuria was evident in all three 
children with carnosine excretion higher in the sister (312 jcmol d-1) than in the brothers (63 and 
204 umol d-1). Serum carnosinase activities were < 0.03 jtmol ml-1 h-'. All three subjects 
excreted 1-methylhistidine when fed a meal comprising chicken breast, which indicated an 
unimpaired ability to catabolise anserine (Murphey et at. 1973). Electrophoresis of extracts of 
post mortem liver, kidney and spleen tissue from one of the brothers indicated that one of the two 
electrophoretic forms of carnosinase was absent and that the one present corresponded to the 
slower form of the enzyme and exhibited normal activity. Murphey et at. (1973) postulated that 
the absence of serum carnosinase activity in the physically and mentally normal sister precluded 
a causal relationship between serum carnosinase deficiency and neurological disease. Reduced 
serum carnosinase activity has also been reported in urea cycle defects which in some cases 
correlated with carnosinemia (Burgess et at. 1975), liver cirrhosis, hepatoma and chronic 
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hepatitis (Bando et at. 1986), Parkinson's disease and multiple sclerosis (Wassif et al. 1994), 
Duchenne muscular dystrophy (Bando et u!. 1984) and alcoholic chronic skeletal muscle 
myopathy (Duane and Peters 1988). 
Homocarnosinosis 
Homocarnosinosis characterized by an increased homocarnosine concentration in cerebrospinal 
fluid (CSF) and brain, serum carnosinase deficiency and carnosinuria often associated with 
progressive mental retardation, spastic paraplegia and retinal pigmentation was first described in 
a 37 year-old woman (Gjessing and Sjaastad 1974). Her two brothers displayed increased CSF 
homocarnosine concentrations and similar clinical symptoms, her mother showed no 
neurological abnormalities but had elevated CSF homocarnosine concentrations, and the father, 
other sibling and two maternal aunts were physiologically, biochemically and mentally normal 
(Sjaastad et al. 1976). CSF homocarnosine concentrations in the mother, two brothers and 
daughter were 48-75 uM in contrast to the unaffected father and second daughter (0.5 - 2.0 jtM 
). The normal range was 0.9 ± 0.1 to 1.8 ± 1.8 pM (Perry et al. 1975; Perry et al. 1982). 
Homocarnosine concentration in the brain of one brother was four-fold higher than in controls. 
The mother and three children all showed a marked elevation of carnosine excretion on a meat- 
free diet and after oral carnosine administration, minimal excretion of 1-methylhistidine 
following a chicken meal and oral anserine administration. These findings were consistent with 
a deficiency in serum carnosinase activity. Subsequent analysis of carnosinase activity in the 
four homocarnosinosis patients indicated zero or minimal activity present in both serum and 
CSF, in contrast to both controls and the unaffected father and daughter (Lenney 1985; Lenney et 
al. 1983). These findings were identical with those associated with carnosinemia and a 
deficiency in serum carnosinase activity was probably responsible for the increased 
homocarnosine concentrations evident in homocarnosinosis patients (Lenney et al. 1983). A 
causal relationship between homocarnosinosis, impaired serum carnosinase activity and 
neurological disorder was considered unlikely (Gjessing et at. 1990). No homocarnosinosis was 
found in twenty-five patients afflicted with various forms of spastic paraplegia (Sjaastad et al. 
1977). 
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Other disorders 
Increased urinary excretion of carnosine, has been reported in Juvenile Amaurotic idiocy 
(Stengel/Batten/VogtlSpielmeyer disease) (Bessman and Baldwin 1962; Levenson et al. 1964). 
Raised homocarnosine concentrations were reported in some untreated cases of Phenylketonuria 
(Follings disease) (Sande et a!. 1970). Reduced carnosine concentration in human lens was 
correlated with the severity of senile cataracts (Boldyrev et al. 1987). 
1.3 Objectives 
The principal objectives of this research were as follows: 
To develop and validate sensitive, selective and accurate analytical methods for the 
determination of the concentrations carnosine and other associated biogenic imidazoles in 
equine tissues and fluids. (Chapter 3) 
ü To determine the normal concentration range of carnosine and associated compounds in 
equine plasma, and to investigate the effects of normal feeding and exercise. (Chapter 4) 
iii To determine by direct measurement carnosine concentrations in type I, IIA and IIB 
fibres from normal and abnormal equine skeletal muscle, and to investigate the effect of 
training. (Chapter 5) 
iv To measure carnosine concentrations in other equine tissues. (Chapter 5) 
v To study aspects of carnosine metabolism, transport and excretion in vivo. (Chapter 6) 
vi To examine the effectiveness of oral carnosine or histidine and ß-alanine administration 
in increasing endogenous skeletal muscle carnosine concentrations. (Chapter 7) 
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CHAPTER 2 
GENERAL METHODOLOGY 
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?. 1 SAMPLE COLLECTION AND PREPARATION PROCEDURES 
2.1.1 Blood collection 
Single blood samples were obtained by venepuncture using disposable sterile (1.2 mm i. d. x 40 
mm) 'Monoject' needles and 10 ml plastic syringes (Sherwood Medical, Balmoney, N. Ireland). 
Serial blood samples were collected via an indwelling catheter. A2 cm2 area over the left jugular 
vein was scrubbed and shaved. Following local anaesthesia with Xylocaine (0.5 ml 2%) 
administered subcutaneously, an 'Intraflon 2' (2.4 mm i. d. x 120 mm) Teflon trocart catheter 
(Vygon UK Ltd., Cirencester. UK. ) was inserted, closed with a three-way tap and sutured in 
place. The catheter was flushed with physiological saline (10 ml) containing 5000 IU 1-1 heparin 
(CP Pharmaceuticals Ltd., Wrexham, UK. ) as anticoagulant. Blood (5 ml) was drawn through 
the catheter and discarded immediately prior to collecting each 10 ml blood sample. The catheter 
was flushed with saline (5 ml) after each sample withdrawl. Blood was collected into 5 ml 
lithium heparin tubes (LIP Ltd., Shipley, UK. ) and stored in ice prior to centrifugation (2000 g 
for 4 min at 4°C). Plasma was aspirated and stored at -20°C prior to analysis. 
2.1.2 Urine collection 
Twelve-hour urine collections from both fillies and geldings were performed by the free-flow 
technique using a collection harness (Harris and Snow 1988). Individual samples were retained 
in polythene bags suspended under the harness. Samples were mixed thoroughly, the volume 
recorded, and a 20 ml aliquot taken and stored at -20°C prior to analysis. 
2.1.3 Muscle sampling 
Muscle samples were collected both from live experimental animals using the percutaneous 
biopsy technique and by dissection at post mortem from euthanased horses which had failed to 
respond to treatment for a variety of chronic orthopaedic conditions. All animals, with one 
exception, (see Chapter 4) had no clinical history of muscle disorders or significant weight loss. 
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Biopsy sampling 
Percutaneous muscle biopsies were collected from the right gluteus medius muscle at a point one 
third of the distance along a line running from the tuber coxae to the head of the tail using a5 
mm Bergstrom-Stille biopsy needle (Bergstrom 1962; Snow and Guy 1976). The biopsy site was 
shaved and disinfected prior to local anaesthesia with 2% XylocaineTMM (1 -2 ml). The biopsy 
needle was introduced through a small stab incision made through the skin and muscle fascia 
with a scalpel blade. Biopsies were taken at depths of 6 cm. Biopsy samples were blotted on 
filter paper to remove excess blood, placed in a screw-cap tube, frozen in liquid nitrogen (- 
196°C) and subsequently freeze-dried. Freeze-dried samples were stored in liquid nitrogen. 
Post mortem sampling 
Tissue samples were collected as quickly as possible, and always within 90 min of euthanasia. 
The entire left or right middle gluteal muscle was removed and a1 cm-thick transverse section 
was dissected from the intact muscle at the mid-point and at points one quarter of the muscle 
length from each end. Triplicate tissue samples approximately 5 mm2 by 20 mm were dissected 
from 9 pre-determined sites (Figure 2.1) such that the fibre orientation was parallel with the long 
edge. Samples were blotted on filter paper to remove excess blood, stretched slightly to 
straighten the fibres, frozen in liquid nitrogen (-196°C) and subsequently freeze-dried. Freeze- 
dried samples were stored in liquid nitrogen. 
Muscle powdering 
Freeze-dried muscle was allowed to reach ambient temperature in sealed tubes before powdering. 
The outer surfaces of the samples were removed in order to minimize the contamination from 
dried blood. The remaining muscle was coarsely powdered with an agate pestle and mortar and 
finely powdered by drawing the tissue between the serrated tips of sharp curved forceps. 
Contaminating connective tissue and blood were removed as far as possible. Powdered muscle 
was stored in liquid nitrogen. 
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2.1.4 Sampling of other tissues 
Other tissue samples comprising liver, kidney, lung, spleen, diaphragm, heart (myocardium), 
brain (medulla and cerebellum) and gastro-intestinal tract (small intestine, colon, stomach and 
rectum) were prepared and stored using the procedures described previously for muscle. 
2.2 SAMPLE EXTRACTION PROCEDURES 
2.2.1 Plasma extraction 
Several plasma extraction procedures were employed; the exact procedure used being dependent 
on the particular analytes to be determined. Samples for carnosine, histidine, ß-alanine and 
taurine determination were deproteinized and extracted with sulphosalicylic acid, as described in 
detail in Chapter 3. Samples for N-ct-acetylcarnosine determination were deproteinized and 
extracted with perchloric acid/phosphoric acid, as described in detail in Chapter 3. 
2.2.3 Urine extraction 
Frozen urine samples were thawed at 37°C and mixed thoroughly. Samples were vortex-mixed 
for one minute to re-suspend any particulate material immediately prior to taking a1 ml aliquot 
for extraction. 
2.2.4 Muscle extraction 
Powdered muscle (8 - 10 mg) was extracted with aqueous 0.5 M perchloric acid containing I 
mM EDTA (100 pI mg-1), as described previously (Harris et al. 1974). Extracts were vortex- 
mixed at 2 min intervals over a total period of 15 min, or until the floating muscle particles sink. 
During mixing intervals samples were stored on ice. Extracts were centrifuged for 5 min at 
12000 g at ambient temperature. Aliquots of the acid extracts, for the determination of low 
concentrations, were stored at -20°C prior to further extraction and analysis. The remaining 
volumes of the extracts were neutralized with aqueous 2.1 M potassium hydrogen carbonate and 
centrifuged. The supernatants were stored at -20°C prior to analysis. Neutralized supernatant 
fluid (1 ml) was equivalent to 10 mg of freeze-dried muscle. 
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?. 3.5 Extraction of other tissues 
Powdered tissue samples were extracted with perchloric acid as described previously (Harris et 
at. 1974). Acid extracts were stored at -20°C until analysis. 
2.3 INDIVIDUAL MUSCLE FIBRE PREPARATION, WEIGHING AND EXTRACTION 
PROCEDURE 
2.3.1 Dissection 
A thin longitudinal slice was cut from the freeze-dried muscle sample whilst ensuring that the 
long edge was parallel with the fibre bed orientation. The thin muscle slice was placed in an 
agate mortar and compressed gently with the pestle. Gentle rocking of the pestle helped to 
partially separate the muscle fasciculi. Further separation of the fasciculi was obtained using a 
pair of dissection needles. One fasciculus was transferred to a pre-cleaned (IMS followed by 
acetone) microscope slide. With the aid of a stereo dissection microscope and a pair of very fine 
dissection needles (0.1 mm sharp-point ophthalmic suture needles), individual muscle fibres 
were separated. Between 30 and 50 fibres per sample were dissected. Separated fibres were 
stored overnight at -85°C. 
2.3.2 Mounting and weighing 
Each of three pre-cleaned microscope slides were engraved with a small central grid of 25 
squares and labelled with the identity of the horse, the sample No. (i. e. MG3, MG4 etc. ), the 
horse colour code label and the slide number (Figure 2.2). 
One individual fibre was removed from the flip-top Eppendorf tube and the tube was re-capped. 
Three small fragments were cut from one end of the fibre. A small drop of water was placed in 
the first square of the grid on each slide. One fragment was placed in the first grid-square on each 
slide. The remaining larger fibre portion was transferred on a microscope slide to a pre- 
calibrated quartz-fibre fish-pole balance for weighing (Lowry and Passoneau 1972). The cover 
glass was removed from the glass barrel of the balance and the a dissection needle was used to 
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transfer the muscle fibre to the end of the quartz fibre. The muscle fibre is held by static 
attraction. The cover glass was replaced and the deflection recorded using a graticule eyepiece. 
The muscle fibre was removed from the balance and placed in a 200 Fp1 glass micro-vial which 
was immediately capped. The above procedures were repeated until 25 fibres were mounted in 
triplicate and weighed. Completed slides were stored at -20"C prior to histochemical staining. 
Fibres for extraction were stored at -85"C. 
2.3.3 Metabolite extraction 
Individual muscle fibres were extracted as described in detail in Chapter 3. 
2.4 HISTOCHEMICAL STAINING OF INDIVIDUAL MUSCLE FIBRES. 
Freeze-dried individual muscle fibre fragments and frozen muscle sections were characterized as 
type I, type IIA or type IIB by histochemical staining for myosin ATPase activity by a 
modification of a published method (Brook and Kaiser 1970). 
2.4.1 Preparation of reagents 
Sodium acetate solution (0.2 M ): Sodium acetate trihydrate (27.22 g) was dissolved 
in distilled de-ionised water (1000 ml). 
Acetic acid solution (50% v/v): Glacial acetic acid (50 ml) was diluted with distilled 
de-ionised water (50 ml). 
Glycine/calcium chloride buffer: Glycine (3.00 g) and calcium chloride dihydrate 
(2.94 g) were dissolved in distilled de-ionised water 
(1000 ml). 
Potassium hydroxide solution (0.1 M ): Potassium hydroxide (5.60 g) was dissolved in 
distilled de-ionised water (1000 ml). 
Calcium chloride solution (2% w/v): Calcium chloride dihydrate (10.00 g) was dissolved 
in distilled de-ionised water (500 ml). 
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Cobalt chloride solution 0% w/v): 
Ammonium sulphide solution (1% w/w) 
2.4.2 Staining procedure 
Cobalt chloride hexahydrate (5.00 g) was dissolved 
in distilled de-ionised water (500 ml). 
20% w/w ammonium sulphide solution (1 ml) was 
diluted with distilled de-ionised water (19 ml). 
The pH meter (Corning, pH/ion meter, CIBA-Corning) was calibrated between pH 7.0 and 10.0 
using a two-point calibration. Glycine/calcium chloride solution (- 45 ml) was added to two 
Coplin jars which were incubated at 20°C. One solution was subsequently titrated to pH 9.6 and 
the other to pH 9.8 using 0.1 M Potassium hydroxide. ATP disodium salt (75 mg) was added to 
the glycine/calcium chloride buffer at pH 9.8 and the solution re-titrated to pH 9.6. The pH 
meter was re-calibrated between pH 4 . 000 and 7.000 using a two-point calibration. Sodium 
acetate solution was incubated, in a Coplin jar at 20°C and susequently titrated to precisely pH 
4.500 with acetic acid (50% v/v). Solutions of calcium chloride (2% w/v) and cobalt chloride 
(1% w/v) were incubated at 20°C. Two slides of mounted fibres were incubated in the sodium 
acetate /acetic acid buffer for exactly 5 min, rinsed briefly four times in distilled water and once 
in the glycine/calcium chloride solution for 30 s prior to incubation in the ATP/glycine/calcium 
chloride solution for 30 min. After rinsing the slides were incubated in the calcium chloride 
solution for 90 s, rinsed, incubated in cobalt chloride for 3 min, rinsed and flooded with the 
ammonium polysulphide solution for 2 min. The slides were rinsed, coverslips were mounted on 
the slides using UV free aqueous mountant and the edges of the coverslips sealed using clear nail 
varnish. The stained fibres were viewed using low power microscopy using and characterized as 
type I, IIA or IIB according to stain intensity; type I fibres stained black, type IIA fibres white 
and type IIB fibres grey. 
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Figure 2.1 Muscle sampling sites within the middle gluteal muscle. 
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Figure 2.2 Individual muscle fibre mounting procedure. 
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2.5 DETERMINATION OF ß-ALANINE AND TAURINE CONCENTRATIONS IN 
PLASMA, URINE AND MUSCLE 
Neutralized perchloric acid extracts of muscle and sulphosalicylic acid extracts of plasma were 
prepared as described in Section 2.2. Extracts (20 Ftl) were buffered to pH 9.65 with aqueous 
400 mM borate buffer (100 Fcl) in 300 ßi1 glass micro-vials. Buffered extracts were analysed by 
the high-performance liquid chromatography (HPLC) method developed for the determination of 
muscle imidazoles, as described in Chapter 3. Extracts were not subjected to solid-phase 
extraction for the analysis of taurine and ß-alanine. Chromatograms of a mixed standard solution 
of taurine and ß-alanine, and typical plasma and urine extracts are shown in Figures 2.3,2.4 and 
2.5, respectively. Extract concentrations were calculated from a range of known external 
standards (10 - 1000 pM) buffered as per samples. 
2.6 DETERMINATION OF PLASMA CARNOSINASE ACTIVITY 
Plasma camosinase activity was determined using a modification of a previously published 
method (Bando et al. 1984). 
2.6.1 Preparation of reagents 
Buffer, 50 mM TRIS. HCI : 
Substrate, 50 mM carnosine: 
2.6.2 Assay 
Tris -(hydroxymethyl)-methylamine (3.028 g) was 
dissolved in distilled water (500 ml) and titrated to 
pH 8.40 with 1.0 M and 0.1 M hydrochloric acid. 
Carnosine (1.131 g) was dissolved in 50 mM 
TRIS. HCI buffer, pH 8.40 (100 ml). 
Plasma (50 µl) was diluted with aqueous 50 mM TRIS. HCI buffer, pH 8.40 (150 pl), vortex- 
mixed and pre-incubated for 5 min at 37"C. Aqueous 50 mM carnosine (50 µl) was added. The 
solution was vortex-mixed briefly and incubated for 120 min at 37"C. The reaction was stopped 
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and protein precipitated by the addition of ice-cold perchloric acid (750 111). The extract was 
vortex-mixed, cooled on ice for 5 min and subsequently centrifuged for 5 min at 12000 g at 
ambient temperature. The supernatant fluid (500 /11) was neutralized with aqueous 2.1 M 
potassium hydrogen carbonate (200 jil). The neutralized extract was mixed, cooled on ice and 
centrifuged as described previously. The supernatant fluid was collected and analysed for 
histidine concentration by HPLC. A linear relationship between incubation time and histidine 
produced was evident for incubation times up to 120 min. The plasma carnosinase assay was 
established and validated using human plasma 
2.7 DETERMINATION OF TISSUE CARNOSINASE ACTIVITY 
Tissue carnosinase activity was determined by a modification of a previously published method 
(Lenney 1990). 
2.7.1 Preparation of reagents 
Buffer, 50 mM TRIS. HCI: 
Substrate, 100 mM carnosine: 
Co-factors, 0.5 mM Mn2+ 
and 20 mM dithiothreitol 
2.7.2 Assay 
Tris -(hydroxymethyl)-methylamine (3.028 g) was 
dissolved in distilled water (500 ml) and titrated 
to pH 8.8 with 1.0 M and 0.1 M hydrochloric acid. 
Carnosine (2.262 g) was dissolved in 50 mM 
TRIS. HCI buffer, pH 8.8 (100 ml). 
Manganese dichloride tetrahydrate (9.90 mg) and 
DL-dithiothreitol (0.308g) were dissolved in 
distilled water (100 ml). 
Freeze-dried powdered tissue (5 mg) was homogenized (Ultra-Turax motorized homogenizer) for 
15 sec in ice-cold 50 mM TRIS. HCI buffer, pH 8.8 (700 p1). Further TRIS. HCI buffer (100 µl) 
or co-factor solution containing 0.5 mM Mn2+ and 20 mM dithiothreitol was added. The 
homogenate was vortex-mixed briefly and pre-incubated for 5 min at 37"C. Aqueous 100 mM 
carnosine (200 pl) was added, and the homogenate was vortex-mixed and incubated for 120 min 
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at 37°C. The reaction was stopped by the addition of ice-cold 0.5 M perchloric acid (1000 ill). 
The extract was vortex-mixed, cooled on ice for 5 min and subsequently centrifuged for 5 min at 
12000 g at ambient temperature. The supernatant fluid (500 jil) was neutralized with 2.1 A'! 
potassium hydrogen carbonate (200 ill), mixed, cooled on ice and centrifuged as described 
previously. The supernatant fluid was collected and analysed for histidine concentration by 
HPLC. A linear relationship between incubation time and histidine produced was evident for 
incubation times up to 120 min. 
Values for the coefficients of variation for the enzyme assays are given in Table 2.1. 
2.8 STATISTICAL METHODS 
Unless specified otherwise all data are presented as the mean and standard deviation (mean ± 
SD). Coefficient of variation (CV) was calculated as follows: 
CV = (SD. 100) /X 
Pooled standard deviation (SP)was calculated according to the following formula: 
Sp= E(n; - I. SD; 
2)/En-1 
Where differences in measured parameters between groups were to be compared initial statistical 
analysis was performed using 1-factor analysis of variance (ANOVA). Where differences were 
detected significance was determined by the use of a multiple comparison test; Fisher's Protected 
Least Significant Difference (PLSD). Significance was declared at p<0.05. Simple linear 
regression analysis where performed was by the least squares method. 
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Table 2.1 Coefficients of variation for the HPLC analyses and enzyme assays. 
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Metabolite Sample Technique n Coefficient of variation (%) 
Intra-assay Inter-assay 
ß-Alanine Plasma HPLC 5 2.0 2.6 
Urine HPLC 5 1.1 2.4 
Taurine Plasma HPLC 5 0.9 1.6 
Muscle HPLC 5 2.5 5.6 
Carnosinase Plasma Enzyme assay/HPLC 10 5.6 10.6 
Tissue Enzyme assay/HPLC 10 9.9 10.1 
Figure 2.3 Chromatogram of a mixed standard solution containing taurine and ß-alanine 
at 100 ppM. 
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Figure 2.4 Chromatogram of a typical sulphosalicylic acid extract of equine plasma. 
(* Indicates the position where ß-alanine would appear if it was present in normal 
equine plasma. ) 
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Figure 2.5 Chromatogram of a typical sulphosalicylic acid extract of equine urine. 
(* Indicates the position where ß-alanine would appear if it was present in normal 
equine urine. ) 
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2.9 REAGENTS (Ordering information) 
Glacial acetic acid 99-101 % w/w Fisons A/0400/PB 17 
Acetonitrile 190 (Far UV) super purity solvent Romil Chemicals H718 
Acetone super purity solvent Romil Chemicals H031 
N-a-acetyl-L-carnosine Dr. E. Hultman (gift) - 
ß-Alanine Sigma A 7752 
Ammonium dihydrogen phosphate Aldrich 21,600-3 
Ammonium sulphide 20% w/w Aldrich 30,941-9 
L-Balenine Dr. H. Abe (gift) - 
L-Anserine nitrate Sigma A 1131 
ATP disodium salt: From equine muscle. Sigma A 5394 
Orthoboric Acid AnalaR BDH 10058 
Calcium chloride dihydrate AnalaR BDH 10070 
L-Carnosine Sigma C 9625 
Cobalt (II) chloride hexahydrate AnalaR Sigma C 2644 
Diammonium hydrogen phosphate Aldrich 33,879-6 
DL-Dithiothreitol Sigma D 5545 
Glycine Sigma G 7126 
L-Histidine free base Sigma H 8000 
L-Homocarnosine Sigma H 4885 
Hydrochloric acid 34.5% v/v AnalaR BDH 10125 
Manganese(II) chloride tetrahydrate Aldrich 22,127-9 
3-Mercaptopropionic acid Sigma M 6750 
Methanol (205) super purity solvent Romil Chemicals H410 
Methanol (215) super purity solvent Romil Chemicals H409 
L-1-Methylhistidine Sigma M 9005 
L-3-Methylhistidine Sigma M 3879 
p =Nitrophenol Sigma 104-8 
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Perchloric acid 70% w/w BDH 10176 
Phosphoric acid 85% w/w Aldrich 21,510-4 
Potassium hydrogen carbonate AnalaR BDH 10206 
Potassium hydroxide 87% Sigma P 1767 
o -phthaldialdehyde reagent solution (incomplete) Sigma P 7914 
Sodium acetate anhydrous Sigma S5889 
Sodium acetate trihydrate Sigma S 8625 
Sodium hydroxide 97.5% Sigma S0899 
Sodium pentanesulphonate Sigma P 0299 
5-Sulphosalicylic acid Sigma S0640 
Taurine Sigma T 0625 
Tetrahydrofuran super purity solvent Romil Chemicals H718 
Triethylamine 99+% Aldrich 23,962-3 
Tris-(hydroxymethyl)-methylamine Sigma T 1503 
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CHAPTER 3 
DEVELOPMENT OF HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
METHODS FOR THE ANALYSIS OF CARNOSINE, ITS ANALOGUES, AND THEIR 
METABOLITES IN EQUINE BODY FL UIDS AND TISSUES. 
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3.1 GENERAL INTRODUCTION 
The, quantification of the concentrations of carnosine, its analogues anserine, balenine, 
homocarnosine and N-u-acetylcarnosine, and their metabolites histidine, 1-methylhistidine, 3- 
methylhistidine in equine plasma. urine and tissues (skeletal and smooth muscle, diaphragm, 
myocardium, liver, kidney, lung, spleen, cerebellum and medulla), required the development of 
selective and sensitive analytical methodologies. 
Thin-layer chromatography, electrophoresis. and ion-exchange chromatography have previously 
been used for the measurement of amino acid and imidazole concentrations in biological fluids 
and tissues (Efron 1969; Smith 1969; Wadman et at. 1971; Wadman and de-Bree 1976). 
However, limitations associated with these techniques including limited selectivity, poor 
sensitivity and long analysis times, have resulted in their replacement by high-performance liquid 
chromatography (HPLC). HPLC has proved to be a highly versatile and adaptable analytical 
technique for the determination of the concentrations of very many low molecular mass 
compounds in physiological samples including; lipids, vitamins, steroid hormones, 
carbohydrates, nucleotides, nucleosides and nucleo-bases, organic acids, catecholamines, 
imidazoles, amines, amino acids and small peptides. Probably the greatest advantage of HPLC 
over the more traditional techniques is its capacity to resolve and quantify many, often 30 or 
more, compounds simultaneously with high accuracy, precision and sensitivity; although the rate 
of sample throughput may be compromised somewhat. 
3.2 DETERMINATION OF CARNOSINE AND OTHER BIOGENIC IMIDAZOLES IN 
EQUINE PLASMA BY ISOCRATIC REVERSED-PHASE ION-PAIR HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY 
Dunnett and Harris (1992). 
3.2.1 Introduction 
Difficulties were encountered in the adaptation of previously published methods for the 
measurement of tissue carnosine contents, to the determination of carnosine in equine plasma 
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owing to the low plasma content and tendency for co-elution with amino acids or other small 
peptides. Analysis times were typically 30 - 60 min and the complex chromatograms produced 
contain superfluous information. An HPLC method for the quantification of carnosine and 
anserine in rabbit serum (Kurisaki and Hiraiwa 1988) proved to be grossly inaccurate when 
applied to equine plasma. An new analytical method was developed which combined isocratic 
reversed-phase ion-pair HPLC with sorbent extraction to provide rapid, selective and sensitive 
detection of carnosine, histidine, anserine, and 1-methylhistidine in plasma with previously 
unobtained specificity. 
3.2.2 Experimental 
Instrumentation and reagents 
The HPLC system comprised a Constametric 3000 pump (LDC Analytical, Stone, Staffs., UK), a 
Rheodyne 7125 injector with a 200 yl sample loop (Cotati, CA., USA. ), a LC-UV variable 
wavelength ultra-violet spectrophotometric detector (Unicam, Cambridge, UK) and a LKB 6500 
flat-bed potentiometric recorder (LKB Biochrom, South Croydon, UK). A Sepralyte ODS 40 
jm sacrificial column (50 x 4.6 mm I. D. ) (Analytichem International, Harbor City, CA., USA. ) 
and a Rheodyne in-line filter (0.5 µm pore size) (Cotati, CA, USA. ) were inserted between the 
pump and the injector. Ultra-violet absorption spectra were recorded on a Unicam SP800 ultra- 
violet spectrophotometer (Unicam, Cambridge, UK. ). 
All reagents were analytical reagent grade unless specified otherwise (see Chapter 2). Water was 
purified by reverse osmosis and de-ionization (Elgastat Spectrum RO1, Elga, High Wycombe, 
UK. ). 
Sample deproteinization and solid-phase extraction 
Heparinized plasma (lml) was deproteinized with 200 ycl 30% (w/v) 5-sulphosalicylic acid 
(SSA), and centrifuged. Plasma SSA extracts (500 Ftl) were loaded onto 100 mg /I ml Bond 
Elut PRS (propylsulphonyl) solid-phase extraction (SPE) cartridges (International Sorbent 
Technology, Hengoed, UK) previously conditioned with methanol (4 ml) and 1.0 M phosphoric 
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acid (4 ml). Interfering substances were washed from the cartridges with 1.0 M phosphoric acid 
(2 x 500 1d) and the eluate discarded. The sorbent was air dried and the isolates (carnosine and 
other imidazoles ) were eluted with HPLC mobile phase (2 x 500 111). Solvents at all stages were 
drawn through the cartridges at a flow-rate of 1 ml min-1. A 200 p1 aliquot was injected onto the 
HPLC column. 
Chromatography 
Chromatography was performed on a Hypersil ODS 3 jim (150 x 4.6 mm I. D. ) analytical column 
(Shandon Scientific, Runcorn, UK. ) protected by a Hypersil ODS 5 Jim (20 x 4.6 mm I. D. ) guard 
column. 
The compounds of interest were eluted isocratically at ambient temperature using a mobile phase 
comprising an aqueous solution of 200 mM ammonium dihydrogen phosphate (NH. t)H2PO. t and 
100 mM sodium pentanesulphonate adjusted to pH 2.0 with concentrated phosphoric acid, and 
containing 4% (v/v) acetonitrile. The mobile phase was filtered through 0.45 ytm ( HVLP 047 
PTFE filters, Millipore UK Ltd., Watford, Herts., UK. ) and degassed by helium sparging prior to 
use and periodically throughout the day. The mobile phase was freshly prepared each day. The 
flow-rate was 0.8 ml min-1. UV absorption was measured at 220 nm with the detector sensitivity 
set for full-scale deflection (FSD) at 320 milliabsorbance units (mAU). Plasma concentrations 
were determined by comparing sample peak heights to those of external standards. 
Standard preparation 
Individual 10 mM stock standard solutions of carnosine, anserine, histidine and 1- 
methylhistidine were prepared by dissolving the required weight of each compound in HPLC 
grade water (10 ml). Working standard solutions for each compound were prepared over the 
concentration range 5- 30 yM by dilution of stock standards with mobile phase. Both stock 
standard solutions and working standard solutions were stored at -20°C when not used. 
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Recovery study 
Pooled equine plasma was spiked at 25 u i'I with a mixed standard containing 1-methylhistidine, 
histidine, anserine and carnosine. Overall extraction recoveries (n = 5) for the combined 
deproteinization and sorbent extraction stages were determined by comparing the chromatograms 
obtained from the spiked plasma extracts with those obtained from a mixed standard solution 
containing 25 jiM 1-methylhistidine, histidine, anserine and carnosine. The concentration of 
these compounds in the plasma prior to spiking was determined and taken into account when 
calculating overall recoveries. 
Reproducibility study 
Standards for the determination of the precision and accuracy of the analysis were prepared from 
pooled equine plasma extract which was spiked at 25 yiM with 1-methylhistidine, histidine, 
anserine and carnosine. Repeated injections of the spiked extract (n = 5) were made on day 1, 
day 5 and day 10 to assess the inter-assay variation. Intra-assay variation was determined by 
repeated injections (n = 5) of the spiked extract on three occasions within day 1. 
Lower detection limits 
The lower limits of detection for the compounds of interest were determined by injecting 
individual standards of 1-methylhistidine, histidine, anserine and carnosine sufficient to elicit 
FSD on the recorder at a detector sensitivity setting of 10 mAU. The height of the smallest 
detectable peak was 5mm which was equivalent to a signal : noise ratio of 2: 1. 
3.2.3 Results and discussion 
Chromatography 
Spectra over the UV range 190 - 450 nm were recorded for the imidazole compounds of interest. 
Their mean Xmc values occurred at a wavelength of 220 ±5 nm (carnosine, = 223 nm) in 
0. IM (NH4)H2PO4 (pH 2.0). The reference cell contained 0. IM (NH4)H2PO4. The UV spectra 
of several other amino acids were also recorded and exhibited Amax values at slightly lower 
wavelengths (ß-alanine, ?.. = 205 nm). At 220 nm the absorbance ratio of ß-alanine 
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carnosine was 1.00 : 5.88 for equimolar solutions. A detection wavelength of 220 nm was 
selected. 
Inevitably there is the potential for significant interference when utilizing UV detection at such a 
non-specific wavelength. In addition to the amino acids, many other polar low molecular mass 
compounds (Mr < 2000), endogenous to plasma, display strong UV absorption at 220 nm. Some 
such compounds are; creatine. creatinine, purine nucleotides, nucleosides and bases, and 
carboxylates (lactate and pyruvate). However, it has been demonstrated previously that for a 
non-polar stationary phase and a polar mobile phase, retention of the biogenic imidazoles is 
maximised at low pH (O'Dowd et al. 1988), and furthermore that creatine, creatinine and the 
purine based compounds are minimally retained (Sellevold et al. 1986). 
A variety of columns and mobile phase parameters were evaluated in order to optimize the 
resolution of the various imidazole compounds and to further minimize any potential 
interference. Aqueous potassium, or sodium, dihydrogen phosphate buffers have generally 
formed the basis of previous eluents (O'Dowd et at. 1988) for the HPLC of carnosine and the 
other imidazoles (O'Dowd et al. 1988; Kurisaki and Hiraiwa 1988). The use of alkali metal 
phosphates during the present method development caused considerable peak tailing of these 
basic compounds and was apparent in a previous method (O'Dowd et al. 1988). The alternative 
use of (NH4)H2PO4 resulted in a marked improvement in peak symmetry. The effect of a range 
of ion-pairing agents (sodium pentanesulphonate, sodium heptanesulphonate, sodium 
octanesulphonate and sodium dodecyl sulphate) and acetonitrile as the organic modifier, on the 
retention and resolution of the compounds of interest was investigated. Sodium 
pentanesulphonate (100 mM ) and 4% acetonitrile produced the best resolution within the 
optimum capacity factor (K' ) range , 1< K' >10. Of the different analytical columns evaluated; 
Apex ODS 15 µm, Apex Phenyl 5 pm, Spherisorb ODS2 5 pm. Hypersil ODS 5 pm and 
Hypersil ODS 3 pm, superior resolution was obtained with the latter. The resultant 
chromatography conditions produced a good separation of 1-methylhistidine, histidine, anserine 
and carnosine as shown in Figure 3.1. The retention times for 1-methylhistidine, histidine, 
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anserine and carnosine were 4.6,5.8,7.4 and 9.2 min, respectively. The efficiency of the 
separation is indicated by a resolution factor. RS > 4.2 for all adjacent peaks. 
Sample deproteinization and solid-phase extraction 
Deproteinization of plasma using traditional reagents such as 1.0 M perchloric acid, 0.1% 
trifluoroacetic acid or methanol (3 -4 equivalent volumes) produce an unwanted dilution. This is 
particularly undesirable in the analysis of carnosine where the plasma concentration is known to 
be generally of the order of 10 pM. The addition of a small volume (100 µl) of a concentrated 
solution of SSA efficiently precipitates plasma protein, minimises the dilution effect and is more 
reproducible than adding SSA in solid form. Chromatography of SSA deproteinized plasma was 
inadequate for the determination of carnosine as the carnosine peak eluted within the tailing side 
of a large front peak, thus making quantification impossible at low levels. In addition, the peaks 
arising from 1-methylhistidine, histidine and anserine were entirely obscured by this large front 
peak. Furthermore, large peaks evolving from well retained compounds continued to appear in 
the chromatogram up to 22 min after sample injection and only after this time did the base line 
absorbance begin a significant reduction towards the pre-injection value. SPE was employed to 
provide pre-chromatography sample clean-up. A variety of methodologies were investigated to 
determine the effectiveness of the technique. At low pH values, carnosine (and the other 
imidazole molecules) exist as cationic species. The degree of ionization of the imidazole ring 
and the terminal amine group approaches 100% at pH 2.0. This property was exploited by use of 
a cation-exchange mechanism for sorbent extraction. The requirement for an acid environment 
throughout the extraction procedure was simplified by the inherent acidic nature of the SSA 
deproteinized plasma and by the requirement for an acidic final extract to provide good 
chromatography in the pH 2.0 mobile phase. Using the SPE method described, an excellent 
purification of the deproteinized plasma was achieved, and few, if any, interference peaks were 
present in the final extract. The contrast in sample quality between pre- and post-SPE is 
demonstrated for a typical equine plasma extract in Figure 3.2. 
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Figure 3.1 HPLC separation of a mixed standard containing 1-methylhistidine, histidine, 
anserine and carnosine. 
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Figure 3.2 HPLC separation of a SSA extract of equine plasma: A) Pre-SPE. B) Post-SPE. 
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Spiking of a final equine plasma extract with a mixed standard, prepared from authentic 
compounds, produced only single peaks for putative carnosine and histidine endogenous to 
plasma , as shown in Figure 3.3. Peaks 
for anserine and 1-methylhistidine in the spiked extract 
were absent in the normal final extract. Spiked canine plasma extracts displayed single peaks for 
each of the imidazoles. 
Standards 
Standard curves for carnosine and the other imidazoles showed a linear relationship between 
peak height and concentration in the range 5- 30 yiM. The linear regression equations for each 
compound were 1-methylhistidine, y=6.21x + 0.61 (. r> 0.99); histidine, y=5.91x + 0.14(r> 
0.99); anserine, y=5.48x + 0.54 (r > 0.99); carnosine, y=4.65x + 0.11 (r > 0.99) where y= 
peak height (mm) and x= concentration (QCM). 
Recovery and reproducibility studies 
Overall recoveries (mean ± CV, %) from spiked plasma were 1-methylhistidine, 103.7 ± 9.4 %; 
histidine, 105.4 ± 9.9 %; anserine, 97.0 ± 4.4 %: carnosine. 101.8 ± 9.4 %. This deproteinization 
and extraction technique provided a highly selective determination of the biogenic plasma 
imidazoles. 
Values for typical intra-assay and inter-assay variation are given in Tables 3.1 and 3.2, 
respectively. In these tables, imidazole concentrations above 25 µM are a consequence of the 
endogenous plasma content. The mean intra-assay coefficients of variation (CV) were 7.9% or 
less for the compounds of interest in spiked plasma. Inter-assay mean CV were 6.4% or less for 
the compounds of interest. 
Lower detection Limits 
Lower detection limits for 1-methylhistidine, histidine, anserine and carnosine were 58.3,65.9, 
71.5 and 80.1 nM, respectively. 
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Figure 3.3. HPLC separation of a SSA extract of plasma spiked with a mixed standard 
containing 1-methylhistidine, histidine, anserine and carnosine. 
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Table 3.1 Intra-assay precision and accuracy for the determination of the biogenic 
imidazoles in equine plasma. 
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Table 3.2 Inter-assay precision and accuracy for the determination of the biogenic 
imidazoles in equine plasma. 
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Equine plasma extracts were also injected and analysed at 254 nm and 280 nm, however, no 
peaks were present in the chromatograms. No detectable peaks at these two wavelengths is clear 
evidence for the absence of interfering compounds such as; purine nucleotides, nucleosides and 
bases, tyrosine, phenylalanine. tryptophan and their metabolites, and other aromatic species. 
The HPLC method developed provided a rapid, selective, sensitive and reproducible analysis of 
carnosine, histidine, anserine and 1-methylhistidine in plasma. 
3.3 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF 
IMIDAZOLE DIPEPTIDES, HISTIDINE, 1-METHYLHISTIDINE AND 3- 
METHYLHISTIDINE IN EQUINE TISSUES AND INDIVIDUAL MUSCLE FIBRES 
Dunnett and Harris (1995b) 
3.3.1 Introduction 
Several HPLC methods have been developed to determine imidazole compounds in tissue 
samples. The techniques employed include ion-exchange elution with UV detection (Abe and 
Ohmama 1987) or with derivatization and fluorescence detection (Carnegie et al. 1983), isocratic 
reversed-phase elution with UV detection (O'Dowd et at. 1988; O'Dowd et al. 1992), iso-cratic 
reversed-phase elution with pre-column derivatization and fluorescence detection (Kasziba et at. 
1988), combined reversed-phase and ion-exchange gradient elution with pre-column 
derivatization and fluorescence detection (Teahon and Rideout 1992), and reversed-phase 
gradient elution with pre-column derivatization and fluorescence detection (Wideman et at. 
1978; Godel et al. 1984; Qureshi et al. 1984; Boon et al. 1989). 
Since reversed-phase HPLC of o -phthaldialdehyde / 2-mercaptoethanol pre-column derivatized 
amino acids was introduced (Lindroth and Mopper 1979), various modifications have been 
incorporated into the technique. Initially the only imidazole measured was histidine (Jones et al. 
1981; Godel et al. 1984), although subsequent alterations made possible the additional 
measurement of 1-methylhistidine and 3-methylhistidine (Jones and Gilligan 1983). Later 
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modifications to the separation parameters and the derivatization chemistry (substituting 3- 
mercaptopropionic acid for 2-mercaptoethanol) enabled the resolution of histidine, 1- 
methylhistidine and 3-methylhistidine and carnosine in extracts of plasma, tissues and urine 
(Qureshi et at. 1984; Jones and Gilligan 1983, Qureshi et at. 1986; Furst et at. 1990). These 
methods, however, were not developed for the specific analysis of imidazole-derived amino acids 
and small peptides. In an attempt to provide specificity in the analysis of carnosine, anserine and 
3-methylhistidine, reversed-phase HPLC of o-phthaldialdehyde / 3-mercaptopropionic acid 
(OPT) derivatives has been adapted by incorporating column-switching (Teahon and Rideout 
1992). 
None of the previous methods encompassed all of the imidazoles. A new method was developed 
which combined solid-phase extraction, reversed-phase HPLC with binary gradient elution, 
automated pre-column derivatization with o-phthaldialdehyde / 3-mercaptopropionic acid, and 
fluorescence detection to enable the selective determination of carnosine, anserine, balenine, 
homocarnosine, histidine, 1-methylhistidine and 3-methylhistidine in tissue extracts within a 
single chromatographic run. In conjunction with a micro-extraction technique the method 
allowed the quantification of the compounds of interest in individual skeletal muscle fibres, 
where sample weights can be as low as 0.8 pg. 
3.3.2 Experimental 
Instrumentation and reagents 
The HPLC system comprised two Constametric 3000 pumps (LDC Analytical, Stone, Staffs., 
UK. ), a LDC high pressure solvent mixer, a Waters WISP 712 autosampler with auto-addition 
facility (Waters Chromatography, Watford, Herts., UK. ), a Spectrovision FD 300 dual 
monochromator fluorescence detector (Severn Analytical Ltd., Shefford, Beds., UK. ), a LDC MP 
3000 chromatography workstation - gradient controller, and a LDC printer. A Sepralyte ODS 
pellicular 40 µm sacrificial column (20 x 2.1 mm I. D. ) (Analytichem International, Harbor City, 
CA., USA. ) and a Rheodyne 0.5 µm in-line filter (Cotati, CA., USA. ) were connected between 
the high pressure mixer and the autosampler. 
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All reagents were analytical reagent grade unless specified otherwise (see Chapter 2). Water was 
purified by reverse osmosis and de-ionization (Elgastat Spectrum RO1, Elga, High Wycombe, 
UK. ). 
Tissue deproteinization and solid-phase extraction 
Powdered freeze-dried tissue (10.00 ± 2.00 mg) was extracted in 0.5 M perchloric acid (100 Ftl / 
mg tissue) on ice for 15 min with regular vortex mixing. The extraction mixture was centrifuged 
at 12,000 g for 5 min at ambient temperature. Tissue perchloric acid extracts (500 µl) were 
loaded onto 100 mg /1 ml Isolute PRS (propylsulphonyl) SPE columns previously conditioned 
with methanol (4 ml) followed by 1.0 M phosphoric acid (4 ml). Interfering compounds were 
washed from the columns with 1.0 M phosphoric acid (2 x 500 µl), water (500 pul) and 0.4 M 
disodium tetraborate buffer, pH 9.65 with sodium hydroxide (250 µl). The sorbent was dried 
under vacuum for two minutes. The isolates were eluted with 0.4 M disodium tetraborate buffer, 
pH 9.65 (3 x 250 µl). A flow-rate of 2 ml min-1 was used at all stages. 
Individual muscle fibre extraction 
Individual muscle fibres were extracted with 75% methanol / 25% 0.4 M disodium tetraborate 
buffer pH 9.65 (100 ytl). Extractions were performed on ice with regular vortex mixing for 15 
min whilst ensuring that the muscle fibres were permanently submerged. Extracts were frozen in 
liquid nitrogen, freeze-dried, re-dissolved in 0.4 M disodium tetraborate buffer pH 9.65 (50 pl) 
and stored at -85°C until analysis. 
Chromatography 
Chromatography was performed on a Hypersil ODS (3 ym, 150 x 4.6 mm I. D. ) analytical 
column protected by a Hypersil ODS (5 pm, 20 x 4.6 mm I. D. ) guard column, at ambient 
temperature, utilizing a binary gradient formed from Solvent A; 12.5 mM sodium acetate, pH 
7.2 (995 ml) and tetrahydrofuran (5 ml), and Solvent B; 12.5 mM sodium acetate, pH 7.2 (500 
ml), methanol (350 ml) and acetonitrile (150 ml). The 12.5 mM pH 7.2 acetate buffer was 
prepared by mixing isomolar solutions of sodium acetate and acetic acid. The solvents were 
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filtered to 0.45 jim and degassed by helium sparging prior to and throughout the analytical run. 
The mobile phase was freshly prepared for each new sample batch. The composition of the 
gradient was: 0-3 min., 0% solvent B; 20 min., 35% B; 36 min., 60% B; 40 min., 100% B; 43 
min., 100% B; 45 - 55 min., 0% B. The flow-rate was 1.0 ml min-1 and chromatographic run- 
time was 55 min. per sample. The excitation wavelength of the detector was 330 nm and the 
emission wavelength was 450 nm. The derivatization reagent was prepared by mixing 3- 
mercaptopropionic acid (80 1d) with o -phthaldialdehyde reagent solution (4 ml). The 
derivatization reagent was stored in the dark at 2"C for 24 hours before use. During the 
automated derivatization, 25 yl of the extract was mixed with 25 Ecl of reagent. The reaction 
proceeded for 90 s before injection onto the column. Fresh reagent was used with each new 
sample batch. Tissue concentrations were calculated by comparison of the integrated peak areas 
with those from a range of external standards. 
Standard preparation 
A mixed stock standard (10 mM ) solution containing histidine, 1-methylhistidine, 3- 
methylhistidine, anserine, carnosine, balenine and homocarnosine was prepared by dissolving the 
required weight of each compound in HPLC grade water (10 ml). Working standard solutions 
were prepared over the concentration range 0.010 - 1.000 mM by dilution of the stock standard 
with borate buffer. The stock standard solution was stored at -20°C when not used. 
Recovery study 
Aliquots of pooled perchloric acid extracts of freeze-dried powdered diaphragm muscle were 
spiked with a mixed standard containing imidazole dipeptides, histidine, 1-methylhistidine and 3- 
methylhistidine. These samples were spiked to simulate tissue concentrations of 100 mmol kg-1 
DW (n = 5), 50 mmol kg-1 DW (n = 5), 5 mmol kg-1 DW (n = 5) and 1 mmol kg-1 DW (n = 5). 
Recoveries following SPE were calculated by comparison with equivalent standards. The 
concentrations of the endogenous compounds prior to spiking were determined and subtracted 
when calculating the recoveries. 
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Reproducibility study 
A perchloric acid extract of pooled diaphragm muscle was spiked with a mixed standard of 
imidazole dipeptides, histidine, 1-methylhistidine and 3-methylhistidine to simulate individual 
muscle concentrations of 100 mmol kg-1 DW. The spiked extract was divided into 25 aliquots. 
Intra-assay variation of the combined SPE and HPLC analysis was determined by repeated 
injections (n = 5) of the SPE eluates on three occasions within day 1. Inter-assay variation was 
determined by repeated injections (n = 5) of the SPE eluates on day 1, day 5 and day 10. 
Lower detection limits 
The lowest levels of detection for the imidazole dipeptides, histidine, 1-methylhistidine and 3- 
methylhistidine were quantified by injecting of 100 Id of a mixed standard which resulted in FSD 
at a detector sensitivity setting of 20 nA. The minimum area reliably measurable was 3000 area 
units which approximated to a5 mm peak at a signal to noise ratio of 3: 1. The concentration of 
the minimum peak was interpolated from the mixed standard. 
3.3.3 Results and discussion 
Chromatography 
Use of pre-column derivatization with OPT for the HPLC analysis of amino acids and primary 
amines in physiological samples can produce detailed chromatograms containing as many as 30 - 
40 peaks (Turnell and Cooper 1982). Such complexity may be advantageous, for example in the 
clinical diagnosis of aminoacidaemias (Moretti et al. 1990) and muscle amino acid profiles 
during uraemia (Qureshi et al. 1989), however, poor resolution between certain amino acid pairs 
makes it difficult to accurately quantify the area of either peak. 
Previously published chromatographic methods applied to the determination of imidazole 
dipeptides, histidine, 1-methylhistidine and 3-methylhistidine in equine tissue extracts failed to 
resolve all the compounds of interest. Various combinations of columns (Apex Phenyl 5 pm, 
Apex ODS 5 pm, Spherisorb ODS 25 pm and 3 pm, Hypersil ODS 3 µm, Hypersil ODS HC 3 
pm and Primesphere ODS 3 pm) and mobile phases (10 mM, 12.5 mM and 25 mM acetate, 
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phosphate and mixed acetate / phosphate buffers) were evaluated to optimize the resolution of 
the imidazole compounds from interfering amino acids. An acceptable resolution of the seven 
imidazole standards alone could not be achieved using the 5 µm packed columns. The optimal 
separation of the imidazole dipeptides, histidine, 1-methylhistidine and 3-methylhistidine from 
22 amino acids (including taurine, ß-alanine and GABA) was achieved using the Hypersil ODS 3 
/im column in conjunction with the 12.5 mM acetate buffer binary gradient. As shown in Figure 
3.4, the final chromatographic parameters resulted in a good separation of the imidazole 
dipeptides, histidine, 1-methylhistidine and 3-methylhistidine, although base-line separation was 
not quite achieved between 1-methylhistidine and 3-methylhistidine. Retention times for the 
individual compounds were: histidine, 20.19 min. ; 1-methylhistidine, 21.82 min. ; 3- 
methylhistidine, 22.23 min. ; anserine, 26.43 min. carnosine, 27.45 min. ; balenine, 30.08 min. ; 
homocamosine, 31.71 min. 
Solid-phase extraction 
During the analysis of physiological samples for low levels of the compounds of interest there is 
the possibility of impaired resolution from citrulline, alanine, taurine and arginine when these 
amino acids are present at relatively much higher concentrations. SPE employing a benzene 
propylsulphonyl bonded phase had been used for the extraction of amino acids from urine 
(Moodie et al. 1989), however, this procedure did not discriminate between different classes of 
amino acids. The presence of the benzene ring in the bonded phase may also induce secondary 
non-polar interactions thus complicating the adaptation of this method. A propylsulphonyl 
strong cation-exchange bonded phase was previously shown to be effective in retaining biogenic 
imidazole compounds from acidic plasma extracts (Dunnett and Harris 1992). SPE was adopted 
to provide a selective extraction of the imidazole dipeptides, histidine, 1-methylhistidine and 3- 
methylhistidine from the other amino acids and small peptides present in tissues. The present 
SPE method proved highly selective for the imidazole compounds. Most amino acids, including 
citrulline, alanine and taurine, were absent from the final extract, however arginine (26.01 min. ) 
was fully recovered. Chromatograms of perchloric acid extracts of myocardium pre- and post- 
SPE are shown in Figure 3.5 and gluteus medius muscle post-SPE in Figure 3.6. 
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The SPE resulted in an effective concentration of the analytes as separate neutralization and 
buffering (pH 9.65) of the perchloric acid extracts was avoided. Post SPE extracts of equine 
tissues were spiked with a mixed standard of the authentic compounds. Subsequent HPLC 
produced only single peaks at the retention times for the putative compounds. 
Standards 
The standard curves demonstrated a linear relationship between integrated peak area and 
concentration in the range 0.010 - 1.000 mM. Linear regression equations for each compound 
were: histidine, y= 65510x + 103 (r = 0.998); 1-methylhistidine, y= 103497x + 1164 (r = 
0.997); 3-methylhistidine, y= 100599x + 3682 (r = 0.996); anserine. y= 257649x + 2977 (r = 
0.997); carnosine, y= 247476x + 833 (r = 0.997); balenine, y= 211263x + 5845 (r = 0.995), and 
homocarnosine, y= 294440x + 2597 (r = 0.995). (y = integrated peak area in arbitrary units, x= 
concentration, mM). 
Recovery and reproducibility studies 
The overall recoveries (mean ± CV, %) of the imidazole compounds from spiked tissue samples 
following SPE are shown in Table 3.3. Excellent recoveries were obtained for all the compounds 
of interest. The intra-assay and inter-assay reproducibility (mean ± SD and CV, %) of the 
combined SPE-HPLC analysis of the compounds of interest are given in Tables 3.4 and 3.5, 
respectively. The intra-assay mean CV for all the compounds of interest in spiked muscle 
extracts ranged from 1.2 - 6.3% . The inter-assay mean 
CV ranged from 1.7 - 2.9%. 
Lower detection limits 
Lower limits of detectability determined for 100 yl injected at a detector sensitivity setting of 20 
nA FSD were 0.010 mmol kg-' DW (1.6 pmoles on column) for histidine, 1-methylhistidine and 
3-methylhistidine, and 0.005 mmol kg-' DW (0.8 pmoles on column) for carnosine, anserine, 
balenine and homocarnosine. Detector sensitivity settings at 10 nA FSD or less resulted in 
unacceptable signal-to-noise ratios. Injection volumes greater than 100 µl resulted in peak 
broadening and reduced resolution between 1-methylhistidine and 3-methylhistidine. 
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Individual fibre extraction validation 
Owing to the extremely low sample weights, typically 0.8 - 8.0 Fig, it was necessary to minimize 
the sample extract volume by maximizing detector response. The sample extracts were therefore 
concentrated by freeze-drying and re-dissolution. As perchloric acid cannot be removed by 
freeze-drying an alternative solvent for tissue extraction had to be found. Comparative 
extractions of freeze-dried powdered middle ýluteal muscle (1 mg m1-') between perchloric acid 
and 3 alternative solvents were performed (n =4 for each solvent). The relative recoveries of 
carnosine in three alternative solvents compared to perchloric acid were, 100.9% (75% methanol 
/ 25% 0.4 M borate buffer pH 9.65), 87.3% (75% acetonitrile / 25% 0.4 M borate buffer pH 
9.65) and 101.0% (4% sulphosalicylic acid). Comparative extractions between perchloric acid 
and 75% methanol / 25% 0.4 M borate buffer were made in 12 individual equine muscle fibres. 
Each fibre was halved; one half was extracted with perchloric acid the other with methanol- 
borate buffer. The mean (± SD) carnosine in the perchloric acid extracted fibres and the 
methanol / borate buffer extracted fibres, 46.94 ± 9.66 mmol kg -I DW and 47.21 ± 11.44 mmol 
kg-' DW were not significantly different (p>0.05). 
The present SPE-HPLC method developed and validated for the isolation and quantification of 
carnosine, anserine, balenine, homocarnosine, histidine, 1-methylhistidine and 3-methylhistidine 
in equine tissues and individual muscle fibres across a broad concentration range in tissue 
samples weighing from <1 pg to 10 mg proved to be selective, sensitive and reproducible. This 
method avoids the interference from other physiological amino acids and small peptides 
associated with earlier techniques and for the first time enables the resolution of all seven 
compounds within a single chromatographic run. 
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Figure 3.4 HPLC separation of a mixed standard containing the imidazole dipeptides, 
histidine, 1-methylhistidine and 3-methylhistidine. 
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Figure 3.5 HPLC separation of a perchloric acid extract of myocardium: A) Pre-SPE. B) 
Post-SPE. 
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Figure 3.6 HPLC separation of a perchloric acid extract of equine middle gluteal muscle 
post-SPE. 
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Table 3.3 Mean recoveries ± CV(%) of the imidazoles from muscle. 
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Table 3.4 Intra-assay precision and accuracy for the determination of imidazoles in muscle. 
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Table 3.5 Inter-assay precision and accuracy for the determination of imidazoles in muscle. 
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3.4 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC ANALYSIS OF N-a- 
ACETYLCARNOSINE IN EQUINE PLASMA 
3.4.1. Introduction 
Owing to the absence of a free primary amine group in N-a-acetylcarnosine plasma 
concentrations could not be determined by high-performance liquid chromatography (HPLC) 
with fluorescence detection following derivatization with o -phthaldialdehyde/3- 
mercaptopropionic acid or fluorescamine. Concentrations of N-a-acetylcarnosine and 
acetylamino acids have been determined in skeletal muscle, myocardium and brain of several 
species, including the rat, frog and rabbit. The analytical techniques employed for the analysis 
included thin layer chromatography (TLC) (Sobue et al. 1975), HPLC (O'Dowd et al. 1992; 
O'Dowd et al. 1990; O'Dowd et al. 1988) and more recently liquid chromatography-mass 
spectrometry (LC-MS) (Sugahara et at. 1994). However, these methods were not developed for 
the analysis of plasma and with the exception of the latter technique the earlier methods lacked 
the necessary sensitivity to quantify low concentrations of the compounds of interest in plasma. 
A new analytical method which combined isocratic reversed-phase HPLC with SPE to provide 
rapid, selective and sensitive detection of N-a-acetylcamosine in equine plasma was developed. 
3.4.2. Experimental 
Instrumentation and reagents 
The HPLC system comprised a Hewlett-Packard HP1050 quaternary-gradient solvent delivery 
system, a Rheodyne 7125 injector (with 200 jtl volume sample loop), a HP1040 diode array 
detector, a Hewlett-Packard Chemstation and Thinkjet printer. A Sepralyte ODS 40 Jim (30 x 
4.6 mm) sacrificial guard column (Analytichem International, Habor City, CA, USA) and a 
Rheodyne in-line filter (0.5 yim pore size) were inserted between the pump and the injector. 
All reagents were analytical reagent grade unless specified otherwise (see Chapter 2). Water was 
purified by reverse osmosis and de-ionization (Elgastat Spectrum RO1, Elga, High Wycombe, 
UK. ). 
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Deproteinization and solid-phase extraction 
Plasma (250 pit) was deproteinized and extracted with 1.2 M perchloric acid in 1.0 A'1 
phosphoric acid (350 p1 ), vortex-mixed. centrifuged and the supernatant collected. The 
precipitate was re-extracted with 1.0 M phosphoric acid (400 fil). The supernatants were 
combined. N-a-acetylcarnosine was isolated from interfering substances by SPE. Plasma 
extracts (250 }il) were loaded onto 1 ml / 100 mg Isolute PRS (propylsulphonyl) strong cation- 
exchange columns previously conditioned with methanol (3 x 1000 p1. ) and 1.0 M phosphoric 
acid (3 x 1000 pl. ). Columns were washed with 50 mM potassium dihydrogen phosphate 
(KH1PO4), pH 2.5 (2 x 250 p1) and air-dried for 2 min. The analyte was eluted with 100 mM 
KH, PO. t, pH 2.5 (2 x 250 pal). A flow-rate of 0.5 ml min-I was used at all times. 
Chromatography 
HPLC of N-a-acetylcarnosine was performed on a Hypersil ODS (3 µm, 150 x 4.6 mm) 
analytical column protected by a Hypersil ODS (5 µm, 20 x 4.6 mm) guard column. N-a- 
acetylcarnosine was eluted using a mobile phase comprising 5 mM phosphoric acid and 1 mM 
triethylamine, pH 2.5 in HPLC grade water. The mobile phase was filtered to 0.45 pm and 
degassed by helium sparging prior to and continually during use. The mobile phase was freshly 
prepared each day. The flow-rate was 0.8 ml min-1 and the injection volume was 200 µ1. 
Detection was by UV absorbance at 220 nm. 
Standards 
A1 mM stock standard of N-a-acetylcarnosine was prepared by dissolving the required weight 
in HPLC grade water (10 ml). Working standards over the concentration range 0.1 - 100.0 pM 
were prepared daily by dilution of the stock standard with 100 mM KH, P04 buffer, pH 2.5. 
Recoveries study 
Plasma was spiked at 800 pM and 0.8 QCM with a standard containing N-a-acetylcarnosine, to 
produce nominal concentrations in the final eluate of 100 and 0.1 pM , assuming recoveries of 
100%. Extraction recoveries (n = 5), at each concentration, for the combined deproteinization 
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and SPE were determined by comparing concentrations found in the final eluates with standards 
at the nominal concentrations. 
Reproducibility studv 
The reproducibility of the method was assessed by calculation of the intra- and inter-assay 
accuracy and precision. Plasma was spiked with N-a-acetylcarnosine at 800'uM and 0.8 jiA'! 
concentrations. The precision of the method was derived from intra- and inter-assay coefficients 
of variation (CV) of replicate analyses (n = 5) at each concentration. The accuracy of the assay 
was expressed as: (measured concentration / nominal concentration). 100. Inter-assay CV were 
determined by analysis on days 1,5 and 10 over a 10-day period. 
Lower detection limit 
The lower limit of detection for N-a-acetylcarnosine was quantified by injecting 200 µl of a 10 
pM standard which resulted in FSD at a detector sensitivity setting of 10 mAU. The minimum 
area reliably measurable was 30 area units which approximated to a5 mm peak at a signal to 
noise ratio of 3: 1. The concentration of the minimum peak was interpolated from the standard 
curve. 
3.4.3. Results and discussion 
Chromatography and solid-phase extraction 
A method developed for the determination of N-a-acetylcarnosine in tissue samples (O'Dowd et 
al. 1988) which utilized 100 mM sodium dihydrogen phosphate, pH 2.0 buffer as the mobile 
phase, was applied to the measurement of these analytes in equine plasma. However, this proved 
unsuccessful. Spiked plasma samples indicated an interfering peak co-eluting with N-a- 
acetylcarnosine. Furthermore, N-a-acetylcarnosine exhibited poor peak symmetry; the 
asymmetry factor was 2.56. The degree of interference was reduced and retention time increased 
by using a mobile phase containing only 5 mM phosphoric acid. The inclusion of triethylamine 
at 20% of the phosphate concentration further improved peak symmetry; asymmetry factor was 
1.07. However, triethylamine concentrations >1 mM had an adverse effect. The combination 
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of 5 mM phosphoric acid. and 1 mN/ triethylamine resulted in the pH 2.5 solution. No further 
mobile phase pH adjustment was made and the batch-batch reproducibility of pH was excellent. 
Analytical columns with several different ODS 3 /im stationary phases were assessed during 
method development, including Spherisorb, Apex. Primesphere and Hypersil. The latter 
provided superior performance in terms of resolution and peak symmetry. The retention time for 
N-a-acetylcarnosine was 5.25 min. 
Complete resolution of the N-a-acetylcarnosine peak from the interfering peak was not achieved 
by column selection alone, and it proved necessary to employ SPE to achieve the sample purity 
required for accurate quantification of the N-a-acetylcarnosine peak. Despite the absence of a 
charged terminal amine group on N-a-acetylcarnosine unlike carnosine, the presence of a 
positive charge on the imidazole ring allowed sufficient retention on cation-exchange sorbents. 
Optimum retention was obtained on PRS sorbent. The use of 50 and 100 mM. phosphate buffers 
for washing the SPE column resulted in a significant reduction in the number of interfering 
compounds in the final eluate. A comparison of plasma extracts pre- and post SPE is shown in 
Figure 3.8. 
Standards 
The standard curve demonstrated a linear relationship between concentration and integrated peak 
area. The linear regression equations for the N-a-acetylcarnosine standard curve was y= 
11.713x - 0.028 (r = 0.999), where y= peak height (mm) and x= concentration (JIM). 
Lower detection limit 
The lower limit of detection in plasma was 0.1 jiM. 
Recovery and reproducibility studies 
Mean (± CV) recoveries of N-a-acetylcarnosine from equine plasma at 800 pM and 0.8 pM 
concentrations were 93.9 ± 5.0% and 99.7 ± 0.5%, respectively. The intra- and inter-assay 
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accuracy and precision of the combined SPE and HPLC method at high and low concentrations 
are given in Table 3.6. 
The combined SPE procedure and isocratic reversed-phase HPLC method developed provided a 
selective, sensitive and reproducible analysis of N-a-acetylcarnosine concentrations in equine 
plasma. 
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Figure 3.7. HPLC separation of a of N-a-acetylcarnosine standard. 
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Figure 3.8. HPLC separation of a perchloric acid extract of plasma; A) Pre-SPE. 
B) Post-SPE. 
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Table 3.6 Intra- and inter-assay accuracy and precision of the N-a-acetyicarnosine analysis. 
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Concentration Intra-assay (n = 5) Inter-assay (n= 15) 
Mean ± SD CV Mean ± SD CV 
100 µN1 
0.1yiM 
98.3 ± 3.3 3.4 93.9 ± 3.4t 3.6 
100.1 ±0.1-, ' 0.1 99.8±0.1 i 0.1 
= Pooled SD. 
CHAPTER 4. 
CARNOSINE DISTRIBUTION IN TYPE I, IIA AND JIB FIBRES IN THE MIDDLE GL UTEAL 
MUSCLE, AND OTHER TISSUES OF THE THOROUGHBRED HORSE. 
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4.1 INTRODUCTION 
Carnosine and the other imidazole dipeptides, with the exception of homocarnosine, occur at 
high concentrations, often in excess of 100 mmol kg-1 DW, within the skeletal muscles of many 
mammalian species (Crush 1970; Carnegie et at. 1983; Plowman and Close 1988). Carnosine 
also occurs at low millimolar concentrations in other organs such as, the heart, and liver, and 
tissues of, the CNS and gastro-intestinal tract (GIT). Accordingly additional roles, other than 
acid-base regulation, have been ascribed to carnosine. For example, millimolar concentrations of 
both carnosine and homocarnosine have been detected in various regions of the central nervous 
systems of several species (Margolis 1974; Margolis and Grillo 1984). Carnosine is particularly 
abundant in the olfactory bulb and epithelium of mice and rats (Wideman et at. 1978). It has 
been fairly well established that both carnosine and homocarnosine function as 
neurotransmitters/neuromodulators in the CNS, and that this role for carnosine is particularly 
significant within the olfactory pathway (Margolis 1980; Margolis 1981). Owing to the presence 
of significant amounts of carnosine in certain tissues it has been proposed that carnosine may 
represent a reservoir of histamine since its catabolism involves hydrolysis to histidine and 
subsequent decarboxylation to histamine (Flancbaum et al. 1990). 
Species which possess high intra-muscular concentrations of these dipeptides are generally 
characterized by an adaptation to either high speed running, such as the horse, or to prolonged 
periods of hypoxia, such as the whale, where muscle contraction is reliant upon a rapid anaerobic 
turnover of ATP. Without an integrated system for the maintenance of acid-base balance, the 
consequential production and accumulation of H+ ions within the working muscle cells would 
result in a rapid reduction in intra-cellular pH with a concomitant impairment of the contractile 
process. The imidazole dipeptides have pKa values in the range 6.8 to 7.1 enabling them to 
function as effective proton buffers over the physiological pH range (Bate-Smith 1938; Davey 
1960a; Harris et al. 1990; Sewell et al. 1990). Maintenance of intra-muscular acid-base status 
during exercise may be as important to athletic performance as the ability to transport oxygen via 
the cardio-vascular system. 
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It has been shown that within a species the highest carnosine concentrations are found in skeletal 
muscles which have the greatest proportion of type II fibres (Tamaki et al. 1976; Castelini and 
Somero 1981). Sewell et at. (1990) used multiple linear regression analysis to estimate the 
carnosine concentrations in types 1, IIA and JIB fibres from mixed fibre samples taken from the 
middle gluteal muscles of horses of different ages and training status. The estimated carnosine 
concentrations were 21,86 and 116 mmol kg-1 DW in type I, IIA and IIB fibres, respectively. 
The same approach was used in a comparative study, where muscle samples were obtained by 
percutaneous biopsy exclusively from young highly trained horses. Estimated carnosine 
concentrations in this study were found to be higher in type I and IIB fibres, than in the previous 
study. The estimated carnosine concentrations in type 1, IIA and IIB fibres were 54,85 and 180 
mmol kä t DW, respectively (Sewell et al. 1992). 
Taurine, a ß-amino acid (2-aminoethanesulphonic acid), is found in most vertebrate tissues and at 
millimolar concentrations in excitable tissues such as skeletal muscle, heart and CNS (Jacobson 
and Smith 1968). Skeletal muscle accounts for an estimated 75 % of the total body taurine pool 
(Stern and Stim 1959). Significant variation in taurine concentration exists between different 
muscles within and between species. Human muscle taurine concentrations range 8.0 - 21.6 
mmol kg-I DW (Zachmann et al. 1966) and in the rat values are higher and the range greater; 28.0 
- 83.2 mmol kä-1 DW (Airaksinen et a!. 1990). The soleus muscle of the rat, a predominantly 
slow-twitch muscle, has a two-fold higher taurine content than the extensor digitorum longus, a 
predominantly fast-twitch glycolytic muscle (Iwata et al. 1986). This suggested that an inverse 
relationship existed between the carnosine and taurine contents of a given muscle which may 
have been related to the relative proportions of type I (slow-twitch) and type II (fast-twitch) 
fibres within a given muscle. Subsequent studies in both young highly trained horses and older 
horses of variable training status indicated that taurine concentrations in equine skeletal muscle 
were strongly correlated to type I% FSA (p<0.001, r=0.94) and that type I fibres were 
estimated to contain 35.4 - 45.4 mmol kä-1 DW of taurine, whereas type IIA fibres contained only 
4.5 - 7.9 mmol kg-1 DW, and taurine appeared to 
be absent from type IIB fibres (Dunnett et al. 
1992). 
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4.2 STUDY A: CARNOSINE CONCENTRATIONS AND CARNOSINASE ACTIVITIES 
IN OTHER EQUINE TISSUES 
4.2.1 Objectives 
The aims of this study were to determine the carnosine concentrations and carnosinase activities 
in various equine skeletal muscles and other tissues. 
4.2.2 Experimental methodology 
Sampling procedure 
Samples from tissues were collected at post mortem, as described in Chapter 2, from eighteen 
thoroughbred horses aged from 7 months to 4 years and from two foetuses. 
Analytical methods 
Tissue extracts were analysed for carnosine and other imidazole concentrations by high- 
performance liquid chromatography as described in Chapter 3 (Dunnett and Harris 1995). Tissue 
carnosinase activity was determined by a modification of the method of Lenney (1990), as 
described in Chapter 2. 
4.2.3 Results 
Samples were collected from the following tissues; myocardium, kidney, liver, spleen, 
cerebellum, medulla, lung, stomach, small intestine, colon and rectum. Mean (± SD) tissue 
concentrations of carnosine and histidine, and tissue carnosinase activities are presented in Table 
4.1. Mean values for carnosine concentrations determined in middle gluteal and internal 
intercostal muscle samples are included for comparative purposes. Carnosine was present at 
much lower concentrations in myocardium, kidney, liver, spleen, lung and tissues from the CNS 
and GIT, than those found in typical locomotory skeletal muscles such as the middle gluteal. 
The carnosine concentration in the diaphragm is two to three-fold lower than the concentration 
typically found in mixed fibre samples from the middle gluteal muscle. However, the diaphragm 
carnosine concentration is similar to the value found in type I skeletal muscle fibres. Carnosine 
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concentrations measured in cardiac muscle (myocardium) and smooth muscle (small intestine, 
colon, stomach and rectum) were twenty-fold or more lower than those found in diaphragm. 
Anserine and balenine were also detected in equine skeletal muscle and diaphragm at 
concentrations two to three orders of magnitude lower than for carnosine. Anserine was present 
at 0.66 ± 0.27 and 0.66 ± 0.13 mmol kß-1 DW in the middle äluteal and intercostal muscles, 
respectively, and at 0.82 ± 0.10 mmol kg-1 DW in the diaphragm. Balenine was present at 0.20 ± 
0.06 and 0.10 ± 0.05 mmol kg-! DW in the middle gluteal and intercostal muscles, respectively, 
and at 0.08 ± 0.03 mmol kä-' DW in the diaphragm. Anserine and balenine were not detected in 
other tissues. Homocarnosine was detected only in tissues from the CNS. It was present at 
concentrations of 0.09 ± 0.09 and 0.04 mmol kg-1 DW in cerebellum and medulla, respectively. 
Trace amounts only of 1-methylhistidine were present in skeletal muscle and it was not detected 
in other tissues. No free 3-methylhistidine was detected in muscle samples although it is a 
constituent of the contractile proteins, actin and myosin. 
Tissue carnosinase activities were highest in the kidney, and other tissues exhibiting relatively 
high activities were, the small intestine, spleen and lung. Carnosinase activity in the middle 
gluteal muscle, internal intercostal muscle and the diaphragm was below the lower limit of 
quantification of the assay (1.4; mol g-1 h-1 DW). 
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Table 4.1 Carnosine and histidine concentrations, and carnosinase activities in 
various tissues of the thoroughbred horse. 
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Tissue n Carnosine 
(mmol kg-' DW) 
Histidine 
(mmol ka-' DW) 
Carnosinase 
(jimol 1h DW) 
Middle gluteal 7 107.81 ± 12.87 0.25 ± 0.05 ND 
Internal intercostal 3 63.70 ± 16.16 0.39 ± 0.01 ND 
Diaphragm 5 38.62 ± 5.09 0.60 ± 0.36 ND 
Stomach 2 2.43 ± 0.80 1.30 ± 0.06 4.2 ± 3.3 
Myocardium 6 2.22 ± 1.21 0.56 ± 0.06 3.0 ± 2.5 
Rectum 1 1.27 1.57 4.4 
Small intestine 11 0.93 ± 0.47 1.44 ± 0.41 22.9 ± 17.7 
Colon 1 0.58 1.46 3.6 
Lung 2 0.43 ± 0.05 0.86 ± 0.52 13.7 15.1 
Kidney 7 0.13 ± 0.04 0.33 ± 0.10 604.0 ± 24.2 
Spleen 3 0.12±0.07 0.61 ±0.14 23.7± 7.3 
Liver 8 0.11 ± 0.05 0.90 ± 0.43 5.6 ± 2.0 
Cerebellum 9 0.04 ± 0.03 0.25 ± 0.10 1.8 ± 1.4 
Medulla 1 0.04 0.40 ND 
ND = Not detected 
4.3 STUDY B: CARNOSINE AND TAURINE CONTENTS IN TYPE I, IIA AND IIB 
FIBRES IN THE MIDDLE GLUTEAL MUSCLE OF THE NORMAL 
THOROUGHBRED HORSE. 
Dunnett and Harris (1995a) 
4.3.1 Objectives 
The aims of the present study was to determine by direct measurement the carnosine and taurine 
concentrations in type I, type IIA and type IIB fibres from the middle gluteal muscle of the 
thoroughbred horse, and to assess whether taurine : carnosine ratios could be used as a 
biochemical means for determining fibre type in individual muscle fibres. 
4.3.2 Experimental methodology 
Protocol and sampling procedure 
Muscle samples from the left or right middle gluteal muscle were collected at post mortem from 
5 thoroughbred horses (3 colts, 2 geldings) which had no history of muscle disorders. The horses 
were aged between 2 and 13 years and had a variety of training backgrounds. However, all the 
horses had been out of training for at least 6 months. All of the horses were euthanased having 
failed to respond to treatment for a variety of chronic conditions. One entire middle gluteal 
muscle was removed from each horse and samples were collected, as described in detail in 
Chapter 2. Owing to the relatively low abundance of type I fibres within equine middle gluteal 
muscle, the number of individual type I fibres retrieved was maximized by selecting some of the 
darker (more red) samples for dissection. Individual muscle fibres were dissected from freeze- 
dried muscle samples as described in Chapter 2. 
Histochemistrv 
Fragments of individual muscle were characterized as either type 1, IIA or 1113 by histochernical 
staining for myosin ATPase activity at pH 9.6 following pre-incubation at pH 4.50 as described 
previously (Chapter 2). 
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Individual muscle fibre analysis 
Weighed individual muscle fibres were extracted and analysed for carnosine and taurine content . 
simultaneously by reversed-phase high-performance liquid chromatography, as described in 
Chapter 3 (Dunnett and Harris 1995b). 
Statistics 
Data on the mean carnosine and taurine concentrations of each fibre type are given together with 
a pooled estimate of the within-horse standard deviation (SDp). SDp was calculated using the 
equation 
SDP ='(lSSQh / Enh-1) 
where SSQh is the sum of squares calculated within each horse and nh-1 is the degrees of 
freedom upon which this value is based. Analysis of carnosine and taurine distribution in type I, 
IIA and IIB fibres was performed by normalization of individual values which enabled data from 
all horses to be combined. Individual values were divided by the mean value for that horse and 
the results were normalized by multiplying by the overall mean value for all horses. Type I, IIA 
and I113 fibres were treated independently. One-factor ANOVA was used to identify significant 
differences in mean (± SD) values for carnosine and taurine concentrations, and taurine : 
carnosine ratios between type I, IIA and IIB fibres. In the instance where significance was 
detected a multiple comparison test was applied, Fisher's Protected Least Significant Difference 
(PLSD) was applied. Significance was declared at p<0.05. 
4.3.3 Results 
Carnosine and taurine concentrations were determined in a total of 324 individual muscle fibres 
taken from the middle gluteal muscle of 5 thoroughbred horses (FO, TI, DP, GI, EX) at post 
mortem. The number of fibres and mean (± SD) carnosine and taurine concentrations in type I, 
[IA and IIB muscle fibres for individual horses, and mean values (± SDp) for all horses combined 
are given in Tables 4.2 and 4.3, respectively. No carnosine was detected in the type [ fibres of 
one horse (EX), however, this may have been due to an unrepresentative population as only 2 
type I fibres were found in the samples from this horse. Distribution plots of carnosine and 
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taurine concentrations in type I, IIA and IIB fibres from the middle gluteal muscle of the 
individual horses are given in Figures 4.1 and 4.2, respectively. Carnosine concentrations were 
significantly different between the three fibre types (p<0.001). The overall mean (t SDI, ) 
carnosine concentrations in type I, type IIA and type LIB fibres were 24.9 ± 6.4 , 94.8 ± 6.8 and 
104.3 ± 11.9 mmol kg ' DW, respectively. 
There was a significant difference in taurine concentration between type I, and type IIA and 1113 
fibres (p < 0.001), but not between type [IA and type LIB fibres (p>0.05). The overall mean (± 
SDI, ) taurine concentrations in type I. type IIA and type IIB fibres were 54.3 ± 8.3 , 2.8 ± 2.1 and 
1.8 ± 1.9 mmol kg-1 DW, respectively. Taurine: carnosine ratios for individual horses and overall 
mean (± SDp) values are given in Table 4.4. Taurine: carnosine ratios between type I fibres, and 
type I[A and IIB fibres were significantly different (p<0.001). There was however, no 
significant difference between type IIA and type LIB fibres (p>0.05). It was therefore not 
possible to discriminate between type IIA and IIB fibres by use of the taurine : carnosine ratio. 
Frequency distribution plots of normalized carnosine and taurine concentrations for all fibres 
with respect to fibre type are shown in Figures 4.3 and 4.4, respectively. 
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Table 4.2 Individual mean (± SD) carnosine concentrations in type I, IIA and IIB fibres 
from the middle gluteal muscle of 5 thoroughbred horses (FO, TI, DP, GI, EX) 
and overall mean (± SDp) concentrations for all horses. 
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Horse Carnosine, 
Type I 
mmol kg-' DW (number of fibres) 
Type IIA Type IIB 
FO 25.5 ± 6.5 (22) 85.7 ± 24.8 (14) 93.1 ±31.6 (16) 
TI 12.2 ± 6.7 (53) 99.9 ± 10.4 (7) 110.7 ± 14.2 (16) 
DP 27.3 ± 5.9 (50) 89.7 ± 10.3 (6) 96.6 ± 12.9 (30) 
GI 22.2 ± 4.0 (27) 87.6 ± 5.8 (14) 102.8 ± 14.6 (13) 
EX 0.0 ± 0.0 (2) 111.0 ± 17.9 (18) 118.5 ± 24.0 (36) 
Mean ± SDP 20.6 ± 6.0 (154) 94.8 ± 16.7 (59) 104.3 ± 20.7 (111) 
SDp Pooled within-horse standard deviation 
Table 4.3 Individual mean (± SD) taurine concentrations in type I, IIA and 1113 fibres from 
the middle gluteal muscle of 5 thoroughbred horses (FO, TI, DP, GI, EX) and 
overall mean (± SDP) concentrations for all horses. 
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Horse Taurine, mmol k; -' DW (number of fibres) 
Type I Type IIA Type IIB 
FO 62.6 ± 9.0 (22) 3.5 ± 7.0 (14) 2.8±5.7 (16) 
TI 54.9 ± 15.7 (53) 1.7 ± 2.9 (7) 0.5 t 1.8 (16) 
DP 62.7 ± 11.8 (50) 2.7 ± 4.6 (6) 3.0 ±3.3 (30) 
GI 69.8± 8.3 (27) 2.0± 1.6 (14) 0.2±0.7 (13) 
EX 58.4 ± 3.5 (2) 3.9 ± 6.0 (18) 2.8 ±3.1 (36) 
Mean ± SD 61.2±12.5 (154) 2.8 ± 5.2 (59) 1.8±3.4 (111) 
SDP Pooled within-horse standard deviation. 
Table 4.4 Individual mean (± SD) taurine : carnosine ratios in type I, IIA and 1113 fibres 
from the middle gluteal muscle of 5 thoroughbred horses (FO, TI, DP, GI, EX) 
and overall mean (± SDn) concentrations for all horses. 
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Horse Taurine : Carnosine ratio 
Type 1 Type IIA Type IIB 
FO 2.573 ± 0.564 0.057 ± 0.121 0.045 ± 0.093 
TI 5.559 ± 2.872 0.017±0.031 0.005 ± 0.019 
DP 2.331 ± 0.331 0.030 ± 0.050 0.034 ± 0.043 
GI 3.202 ± 0.494 0.022 ± 0.019 0.002 ± 0.007 
EX LARGE -t 0.037 ± 0.057 0.024 ± 0.027 
Mean ± SDp 3.646±2.241,, '- 0.033 ± 0.029 0.022 ± 0.026 
SDP Pooled sithin-horse standard deviation 
Carnosine was not detected in EX type I fibres. Mean calculated from 4 
horses (EX excluded). 
Figure 4.1 Individual distribution plots of carnosine concentrations in type I, IIA and LIB 
fibres from the middle gluteal muscle of 5 thoroughbred horses (FO, TI, DP, GI, 
EX). 
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Figure 4.2 Individual distribution plots of taurine concentrations in type I, IIA and 1113 fibres 
from the middle gluteal muscle of 5 thoroughbred horses (FO, TI, DP, GI, EX). 
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Figure 4.3 Frequency distribution plots of normalized carnosine concentrations in individual 
type 1, IIA and IIB fibres from the middle gluteal muscle of 5 normal 
thoroughbred horses (n = 324). 
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Figure 4.4 Frequency distribution plots of normalized taurine concentrations in individual 
type I, ]IA and 1113 fibres from the middle gluteal muscle of 5 normal 
thoroughbred horses (n = 324). 
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4.4 STUDY C: CARNOSINE AND TAURINE CONTENTS OF TYPE I, IIA AND IIB 
FIBRES IN THE MIDDLE GLUTEAL MUSCLE OF THE UNTRAINED AND TRAINED 
THOROUGHBRED HORSE. 
4.4.1 Objectives 
The aim of the present study was to investigate whether carnosine and taurine concentrations in 
type I, type IIA and type IIB fibres from the middle gluteal muscle of the thoroughbred horse 
were affected by training. 
4.4.2 Experimental methodology 
Protocol and sampling procedure 
Muscle samples from the left middle gluteal muscle were collected at post mortem from 6 three- 
year-old Thoroughbred fillies. Three of the horses, commencing the study as yearlings, 
underwent extensive treadmill based training for a period of 15 months. Each horse underwent 
an identical weekly training protocol which was kept constant over the 15 month period. Details 
of the weekly training protocol are given in Table 4.5. The remaining 3 horses were turned-out 
in paddocks for the 15 month period and received no formal training. The 6 horses were 
humanely euthanased. One entire middle gluteal muscle was removed from each horse and 
samples were collected as described in detail in Chapter 2. Owing to the relatively low 
abundance of type I fibres within equine middle gluteal muscle, the number of individual type I 
fibres retrieved was maximized by selecting some of the darker (more red) samples for 
dissection. Individual muscle fibres were dissected from freeze-dried muscle as described in 
Chapter 2. 
Histochemistry 
Fragments of individual muscle were characterized as either type 1, IIA or IIB by histochemical 
staining for myosin ATPase activity at pH 9.6 following pre-incubation at pH 4.50 as described 
previously (Chapter 2). 
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Table 4.5 Weekly training protocol 
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Day Walk Trot Canter / Gallop (treadmill) 
1 40 min - 5 min @ 12 m s-I (3% incline) 
2 40 min 10 min - 
3 40 min - 2x 90 s@ 13 & 14 m s-1 (3% incline) 
4 40 min 10 min - 
5 40 min - 3x 70 s@ 12,13 & 14 m s-1(3% incline) 
6 40 min 10 min - 
7 40 min - - 
Individual muscle fibre analysis 
Weighed individual muscle fibres were extracted and analysed for carnosine and taurine content 
simultaneously by reversed-phase high-performance liquid chromatography, as described in 
Chapter 3 (Dunnett and Harris 1995b). 
Statistics 
Analysis of carnosine and taurine distribution in type I, IIA and IIB fibres was performed by 
normalization of individual values which enabled data from all horses to be combined. 
Individual values were divided by the mean value for that horse and the results were normalized 
by multiplying by the overall mean value for all untrained or trained horses. Type I, IIA and IIB 
fibres were treated independently. One-factor ANOVA was used to identify significant 
differences in mean (± SDP) values for carnosine and taurine concentrations in type I, IIA and 
IIB fibres between untrained and trained horses. In the instance where significance was detected 
a multiple comparison test was applied, Fisher's Protected Least Significant Difference (PLSD) 
was applied. Significance was declared at p<0.05. 
4.4.3 Results 
Carnosine and taurine concentrations were determined in a total of 468 individual muscle fibres 
(untrained, n= 239; trained, n= 229) taken from the middle gluteal muscle of 6 thoroughbred 
horses at post mortem. The number of fibres and mean (± SD) carnosine and taurine 
concentrations in type I, IIA and IIB muscle fibres for individual horses, and overall mean values 
(± SDp) for untrained and trained horses are given in Tables 4.6 and 4.7, respectively. Carnosine 
concentrations were higher in both type I(p<0.05) and type IIA fibres (p < 0.001) in trained 
horses. There was no significant difference in the carnosine concentration in type IIB fibres 
between untrained and trained horses (p > 0.05). Taurine concentration were higher in type I 
fibres (p < 0.001), and type IIA and IIB fibres (p<0.05) in trained horses. Frequency 
distribution plots of normalized carnosine and taurine concentrations for all fibres with respect to 
fibre type are shown in Figures 4.5 and 4.6, respectively. 
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Table 4.6 Individual mean (± SD) carnosine concentrations in type I, IIA and 1113 fibres of 
the middle gluteal muscle of 3 untrained and 3 trained thoroughbred horses, and 
overall mean (± SDp) concentrations for untrained and trained horses. 
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Training status Horse Carnosine, mmol kä-1 DW (number of fibres) 
Untrained 
Trained 
B 
D 
F 
Mean :t SDp 
A 
C 
E 
Mean ± SDp 
Type I Type IIA Type IIB 
32.2 ± 19.2 (25) 
11.0 ± 15.4 (26) 
26.9 ± 2.1 (2) 
23.4 ± 17.2 (53) 
25.0± 10.4 (41) 
30.9 ± 11.4 (30) 
35.3 ± 26.6 (8) 
30.4 ± 13.1 (79) 
58.9 ± 17.6 (39) 
63.9 ± 18.6 (23) 
81.7 ± 15.4 (27) 
68.2. * 17.2 (89) 
101.9±34.9 (17) 
87.8 ± 19.5 (35) 
87.0±33.8 (21) 
92.2: t 28.1 (73) 
101.5 ± 44.2 (24) 
113.4 ± 23.8 (14) 
136.5 ± 33.1 (49) 
117.1 t 35.3 (87) 
142.4 ± 57.1 (20) 
121.6±48.6 (27) 
106.3 ± 35.8 (40) 
123.4 ± 45.4 (87) 
SDp Pooled standard deviation 
Significantly different to untrained p<0.001 
Table 4.7 Individual mean (± SD) taurine concentrations in type I, IIA and 1113 fibres of 
the middle gluteal muscle of 3 untrained and 3 trained thoroughbred horses, and 
overall mean (± SD, ) concentrations for untrained and trained horses. 
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Training status Horse Taurine, mmol kg-' DW (number of fibres) 
Type I Type IIA Type IIB 
Untrained B 36.4 ± 11.0 (25) 
D 33.6 ± 17.6 (26) 
F 49.9 ± 15.2 (2) 
Mean : L- SDP 40.0* 14.8 (53) 
Trained A 59.6 ± 7.6 (41) 
C 53.2 ± 15.4 (30) 
E 74.6 ± 26.4 (8) 
Mean . -t 
SDp 62.5 ± 13.6 (79) 
SDP Pooled standard deviation 
Significantly different to untrained p<0.05 
Significantly different to untrained p<0.001 
12.1 ± 7.6 (39) 
10.1 ± 6.9 (23) 
13.3 ± 7.7 (27) 
11.8 ± 7.5 (89) 
9.1 ± 11.9 (24) 
9.8 ± 7.1 (14) 
12.4 ± 10.3 (49) 
10.4 ± 10.4 (87) 
11.9 ± 6.6 (17) 
13.5 ± 8.5 (35) 
19.7 ± 12.3 (21) 
15.0 ± 9.4 (73) 1 
9.9 ± 5.5 (20) 
10.9 ± 11.6 (27) 
20.9 ± 14.0 (40) 
13.9 ± 11.8 (87) 
Figure 4.5 Frequency distribution plots of normalized carnosine concentrations in individual 
type 1, IIA and 1113 fibres from the middle gluteal muscle of 3 untrained 
(n = 239) and 3 trained (n = 229) thoroughbred horses. 
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Figure 4.6 Frequency distribution plots of normalized taurine concentrations in individual 
type 1, IIA and 1113 fibres from the middle gluteal muscle of 3 untrained 
(n = 239) and 3 trained (n = 229) thoroughbred horses. 
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4.5 STUDY D: COMPARISON OF THE CARNOSINE AND TAURINE CONTENTS IN 
TYPE I, IIA AND IIB FIBRES FROM AFFECTED AND UNAFFECTED MIDDLE 
GLUTEAL MUSCLE FROM A HORSE WITH UNILATERAL NEUROPATHY OF THE 
HIND-LIMB MUSCLES. 
4.5.1 Objectives 
The aim of the present study was to compare carnosine and taurine concentrations in individual 
type 1, IIA and IIB fibres from normal and abnormal middle gluteal muscle from the same horse. 
4.5.2 Experimental methodology 
Protocol and sampling procedure 
Muscle samples from the left middle gluteal muscle were collected at post mortem from a6 year- 
old Thoroughbred-X pony mare. The horse was diagnosed as having a unilateral neuropathy of 
the left hind limb muscles arising from the development of bony cysts on the 5th and 6th sacral 
vertebra and was euthanased six months after the initial diagnosis. Muscle atrophy was 
pronounced on the affected side. The entire middle gluteal muscle was removed and samples 
were collected at post mortem as described in detail in Chapter 2. The number of individual type 
I fibres retrieved was maximized as described earlier in this chapter. Individual muscle fibres 
were dissected from freeze-dried muscle, as described in Chapter 2. 
Histochemistrv 
Fragments of individual muscle were characterized as either type 1, IIA or IIB by histochemical 
staining for myosin ATPase activity at pH 9.6 following pre-incubation at pH 4.50 as described 
previously in Chapter 2. 
Individual muscle fibre analysis 
Weighed individual muscle fibres were extracted and analysed for carnosine and taurine content 
simultaneously by reversed-phase high-performance liquid chromatography, as described in 
Chapter 3 (Dunnett and Harris 1995b). 
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Statistics 
Mean (± SD) values for carnosine and taurine concentrations in type I, IIA and [IB fibres, were 
calculated. One-factor ANOVA was used to identify significant differences in mean (± SD) 
values for carnosine and taurine concentrations in type I. IIA and IIB fibres between the normal 
and affected (neuropathic) middle gluteal muscles. In the instance where significance was 
detected a multiple comparison test was applied, Fisher's Protected Least Significant Difference 
(PLSD) was applied. Significance was declared at p<0.05. 
4.5.3 Results 
Carnosine and taurine concentrations, and taurine : carnosine ratios were determined in a total of 
68 individual fibres from both normal and neuropathic middle gluteal muscles. Mean (± SD) 
carnosine and taurine concentrations in type I, IIA and IIB fibres are given in Table 4.8. 
Carnosine and taurine concentrations in fibres from the unaffected middle gluteal muscle were 
similar to those found previously in normal horses. Taurine concentrations were slightly higher, 
particularly in type IIA and IIB fibres. This horse however, was not pure Thoroughbred and 
hence the higher taurine contents may been the result of inter-breed differences. As found 
previously in normal horses, carnosine concentrations were significantly different between type I 
fibres and both type IIA and type IIB fibres (p<0.001). There was no significant difference 
between type IIA and IIB fibres (p>0.05). Taurine contents were significantly different 
between type I fibres and both type IIA and IIB fibres (p<0.001). There was no significant 
difference between type IIA and 1113 fibres (p>0.05). 
The taurine concentration in type I fibres from the neuropathic middle gluteal muscle was 
significantly lower than in fibres from the unaffected middle gluteal muscle (p<0.001). 
Taurine concentrations in type IIA and IIB fibres were not significantly different between the 
neuropathic and normal middle gluteal muscles (p<0.05). The carnosine concentration in type 
I fibres from the neuropathic middle gluteal muscle was not significantly different to the 
unaffected muscle (p<0.05). The carnosine concentration in type IIA fibres from the 
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neuropathic middle gluteal muscle was lower than the corresponding value in the normal middle 
gluteal. The difference however, was not significant (p>0.05). The carnosine concentration in 
type IIB fibres from the neuropathic middle gluteal was significantly lower than in type IIB 
fibres from the unaffected middle gluteal (p<0.01). 
Frequency distribution plots of carnosine and taurine concentrations for all fibres with respect to 
fibre type are shown in Figures 4.7 and 4.8, respectively. 
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Table 4.8 Carnosine and taurine concentrations in unaffected and affected (neuropathic) 
muscle fibres. 
126 
Fibre type Muscle n Carnosine 
mmol kg I DW 
Taurine 
mmol k; -' DW 
Type I Unaffected 13 24.5 ± 5.4 73.2 ± 9.4 
Affected 14 27.6 ± 3.1 39.9 ± 4.3* 
Type IIA Unaffected 9 100.8 ± 23.8 9.7 ± 2.2 
Affected 5 96.9 ± 16.0 11.0 ± 1.2 
Type IIB Unaffected 12 122.6 ± 30.0 11.9 ± 2.7 
Affected 15 93.4 ± 20.1-, 10.1 ± 2.1 
n= Number of fibres 
Significantly different to unaffected fibres p <0.01 
Significantly different to unaffected fibres p<0.001 
Figure 4.7 Carnosine distribution in unaffected and affected (neuropathic) type I, IIA and IIB 
muscle fibres. 
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Figure 4.8 Taurine distribution in unaffected and affected (neuropathic) type 1, IIA and IIB 
muscle fibres. 
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4.6 DISCUSSION 
The mean carnosine concentration in the middle gluteal muscle measured in Study A is 
consistent with previous measurements. The low concentration of anserine in the skeletal muscle 
of the thoroughbred horse is comparable with values of 0.80 ± 0.16 and 0.37 ± 0.44 mmol kg-' 
DW reported previously for equine muscle (Carnegie et at. 1983: Plowman and Close 1988). 
Although low concentrations of anserine and balenine are found in equine skeletal muscle they 
are negligible in contrast to the carnosine concentration. Therefore, there is essentially a single 
imidazole dipeptide present in the skeletal muscle of the equine. The occurrence of a single 
imidazole dipeptide in the skeletal muscle of a species is uncommon, although carnosine alone is 
also found in the muscles of some primates, including humans. The reasons for this situation in 
certain species, including the horse, is unclear. However, (Crush 1970) proposed that the 
differences between the occurrence and hence relative ratios of the imidazole dipeptides present 
in the skeletal muscle of different species, result from differences between zoological families 
rather than between species per se. It has been demonstrated in several species, that the 
biosynthesis of carnosine occurs directly from its constituent amino acids, histidine and ß- 
alanine, and is catalysed by the enzyme carnosine synthetase (Kalyanker and Meister 1959; 
Bauer and Schultz 1994). However, it was also shown that carnosine synthetase has a broad 
substrate specificity both in vivo and in vitro and that it is capable of catalysing the synthesis of 
other ß-alanyl-dipeptides, such as anserine, and y-aminobutyryl-dipeptides, such as 
homocarnosine (Kalyanker and Meister 1959; Bauer and Schultz 1994). In addition to the direct 
formation of anserine by carnosine synthetase it has also been reported that the biosynthesis of 
anserine can arise through the subsequent methylation of pre-formed carnosine which involves 
the methyl donor S -adenosyl-methionine and a specific N -methyl transferase (McManus 1962). 
Differences in the occurrence and relative ratios of the imidazole dipeptides between zoological 
families may therefore arise from differences in substrate or methyl donor availability, and the 
activity/specificity of N-methyl transferase. 
The lower concentrations of carnosine in the internal intercostal muscle and diaphragm in 
contrast to the middle gluteal muscle probably reflect the different functions of the former. The 
129 
middle gluteal muscle is essentially a locomotory skeletal muscle which although involved in 
maintaining posture and locomotion during low-intensity exercise, its function is of greater 
importance during high-intensity exercise. such as sprinting and jumping. Consequently there is 
a preponderance of fast-contracting type II fibres in this muscle. In contrast, the internal 
intercostal muscles and the diaphragm are involved in ventilation, a process which requires a 
lower rate of muscle contraction. As such they are likely to have a lesser proportion of type 11 
fibres resulting in a lower overall glycolytic capacity, therefore lower lactic acid production and 
consequently a reduced need for H+ ion buffering. The two to three-fold lower carnosine 
concentrations in these muscles relative to the middle gluteal is consistent with their reduced 
demand for H+ ion buffering. The carnosine concentration in diaphragm is similar to the 
estimated value for type I skeletal muscle fibres which suggests a predominance of these fibres in 
this muscle, although differences in the carnosine concentration within a given fibre type 
between different muscles is also possible. 
Carnosine concentrations measured in cardiac muscle (myocardium), smooth muscle (small 
intestine, colon, stomach and rectum) and other non-muscle tissues were fifty-fold or more lower 
than those found in the middle gluteal muscle. Such low concentrations of carnosine provide a 
minimal H+ ion buffering capacity , therefore its presence in these tissues may be explained by 
some of the other ascribed physiological functions. Carnosine concentrations in equine 
myocardium are similar to values reported in the cardiac muscle of other vertebrate species 
(Sobue et at. 1975; O'Dowd et al. 1988). Total concentrations of acetylated imidazole dipeptides 
in cardiac muscle from rat, guinea pig and frog were greater than 40 mmol kg-' DW (O'Dowd et 
at. 1988) and it is therefore possible that the presence of the non-acetylated forms of the 
dipeptides, including carnosine, arise from metabolism of the acetylated forms, and that 
carnosine per se has no physiological role in cardiac muscle. 
The specific activity attributable to tissue carnosinase was not discriminated from the activity of 
non-specific dipeptidase in the assay employed. However, the total activity for carnosine 
degradation is of greater physiological relevance. The mean total carnosinase and non-specific 
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dipeptidase activity was higher in the small intestine, kidney, spleen and lung of the 
thoroughbred horse than in the other tissues examined. The activity in the small intestine was 
less than the value of 0.36 jimol g-1 mind WW (86 jimol g-i h-1 DW) reported in the rat (Tamaki 
et al. 1985), and considerably lower than the value of 8.8 Eemol g-' min- WW (2112 ; imol g-1 h-1 
DW) reported in the human (Sadikali et al. 1975). As the site of tissue sampling was not 
standardized in the equine small intestine the large standard deviation associated with the tissue 
carnosinase and non-specific dipeptidase activity is probably due to a decrease in the activity of 
these enzymes towards the ileocaecal valve. Such a distribution has previously been described in 
the small intestine of the rat (Tamaki et al. 1985). The lower activity in equine small intestine 
probably reflects the dietary absence of carnosine in the equine, in contrast to the carnosine 
containing diets of the other two species. The mean total carnosinase and non-specific 
dipeptidase activity in the equine kidney was lower than that reported in the rat 4.76 pmol g-1 
min-1 WW (1142 ; imol g-' h-1 DW) (Tamaki et al. 1985). The relatively high values found in the 
spleen and lung of the horse are also consistent with the tissue distribution in the rat. 
Re-determination of tissue carnosinase and non-specific dipeptidase activities in some tissues 
was performed in the presence of 0.2 pi'1 bestatin, an inhibitor of non-specific dipeptidase but 
not tissue carnosinase. Although this does not completely inhibit non-specific dipeptidase, it 
enabled an estimate to be made of the activity attributable to tissue carnosinase alone. This 
indicated that the true tissue carnosinase activity in the kidney, spleen and small intestine was 
only 36.7,15.0 and 14.6% of the total activity, respectively. Enzyme activities measured in vitro 
do not necessarily represent accurately the true in vivo value. However, the apparent low overall 
tissue carnosinase activities, and absence of carnosinase activity in skeletal muscle, in the 
thoroughbred horse are probably indicative of a need to limit carnosine catabolism in order to 
maintain the high muscle carnosine concentrations required for optimum H+ ion buffering. 
The studies described in this chapter are the first to measure the concentrations of carnosine and 
taurine directly in individual skeletal muscle fibres. Earlier studies relied upon indirect estimates 
derived from multiple linear regression analysis of data relating muscle carnosine and taurine 
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concentrations to type I, IIA and [IB % FSA in 'large' mixed fibre muscle samples (Sewell et al. 
1990, Sewell et al. 1992, Dunnett et al. 1992). The present values for carnosine concentrations 
in type [, IIA and IIB fibres are in close agreement with the estimates of (Sewell et al. 1990). 
These earlier studies determined carnosine concentrations in muscle obtained from horses of 
differing ages and states of training. When the present measurements are compared with these 
previous estimates the agreement is not as close with respect to type I and type IIB fibres 
although the same trend is apparent. i. e. the highest carnosine concentration occurring in type IIB 
fibres and the lowest in type I fibres, is apparent. This disparity may be the result of deficiencies 
in the earlier mathematical model, or more probably arose from the exclusive use of young (two 
year-old) highly trained horses. These horses underwent high-intensity training and racing and 
hence would have an increased requirement for intra-muscular buffering capacity. 
The values for taurine concentrations in type I, IIA and LIB fibres in study B are similar to 
previous estimates for older horses sampled at post mortem (Dunnett et al. 1992), and the general 
finding is identical, i. e. taurine is almost exclusively localized within type I fibres. A poorer 
agreement with estimates derived from percutaneous muscle biopsy samples may arise for those 
reasons mentioned previously; namely the exclusive sampling of young intensely trained animals 
(Dunnett et al. 1992). A similar distribution of carnosine and taurine has also been observed in 
type I, IIA and 1113 fibres in the camel (Dunnett and Harris 1995c). 
Previous experimental models have predicted differences between the mean carnosine 
concentrations of type IIA and IIB fibres of 20 and 95 mmol kg-1 DW, respectively (Sewell et al. 
1990; Sewell et al. 1992). The current data however, shows a difference of only 9.6 mmol kb 
Dw. This discrepancy may arise from limitations within the fibre characterization procedure 
where uncertainty may arise owing to variations in fibre thickness. In contrast fewer problems of 
classification are encountered when staining sections of uniform thickness and where the 
assessor is presented with a field of mixed fibres to be viewed simultaneously. The difference in 
carnosine concentrations between type I and type II muscle fibres is consistent with their 
individual metabolic characteristics (Snow 1982). During low intensity exercise type I fibres are 
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predominantly recruited (Lindholm et at. 1974; Snow et al. 1982), H+ ion production is minimal 
and a lower buffering capacity is required (Sewell et al. 1990; Sewell et a!. 1992). During high 
intensity exercise type II fibres are recruited (Lindholm et at. 1974; Snow et at. 1982) and the 
high rate of glycolysis requires a large in situ H+ ion buffering capacity (Sewell et at. 1990; 
Sewell et al. 1992). Some buffering capacity from carnosine within type I fibres may be 
necessary owing to probable diffusion of H+ ions into these fibres during periods of anaerobic 
exercise. It has also been proposed that carnosine functions as an antioxidant in vivo and that it 
is able to protect membrane lipids against damage from reactive oxygen species (Esterbauer et 
at. 1986; Boldyrev et al. 1988; Kohen et al. 1988). This provides an alternative explanation for 
the presence carnosine in the oxidative type I muscle fibres. 
Without a clearer understanding of the functions of taurine within skeletal muscle per se it is 
difficult to establish a rationale for the much higher taurine concentrations in type I fibres. The 
presence of such high concentrations of taurine within these fibres suggest some significant 
physiological or biochemical role. Taurine may possibly compensate for the lower 
concentrations of carnosine by maintaining the osmolarity within type I muscle cells. It has also 
been proposed that taurine functions as an antioxidant and exerts a protective effect against 
reactive oxygen species in vivo (Franconi et al. 1985) and through reaction with 
malondialdehyde (Ogasawara et al. 1993). This may be a further explanation for the presence of 
high a taurine concentration in type I muscle fibres, a highly oxidative tissue. 
Changes in the carnosine and taurine concentrations within the different fibre types, as a 
consequence of training, as described in Study C, are likely to be influenced by the relative 
contributions of aerobic and anaerobic pathways to energy production during exercise as part of 
the training programme. Bump et al. (1989) reported a decrease in muscle carnosine 
concentration in Quarterhorses during training. However, the 7 week training protocol was only 
of moderate intensity, as shown by the relatively low peak mean plasma lactate concentration of 
87.6 mg 100 ml-' (9.7 mA I). A training protocol with a high anaerobic component will result in 
large increases in muscle lactate and associated H+ ion concentrations. As a result of exposure 
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of the musculature to repeated periods of acidosis the significant increase in the carnosine 
concentration in IIA muscle fibres in the middle gluteal muscle suggests an adaptive response 
within the integrated system for the maintenance of intra-muscular pH homeostasis. A 
previously reported increase in ß,,, in the middle gluteal muscle of the horse during high-intensity 
training (McCutcheon et al. 1987, Sinha et al. 1991), could be explained by an increase in the 
muscle carnosine concentration, such as that observed in Study C. It is possible that the 
observed increase in the carnosine concentration in type IIA fibres only, is indicative of greater 
'trainability' in these mixed oxidative-glycolytic fibres. 
Without a clear understanding of the precise function(s) of taurine in skeletal muscle it is 
difficult to explain the observed increase in taurine concentration in all three fibre types as a 
result of training. It has been proposed that taurine functions as an antioxidant in vivo (Franconi 
et al. 1985; Ogasawara et al. 1993), hence the increase in muscle taurine concentration may be a 
consequence of the aerobic component of the training protocol. 
Unilateral ischemic denervation of gastrocnemius muscle in experimental rats has been shown to 
cause a significant decline (p<0.01) in the muscle carnosine concentration over a period of 
three weeks (Tamaki et al. 1976). A similar study involving the denervation of the soleus, 
plantaris and gastrocnemius muscles in experimental rats, showed a non-significant decrease in 
the carnosine content of the soleus and plantaris muscles and a significant increase in the 
carnosine concentration (p<0.05) in the gastrocnemius muscle (Turnisky and Long 1990). 
However, these muscles were analysed only three days after denervation, in contrast to three 
weeks after in the study of Tamaki et at (1976). The present results for changes in muscle 
carnosine concentration during denervation are consistent with the evidence from these two 
earlier studies on whole muscles. 
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CHAPTER 5 
EQUINE PLASMA CARNOSINE CONCENTRATION AND CARNOSINASE ACTIVITY: 
NORMAL VALUES, DAILY VARIATION, AND THE EFFECTS OF EXERCISE AND MUSCLE 
DAMAGE 
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5.1 INTRODUCTION 
Plasma carnosine concentrations appear to have been measured in very few species. Not 
surprisingly most measurements have been made in human plasma. Carnosine is present in the 
plasma of human neonates at concentrations of less than 1.2 mg 1-1 (5.3 hint) in pre-term infants 
on a low protein diet and 2.0 ± 1.6 mg 1-1 (8.8 ± 7.1 jiM) in pre-term infants on a high protein 
diet. Lower concentrations of 0.7 ± 1.7 mg 1-1 (3.1 ± 7.5 yM) were found in older full-term 
infants (Valman et al. 1971). Carnosine is however, absent from the plasma of normal adults. 
This age related disappearance of carnosine appears to be correlated with an increase in serum 
carnosinase activity. Serum carnosinase activity in young children (less than 1 year old) is 0.14 
± 0.07 and 0.22 ± 0.15 jimol ml-1 h-' for males and females, respectively, in contrast to adult 
values of 1.85 ± 0.59 - 9.66 ± 0.42 `imol m1-I h-' (Bando et al. 1986; Bando et al. 1984; Wassif 
et al. 1994). Relatively high plasma carnosine concentrations (hypercarnosinemia) have been 
reported in cases of human serum carnosinase deficiency (Perry et al. 1968; Perry et al. 1967). 
Carnosine has been detected in the plasma and other blood constituents of chicks, rats and 
rabbits. Chick plasma and rabbit serum were reported to contain 27 ±3 pM and 1.9 - 7.7 ppM 
carnosine, whereas only trace amounts were found in rat plasma (Seely and Marshall 1981; 
Kurisaki and Hiraiwa 1988). However, chick erythrocytes contained large amounts of carnosine 
(2510 ± 70 nmol ä-1 cells), a value comparable with chick skeletal muscle. Lower quantities 
were present in rabbit reticulocytes (105 ± 11 nmol g1 cells) and erythrocytes (18 ±2 nmol g-t 
cells), and only trace amounts in rat erythrocytes (< 5 nmol bI cells) (Seely and Marshall 1981). 
The occurrence of carnosine in frog erythrocytes has also been reported (Balgooy et at. 1974). 
The high concentration of carnosine in chick erythrocytes was associated with the presence of 
carnosine synthetase activity (Ng and Marshall 1976b). Carnosine has also been detected in the 
blood of some species of fish, such as trace amounts in Rainbow trout blood (Abe 1991) and a 
concentration of 0.67 ± 0.17 fcmol ä-1 in tuna blood (Abe et al. 1986). The only previously 
reported measurement of carnosine concentration in equine plasma recorded values of between 
1.7 and 5.2 pM (McLean et al. 1987). 
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With the exception of diet (i. e. the consumption of meat and associated foodstuffs) no previous 
investigations appeared to consider other possible factors, such as diurnal variation and exercise, 
which may influence the concentration of carnosine in plasma. Owing to the extremely high 
concentration of carnosine in skeletal muscle relative to plasma it is possible that significant 
increases in the plasma concentration may arise as a consequence of muscle damage. Large 
increases in both plasma carnosine and anserine concentrations in the rat following traumatic 
shock induced muscle damage have been reported (Kurisaki and Hiraiwa 1988). 
5.2 STUDY A: NORMAL PLASMA CARNOSINE CONCENTRATION AND 
CARNOSINASE ACTIVITY IN THE THOROUGHBRED HORSE, AND THE 
INFLUENCE OF AGE AND GENDER. 
5.2.1 Objectives 
The objectives of this study were to establish the normal range in plasma carnosine concentration 
and plasma carnosinase activity in normal thoroughbred horses and to investigate the possible 
influence of age, gender, and plasma histidine and ß-alanine concentrations. 
5.2.2 Experimental methodology 
Protocol and sampling procedure 
Single heparinized venous blood samples (5 ml) were obtained from 112 thoroughbred horses in 
training (26 males, 30 females, 25 geldings), yearlings (13 males, 13 females) and foals (2 males, 
3 females) from four racing yards and one stud farm in the Newmarket area. All blood samples 
were collected between 15.00 and 17.00 h. 
Analytical methods 
Plasma carnosine and histidine concentrations were determined by the method described in 
Chapter 3 (Dunnett and Harris 1992). Plasma ß-alanine concentrations were determined as 
described in Chapter 2. Plasma carnosinase activity was determined using a modification of the 
method of Bando et al. (1984), as described in Chapter 2. 
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Statistical analysis 
A two factor analysis of variance (ANOVA) was used to identify significant effects of age and 
gender. Significance was declared at p<0.05. In the instance where significance was detected 
a multiple comparison test, Fisher's Protected Least Significant Different (PLSD), was applied. 
5.2.3 Results 
Preliminary measurements of plasma carnosine, histidine, anserine and 1-methylhistidine 
concentrations in a small group of experimental horses (n = 8) have been reported (Dunnett and 
Harris 1992). Anserine was absent from equine plasma and 1-methylhistidine was present at 
4.64 ± 0.97 jiM. No further determinations of 1-methylhistidine concentrations were made. 
Carnosine, histidine and ß-alanine concentrations in plasma were measured in a further 104 
Thoroughbreds. Anserine and ß-alanine were absent from the plasma of all horses (n = 112). 
The ranges in plasma carnosine and histidine concentrations in thoroughbred horses of different 
ages and gender are shown in Figures 5.1 and 5.2, respectively. Mean plasma carnosine and 
histidine concentrations for these horses are given in Tables 5.1 and 5.2, respectively. The mean 
(± SD) carnosine and histidine concentrations in all horses were 10.2 ± 3.8 pM and 51.4 ± 10.1 
FiM, respectively. There was no significant difference in either plasma carnosine or histidine 
concentrations between males, females and geldings at any age (p > 0.05), with the exception of 
a significant difference in plasma histidine concentration between 3 year-old geldings and males 
(p<0.05). There was a significant effect of age on both plasma carnosine and histidine 
concentrations which was more marked with respect to the former. Plasma carnosine 
concentrations in both foals and yearlings were approximately half those found in older horses 
p<0.001). Plasma histidine concentrations were significantly lower in foals and yearlings 
compared to older horses (p<0.05). No significant differences in plasma carnosine and 
histidine concentrations were evident between older horses. The range in plasma carnosine 
concentrations in yearlings (3.9 - 8.7 ppM) was also much narrower than in older horses (e. g. 6.5 
- 17.0 and 8.2 - 21.01uM 
in 2 and 3 year-olds, respectively). For horses of 2 years and older 
there was no significant correlation between plasma carnosine and histidine concentrations (r = 
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0.173, p>0.05), however, a weak but significant correlation was found in foals and yearlings (r 
= 0.498, p<0.005), as shown in Figure 5.3. 
Plasma carnosinase activity was absent in samples from all horses. The plasma carnosinase 
assay was validated by making comparative measurements on human plasma (n =5 in duplicate). 
The mean (± SD) activity obtained (2.08 ± 1.48 ; cmol ml-1 h-') was consistent with serum values 
reported in the literature (1.85 ± 0.59 jimol ml-1 h-1 ) (Bando et al. 1984). 
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Figure 5.1 Range in plasma carnosine concentrations at different ages in male, female and 
gelded thoroughbred horses (n = 112). 
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Figure 5.2 Range in plasma histidine concentrations at different ages in male, female and 
gelded thoroughbred horses (n = 112). 
141 
100 
80 
MALES 
. 
. 1: 
" I I. I I S 
I I I 
A 
60 
40 
20 - 
0 
inn 1 W. 
80 
60 
40 
20 
123456 
GELDINGS 
"" 
" 
0 
100 T 
80 
W 
z 
a E, 60 
x d 
40 
d 
a a 
20 4 
0 
123456 
IFEMALES 
" 
" 
", "" 
e 
" 
" 
123456 
AGE (yr) 
Table 5.1 Mean (± SD) plasma carnosine concentrations in male, female and gelded 
thoroughbred horses of different ages (n = 112). 
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Table 5.2 Mean (± SD) plasma histidine concentrations in male, female and gelded 
thoroughbred horses of different ages (n = 112). 
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Figure 5.3 Correlation between plasma carnosine and histidine concentrations in 
thoroughbred horses (n = 112). 
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5.3 STUDY B: VARIATION IN PLASMA CARNOSINE AND HISTIDINE 
CONCENTRATIONS OVER 24 HOURS IN FED AND FASTED HORSES 
5.3.1 Objectives 
The objective of this study was to investigate the within-day variation in the plasma carnosine 
and histidine concentrations in resting thoroughbred horses during a normal dietary regimen and 
following a 12 h overnight fast. A knowledge of the normal within-day variation in plasma 
carnosine and histidine concentration was also necessary for later pharmacokinetic investigations 
following oral and intra-venous carnosine administration. 
5.3.2 Experimental methodology 
Protocol and sampling procedure 
Heparinized venous blood samples (5 ml) were collected at 2 hourly intervals via an indwelling 
catheter from six resting thoroughbred horses, aged 4-7 years (5 geldings and I filly), over a 24 
h period on two separate days. On the first day the horses underwent a normal feeding regimen. 
Five of the horses were fed a normal diet comprising Spillers Stud Cubes and the sixth was fed 
Spillers Racehorse Cubes. Feed (approximately 2 kg) was provided three times per day at 07.00, 
12.30 and 16.30 h. Hay (2 -3 kg) was provided with both the morning and evening feeds. 
Water was provided ad libitum throughout the day. On the second day the horses were fasted 
following the evening feed. The two experimental sessions were separated by a period of two 
days. 
Analytical methods 
Plasma carnosine and histidine concentrations were determined by the method described in 
Chapter 3 (Dunnett and Harris 1992). 
Statistical Analysis 
Plasma carnosine and histidine concentrations at different times in fed and fasted horses were 
compared using Student's t -test for unpaired data. Plasma carnosine and histidine concentrations 
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between fed and fasted horses at different times were compared using Student's t -test for paired 
data. 
5.3.3 Results 
Large between-horse variations in plasma carnosine and histidine concentrations were evident. 
However, values for all six horses were within the normal ranges established in the preceding 
study. The ranges in mean plasma carnosine and histidine concentrations over 24 h in resting 
horses during the normal feeding regime were 8.8 - 11.7 and 56.9 - 68.5 µM, respectively. No 
significant changes in mean plasma carnosine or histidine concentrations were found over 24 h in 
resting horses during normal feeding (p>0.05). The mean within-horse variances in plasma 
carnosine and histidine concentrations during normal feeding were ± 1.6 and ± 9.0 It", 
respectively. Mean (± SD) plasma carnosine and histidine concentrations over 24 h are shown in 
Figures 5.4 and 5.5, respectively. The ranges in mean plasma carnosine and histidine 
concentrations over 24 h in resting horses during fasting were 10.0 - 11.7 and 55.8 - 65.6 111w, 
respectively. No significant changes in mean plasma carnosine and histidine concentrations were 
found over 24 h in resting horses during fasting (p > 0.05). The mean within-horse variance in 
plasma carnosine and histidine concentrations were ± 1.5 and ± 6.4 JIM, respectively. Mean 
plasma carnosine and histidine concentrations were not significantly different between fed and 
fasted horses (p>0.05). Comparisons of mean (± SD) plasma carnosine and histidine 
concentrations between fed and fasted horses over the period 12 - 24 h are shown in Figure 5.6. 
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Figure 5.4 Variation in mean (± SD) plasma carnosine and histidine concentrations in resting 
thoroughbred horses over 24 h during a normal feeding regimen (n = 6). 
(Feeding times are indicated by vertical dotted lines) 
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Figure 5.5 Variation in mean (± SD) plasma carnosine and histidine concentrations in resting 
thoroughbred horses during 24 h fasting (n = 6). 
(Feeding times are indicated by vertical dotted lines) 
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Figure 5.6 Comparison of mean (± SD) plasma carnosine and histidine concentrations over 
24 h in fed and fasted resting thoroughbred horses (n = 6). 
(Feeding times are indicated by vertical dotted lines) 
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5.4 STUDY C: VARIATION IN PLASMA CARNOSINE CONCENTRATION AS A 
RESULT OF HIGH-INTENSITY EXERCISE. 
5.4.1 Objectives 
The aim of the study was to evaluate whether high-intensity exercise in the thoroughbred horse 
elicited a change in plasma carnosine concentration 
5.4.2 Experimental methodology 
Protocol and sampling procedure 
Six thoroug C C, 
hbred horses, NV, NS, OJ, RI, HO and EL (4 geldings, 2 fillies), aged 5- 13 years, 
were trained for 4 weeks prior to undertaking a treadmill based standardized exercise test (SET). 
During the SET the horses were exercised continuously and at an intensity which was increased 
in a step-wise fashion to a point of near-maximal performance during the exercise protocol. 
Horses were walked at 1.6 m s-1 for 10 min on a level surface followed by a succession of 
canters of 1 min duration on a 5" incline at speeds of 6,8,9,10,11 and 12 m s-1, or until the 
onset of fatigue, as defined by the point at which they were no longer able to match the speed of 
the treadmill despite humane encouragement. Heparinized venous blood samples (5 ml) were 
collected immediately prior to exercise and 5 min, 30 min, 2h and 24 h after exercise. 
Analytical methods 
Plasma carnosine and histidine concentrations were determined by the method described in 
Chapter 3. Plasma aspartate transaminase (AST: EC 2.6.1.1) and creatine kinase (CK: EC 
2.7.3.2) activities were determined by kinetic methods using commercial diagnostic reagents 
(AST, Randox Laboratories Ltd., Co. Antrim, N. Ireland.; CK, Kone'T"t Diagnostics, San Diego, 
USA. ) on a KonerMT Specific Autoanalyser. 
Statistical analysis 
Pre- and post-exercise plasma carnosine concentrations were compared using Student's t -test for 
paired data. 
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5.4.3 Results 
The mean (± SD) pre-exercise plasma carnosine concentration (10.3 ± 1.01W) was within the 
normal range established in Study A. Plasma carnosine concentration increased in 5 out of 6 
horses following high-intensity exercise. The peak mean plasma carnosine concentration of 12.4 
± 4.4 jiJW which occurred at 30 min post-exercise was significantly greater than the pre-exercise 
concentration (p<0.05). However, the significance of this increase was due to the 
concentration change in one horse (NV). The mean peak concentration only marginally 
exceeded the upper limit of the normal within-day variation in plasma concentration of 
thoroughbred horses at rest (8.8 - 11.7 IW ), as established in Study B, and was within the 
normal range for older horses. The greater increase in post-exercise plasma carnosine 
concentration in horse NV correlated with a greater increase in plasma AST activity in this horse. 
However, for all horses the mean pre- and post-exercise plasma AST and CK activities were 
within the normal clinical reference range (AST, 105 - 230 IU 1-1; CK, 16 - 49 IU 1-1) and were 
not indicative of the occurrence of skeletal muscle damage. Mean pre- and post-exercise AST 
and CK activities were not significantly different (p > 0.05). 
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Figure 5.7 Individual plasma carnosine concentrations in thoroughbred horses following 
high-intensity exercise (n = 6). 
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5.5 STUDY D: CHANGES IN PLASMA CARNOSINE CONCENTRATION 
FOLLOWING THE ONSET OF EQUINE EXERTIONAL RHABDOMYOLYSIS 
SYNDROME 
S. S. 1 Objectives 
The aim of this study was to evaluate whether damage to skeletal muscle occurring during 
episodes of equine exertional rhabdomyolysis syndrome (ERS) caused a significant increase in 
plasma carnosine (and taurine) concentration(s). 
5.5.2 Experimental methodology 
Protocol and sampling procedure 
Heparinized plasma samples (5 ml each) were obtained by jugular venepuncture from three 
horses after the occurrence of episodes ERS. The occurrence of ERS in each horse was 
diagnosed by the same veterinary surgeon. Established criteria were used to assess the clinical 
severity of the episode in each case (Harris 1989). These criteria included mobility, rigidity and 
swelling of the skeletal muscles, sweating, pulse and respiration rates, and urine colouration. 
Severity was graded on a scale from I to V, with a grading of V signifying the greatest severity. 
The clinical criteria associated with episodes of differing severity are summarized in Table 5.3. 
Initial plasma samples were obtained within 90 min of the onset of the episode and subsequent 
samples were obtained at varying intervals during recovery. 
Analytical methods 
Plasma carnosine concentration was determined by the method described in Chapter 3 (Dunnett 
and Harris 1992). Plasma taurine concentration was determined as described in Chapter 2. 
Plasma AST and CK activities were determined by kinetic methods using commercially 
available reagents on a Kone Specific Autoanalyser, as described in Study C. 
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Table 5.3 Grading of the severity of ERS episodes and the associated clinical criteria. 
Adapted from Harris (1989). 
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5.5.3 Results 
Three cases of ERS were investigated during the course of this study. The clinical details of each 
case are summarised below. 
Case 1A 17 year-old Thoroughbred X Arab mare (AB) experienced an episode of ERS 
following approximately 10 - 20 min of moderate exercise comprising walking, trotting and 
cantering over a series of 6 cross-country fences. The horse showed a reluctance to move, firm 
and swollen gluteal muscles, and a slight discolouration of the urine. The clinical severity of the 
episode in this horse was graded II - III. 
Case 2 An I1 year-old Thoroughbred mare (EL) experienced an episode of ERS following 
moderate exercise comprising approximately 40 min walking, 15 min trotting and 5 min half- 
speed up-hill cantering. The horse lay down immediately on returning to the stables after 
exercise but could be encouraged to stand and move. The clinical severity of the episode in this 
horse was graded II. 
Case 3A 10 year-old Thoroughbred X gelding (PD). Details of the exercise undertaken 
immediately prior to the occurrence of the ERS episode are not known. Some slight stiffness 
was evident but no muscle abnormality was apparent. All other clinical signs appeared normal. 
The clinical severity of the episode in this horse was graded 1. 
The peak increases in plasma carnosine and taurine concentrations, and AST and CK activities 
following the onset of ERS in each of the three cases are detailed in Table 5.4. Changes in 
plasma carnosine and taurine concentrations, and 
AST and CK activities with respect to time 
following the episodes of ERS in the individual horses are shown in Figure 5.8. Peak plasma 
carnosine concentrations were significantly elevated 
(5 - 70-fold) above the normal range in all 
three horses. The increases in plasma carnosine and taurine concentrations, and AST and CK 
activities varied considerably 
between the individual horses and did not necessarily correlate 
with the severity of the clinical signs 
in each case. A large increase in plasma taurine 
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concentration was evident in only one of the horses (PD). The significance of the much smaller 
increases in the other two horses was difficult to assess in the absence of sufficient data relating 
to the normal range and possible within-day variation in equine plasma taurine concentration. 
Plasma AST and CK activities, which are often used as indices of muscle damage, were 
significantly increased above the normal range (see previous study). The highest values for all 
parameters were evident in horse PD. Although only three horses were studied when the data 
were combined there were close correlations between peak plasma carnosine concentration and 
both peak plasma AST and CK activities. Similar correlations were found between peak plasma 
taurine concentration and both peak plasma AST and CK activities. The peak plasma carnosine 
concentration occurred approximately I-2h after the onset of ERS as did peak plasma CK 
activity in the two horses with the lower increases in CK (AB and EL). In contrast, peak plasma 
AST activities occurred approximately 24 - 48 h after the ERS episode. There was a rapid initial 
clearance of carnosine from the plasma, although concentrations did not return to values close to 
the normal range for several days. 
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Table 5.4 Peak values in plasma carnosine and taurine concentrations, and AST and CK 
activities following the onset of ERS in three cases. 
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Figure 5.8 Changes in plasma carnosine and taurine concentrations, and AST and CK 
activities with respect to time following the onset of ERS in the individual horses. 
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5.6 DISCUSSION 
Measurements of plasma carnosine concentrations have been performed in very few species. 
Micromolar concentrations of carnosine in plasma from thoroughbred horses found during this 
study are similar to the only previously reported value for equine plasma in standardbred horses 
(1.7 ± 1.7 to 5.2 ± 2.81iM) (McLean et at. 1987), and are also similar to values reported for 
chick and rabbit plasma (Seely and Marshall 1981; Kurisaki and Hiraiwa 1988). The histidine 
concentration in Thoroughbred plasma is in close agreement with earlier reported values in 
Thoroughbred plasma (53.7 ± 3.0 ICM) (McKeever et al. 1986) and pony sera (48.0 - 57.21up1) 
(Reitnour et at. 1970), but is slightly higher than that reported for Standardbreds (35.6 ± 5.6 to 
40.9 ± 9.4 1iM) (McLean et at. 1987). The age related increase in equine plasma carnosine 
concentration has not previously been reported. However, a similar age related increase in 
equine plasma carnitine concentration has been reported (Foster et al. 1989). Carnosine has been 
reported to be synthesized within the skeletal muscle of some vertebrates. Assuming a similar 
situation exists in the horse, the age-related increase plasma carnosine concentration may arise 
from an increased carnosine bio-synthetic capacity and thus greater 'leakage' from skeletal 
muscle. This is opposite to the trend evident in humans where carnosine is initially present in the 
blood of premature infants, at comparable concentrations to those in foals and yearlings, but 
subsequently declines during later infancy. This reduction coincides with a gradual increase in 
plasma carnosinase activity (Bando et al. 1984). In contrast, plasma carnosinase activity was 
absent from all horses sampled. 
Possible inter-species differences in the characteristics of the enzyme, such as Kit value, 
requisite co-factors and optimum pH which may have impaired the effectiveness of the assay, 
were investigated. However, changes in pH between 7.0 and 9.0, substrate concentrations from 
0.5 - 50 mM , and the presence or absence of co-factors and stabilizers, including Mn2+, Co2+ and 
Cd2+ (2 mM ), and DTT (1 mM ), failed to indicate the existence of plasma carnosinase activity. 
The absence of plasma carnosinase activity in the thoroughbred horse is consistent with earlier 
data from other non-primates including equine serum from an undisclosed breed (Jackson et al. 
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1991). The presence of carnosine in equine plasma is consistent with the absence of plasma 
carnosinase activity. 
In both humans and horses it has been established that the plasma concentrations of certain 
metabolites, such as glucose, triiodothyronine, free fatty acids, cortisol and growth hormone 
exhibit regular fluctuations during the course of the day (Gibson et al. 1985; Orme et al. 1994; 
Youket et al. 1985; Zilva and Parnall 1984). Such changes can be related to feeding. Increases 
in plasma concentrations of proteinaceous amino acids occur as a result of normal food intake, as 
has been demonstrated in lambs and poultry (Featherston 1972; Nimrick et al. 1971), and 
consumption of diets containing an excess of a given amino acid cause produce an increase in the 
plasma concentration of that amino acid (Zimmerman and Scott 1975). The higher mean within- 
horse variance in plasma histidine concentration in normally fed horses (9.0 ; CM) compared with 
fasted horses (6.4 jiM) suggests that normal feeding does to some extent induce alterations in 
circulating concentrations of histidine. This is consistent with data from previous studies in 
horses which showed post-feeding increases in the plasma concentrations of amino acids in 
general (Johnson and Hart 1974; Russell et al. 1986) and histidine in particular (Johnson and 
Hart 1974). Furthermore, Johnson and Hart (1974) reported a significant reduction in plasma 
histidine concentration fasting horses. However, no reduction in mean plasma histidine 
concentration during fasting was observed in the present investigation. This apparent discrpency 
may be due to the use of resting horses in the present study, unlike the fomer, in which the horses 
exercised for 2-4h at low to moderate intensity during the experimental period. Comparison of 
the within-horse variance in plasma carnosine concentration between fed and fasted horses (1.6 
yiM fed, 1.5 jiM fasted) suggests that normal feeding has very little if any influence on 
circulating concentrations of carnosine. 
In conclusion, there appeared to be little influence of feeding on plasma carnosine 
concentrations. The within-day fluctuations in plasma carnosine concentration were random and 
differences in concentration at different times were not statistically significant (p > 0.05). The 
within-day variation in plasma histidine concentration was random and differences in 
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concentration at different times were not statistically significant (p>0.05). However, normal 
feeding appeared to increase the within-day variation in plasma histidine concentration. 
Post-exercise increases in carnosine concentrations in equine plasma were reported briefly in a 
previous investigation of changes in plasma amino acid concentrations in two groups of five 
standardbred racehorses before and after racing. In one group where post-exercise samples were 
collected between 2 and 5 min after racing, the pre- and post-exercise plasma carnosine 
concentrations were 5.2 ± 2.8 and 11.0 ± 9.1 jiM, respectively. In the second group where post- 
exercise samples were collected between 2 and 3h after racing, the pre- and post-exercise 
concentrations were 1.7 ± 2.7 and 8.3 ± 3.3 jiM, respectively (McLean et al. 1987). 
It is possible that increases in plasma carnosine concentrations after high-intensity exercise may 
arise from muscle cell membrane damage and the subsequent transfer of the cellular contents into 
the circulation. Owing to the presence of very high concentrations of carnosine within equine 
skeletal muscle significant increases in plasma carnosine concentrations may arise as a 
consequence of even minor muscle fibre damage. Although no previous investigations appear to 
have addressed this point in association with exercise, 10 to 20-fold increases in plasma 
carnosine and anserine concentrations have been reported following traumatic shock induced 
skeletal muscle damage in rats (Kurisaki and Hiraiwa 1988). Study C indicates that high- 
intensity exercise per se does not result in large increases in plasma carnosine concentration. 
Evidence from this study however, suggests that large increases in plasma carnosine 
concentration may occur as a result of skeletal muscle damage associated with ERS, and that the 
peak concentration is probably proportional to the severity or extent of the damage. The use of 
pharmacokinetic parameters determined after intra-venous injection of carnosine could enable an 
estimate to be made of the mass of muscle damaged. However, it would not be possible to 
discriminate between mild but widespread damage, and severe localized damage. 
Owing to the almost exclusive localization of taurine in type I muscle fibres and the much greater 
concentration of carnosine in type 11 fibres, the appearance of significantly elevated plasma 
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carnosine or taurine concentrations (assuming other causes of plasma taurine elevation are 
eliminated) may be indicative of selective type I or type II fibre damage, respectively. In the one 
horse (PD) large increases in both plasma AST and CK activities are indicative of extensive 
skeletal muscle damage. The large increases also seen in plasma carnosine and taurine 
concentrations suggest the involvement of both type I and type 11 fibre damage. This contradicts 
the earlier suggestion that muscle damage associated with episodes of ERS is confined to the 
type II muscle fibres (Valberg et al. 1993). However, considerable previous investigations have 
attested to the ubiquitous nature of taurine in mammalian tissues in many species (Jacobson and 
Smith 1968) and although no such studies appear to have been conducted in the horse, it is 
reasonable to assume that a similar widespread distribution of taurine in equine tissues exists. In 
view of this it may be difficult to attribute increases in plasma taurine concentrations solely to 
skeletal muscle damage. 
Plasma carnosine concentrations may offer a more reliable estimation of the degree of muscle 
damage incurred than plasma AST and CK activities. Neither plasma AST or CK activities are 
indicative of damage specifically to the skeletal muscles. Although CK activities are relatively 
high in skeletal muscle, significant activities are also present in the brain and heart. AST activity 
is not specific to skeletal muscle but also occurs at significant levels within the heart and liver. 
Hence, increases in these parameters are also likely with various forms of soft tissue damage. 
Owing to the relatively low concentration of carnosine in tissues other than skeletal muscle, 
damage to these other tissues is unlikely to result in increases in plasma carnosine concentrations 
which could be misinterpreted as skeletal muscle damage. For example, from the data given in 
Chapter 4, it can be estimated that complete destruction of the myocardium would result in a 
peak plasma carnosine concentration of only 30 - 40 pM. 
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CHAPTER 6 
METABOLISM OF CARNOSINE AND N- a-ACETYLCARNOSINE FOLLOWING ORAL AND 
INTRA-VENOUS ADMINISTRATION IN THE THOROUGHBRED HORSE 
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6.1 INTRODUCTION 
Carnosine metabolism has been investigated using both in vitro and in vivo techniques. In vivo 
metabolic studies, predominantly in rats and humans, but also in trout, have involved the 
administration of carnosine by intra-muscular injection or orally via naso-gastric intubation or as 
a supplement to the normal feed. There appears to be no previous studies describing the 
metabolism of carnosine in vivo following administration via the intra-venous route. In vitro 
studies, focusing mostly on carnosine transport, have been conducted utilizing isolated kidney 
and intestinal tissue from several species including rats, mice, guinea pigs and rabbits. The 
transport, metabolism and excretion of carnosine and the other imidazole dipeptides varies 
markedly between species. 
Carnosine and other imidazole dipeptides are absent from fasting human plasma and are present 
at only very low concentrations in the urine of normal subjects. They are however, detectable 
following ingestion of meals with a high meat content, although plasma concentrations are still 
low. Perry et al. (1967) reported plasma carnosine concentrations of between 6 and 18 jtM, in 2 
normal subjects, 2h after ingestion of between 16 and 20 g d-I kg-1 BW of chicken, a rich dietary 
source of carnosine. Approximately 3-4 mmol d-1 of carnosine was also excreted in the urine, 
in addition to smaller quantities of the primary metabolites histidine and ß-alanine (Perry et at. 
1967). Similar results describing the urinary excretion of balenine and anserine have also been 
reported following the ingestion of various other meat sources of these imidazole dipeptides, 
including whale, tuna and pork (Undrum et al. 1982; Abe et al. 1993). Oral administration of the 
carnosine in normal human subjects resulted in large increases in plasma histidine and ß-alanine 
concentrations (Asatoor et al. 1970; Sadikali et at. 1975; Cook 1976; Gardner et at. 1991). No 
plasma carnosine was detected however, unless cooling procedures were employed during and 
following sample collection to inhibit plasma carnosinase activity (Gardner et al. 1991). Urinary 
carnosine excretion was rapid and highly variable with 2- 14% of the administered dose 
appearing as carnosine and up to a further 2% appearing as ß-alanine in the urine within 5h of 
administration (Gardner et al. 1991). Both carnosine and anserine are absorbed intact from the 
GIT in rats following force feeding of large doses, up to 4500 mg kg-' BW (Hama et al. 1976), 
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although at lower doses of approximately 3500 and 350 mg kg-' BW partial hydrolysis of 
carnosine to its constituent amino acids occurred within the small intestine of the rat with greater 
hydrolysis being found at the lower dose (Tamaki et al. 1985). 
In vitro studies have shown that active trans-membrane carnosine transport mechanisms exist in 
the GIT of several species including the hamster (Matthews et at. 1974), rat (Nutzenadel and 
Striver 1976), rabbit (Ganapathy and Leibach 1983), mouse (Rajendran et al. 1984) and guinea 
pig (Himuki 1985). Active carnosine transport has also been demonstrated in kidney of rabbits 
(Ganapathy and Leibach 1982; Ganapathy and Leibach 1983) and rats (Nutzenadel and Scriver 
1976). Large doses of carnosine or anserine (approximately 1500 mg kg-i BW) administered by 
injection into trout white muscle were rapidly removed from this tissue and transferred 
predominantly to the blood and kidney, with lesser amounts appearing in red muscle and liver. 
Following carnosine and anserine injection increases in the histidine and 1-methylhistidine 
concentrations, respectively, were observed in all tissues (Abe 1991). 
No previous studies to investigate carnosine transport or metabolism have been conducted in the 
horse either in vivo or in vitro. Furthermore, data on the bioavailability of carnosine from the 
GIT and its metabolic fate are necessary in order to predict the effectiveness of long-term dietary 
carnosine supplementation as a method to enhance the endogenous skeletal muscle 
concentration. 
6.2 STUDY A: DETERMINATION OF CARNOSINE PHARMACOKINETIC 
PARAMETERS FOLLOWING INTRA-VENOUS ADMINISTRATION IN THE 
THOROUGHBRED HORSE. 
6.2.1 Objectives 
The aims of this study were to measure changes in plasma and urine carnosine concentrations 
following bolus injection of carnosine in the thoroughbred horse, and subsequently to determine 
the pharmacokinetic parameters of carnosine clearance from the plasma and to examine aspects 
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of carnosine metabolism in vivo by measuring changes in the plasma and urine concentrations of 
its metabolites, histidine and ß-alanine. 
6.2.2 Experimental methodology 
Protocol and sampling procedures 
Six experimental thoroughbred horses (5 geldings, I filly) aged from 4-9 years were used. All 
horses were fasted overnight, for a minimum period of 12 h, prior to undertaking the study and 
received no feed during the course of the experiment. Water was, however, provided ad libitum . 
Furthermore, the horses undertook no exercise on the day of the study. Horses were weighed on 
the morning of the study to enable doses of carnosine to be administered on a body weight basis. 
Carnosine dissolved in physiological saline (50 ml) was sterilized and administered by intra- 
venous bolus injection through a MillexTht GS 0.22 jim sterile Teflon'ru filter (Millipore UK 
Ltd., Watford, UK) and 16 gauge catheter inserted into the right jugular vein. Heparinized blood 
samples (5 ml) were collected via a 14 gauge catheter inserted into the left jugular vein. 
Catheterization was performed at least 1 hr prior to administration. Carnosine was administered 
at a dose of 20 mg kg-t BW (approximately 10 ö total dose). Pre-administration blood samples 
were collected immediately prior to the carnosine injection, and subsequent blood samples were 
collected at 5,10,20,40,60,120,240,360 and 480 min. Urine samples were collected from 
geldings only over a 12 h period and a 20 ml aliquot retained, as described in Chapter 2 (Harris 
and Snow 1988). 
Analytical methods 
Plasma and urine carnosine and histidine concentrations were determined by the HPLC method 
described in Chapter 3 (Dunnett and Harris 1992). Plasma and urine ß-alanine concentrations 
were determined as described in Chapter 2. 
Pharmacokinetic and statistical analysis 
The disposition kinetics of drugs and other substances administered to animals and humans are in 
general adequately described by a two compartment model, in which the administered dose 
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initially enters the central compartment comprising the blood and the extra-cellular fluids of high 
blood-flow tissues, such as the heart, lungs, liver and kidneys. From here distribution to the 
peripheral compartment occurs, which comprises low blood-flow tissues, such as the muscles 
and the skin. Elimination subsequently occurs from the central compartment. Drug movement 
between these compartments generally conforms to first-order kinetics, hence the rate of drug 
removal from a given compartment is proportional to the drug concentration within that 
compartment, and the concentration decreases exponentially with time. Following bolus intra- 
venous injection the change in plasma concentration (C1, ) with time (t) can be described 
mathematically by the general biexponetial equation: 
Cp = Ae-"t + Be-L4 
where A and B are the zero time concentrations for the component distribution and elimination 
phases, and a and ß are the overall distribution and elimination rate constants, respectively. The 
empirical values for these four constants (A, B, a, ß) can be obtained by curve stripping of a 
semi-logarithmic plot (in Cý, vs. t) from the experimental data. Estimates of the following 
common pharmacokinetic parameters can then be calculated from the empirical constants: 
Co =A +B (Plasma concentration at t= 0) 
Vc = Dose/A+B (Volume of the central compartment) 
AUC = A/a + b/ß (Area under Cp vs. t curve) 
k2l = (Aa + Bß)/(A+B) (Micro-rate constant of distribution from peripheral to 
central compartment) 
k10 = aß/k21 (Micro-rate constant of elimination) 
k12 = a+ ß- k2l -k i0 (Micro-rate constant of distribution from central to 
peripheral compartment) 
Vd(ss) = Ve (1 +k 12 /kit) (Volume of distribution at steady state) 
Vd(area) = Dose/AUC .B (Volume of distribution) 
CLB =k 1(). V, (Total body clearance) 
MRT = Vd(SS)/CLB (Mean residence time) 
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AUMC = MRT . AUC (Area under the first moment curve of C1, .t vs. t) 
tl 2(a) = In 2/a (Distribution half-life) 
t12(ß) = In 2lß (Elimination half-life) 
Pre-administration plasma carnosine and histidine concentrations were subtracted from post- 
administration concentrations prior to the determination of the pharmacokinetic parameters. 
Mean (± SD) pharmacokinetic parameters were calculated from parameters estimated in 
individual horses. 
6.2.3 Results 
The validity of a two compartment model to describe the change in plasma carnosine 
concentration with respect to time, in the thoroughbred horse following administration by bolus 
intra-venous injection, was tested on the mean data for all horses. A plot of In CP vs. t produced 
a straight line for the terminal (elimination phase), i. e. Cp decreases exponentially with time. 
Interpolation of this line to t=0 allowed estimates of B (y-axis intercept) and ß (gradient) to be 
made. Stripping of this line from the original In Cp vs. t curve produced a straight line 
representing the initial (distribution phase). Interpolation of this line to t=0 allowed estimates 
of A (y-axis intercept) and a (gradient) to be made, as shown in Figure 6.1. Superposition of 
these two linear components resulted in a theoretical model curve which was a close 
approximation of the actual plasma clearance curve (Figure 6.2). 
The mean plasma carnosine concentration vs. time curve following bolus intra-venous carnosine 
injection in the thoroughbred horse was described mathematically by the biexponential equation: 
Cp = 629.5e-()-025 lt + 131.1e-0 50 
The mean (± SD) measured plasma carnosine concentration 5 min after intra-venous injection 
(671.8 ± 80.1 pM) was very close to the value estimated from the pharmacokinetic data (683.1 
µM ). The mean (± SD) pharmacokinetic parameters are given in Table 6.1. There was only a 
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small variation in the plasma carnosine clearance curves between individual horses, as shown in 
Figure 6.3. 
Changes in plasma histidine concentrations with time in the individual horses following intra- 
venous carnosine administration are shown Figure 6.4. There was a large between-horse 
variation in plasma histidine concentration. There was no detectable ß-alanine found in the 
plasma of any horse following intra-venous carnosine administration. 
Large concentrations of carnosine, up to 17 mM, were detected in urine from individual 
thoroughbred horses following intra-venous carnosine injection. Urine samples collected from 4 
of the horses (all geldings) over the 12 hr period indicated that up to 36% of the administered 
carnosine dose was excreted unmetabolized in the urine, although the percentage recovered was 
highly variable between horses, as shown in Figure 6.5. Only low concentrations of histidine 
were detected in urine from the individual horses following intra-venous carnosine injection, as 
shown in Figure 6.9. 
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Figure 6.1 Interpolated distribution and elimination components of the In plasma carnosine 
concentration vs. time curve in the thoroughbred horse following intra-venous 
bolus injection at dose of 20 mg kg-' BW. 
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Figure 6.2 Comparison of the actual measured and theoretical model plasma carnosine 
concentration vs. time curves in the thoroughbred horse following intra-venous 
bolus injection at dose of 20 mg kä-1 BW. 
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Figure 6.3 Measured plasma carnosine concentration (Ce) vs. time curves for individual 
horses (n = 6) following bolus intra-venous carnosine injection. 
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Figure 6.4 Changes in plasma histidine concentration in individual horses (n = 6) following 
bolus intra-venous carnosine injection. 
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Table 6.1 Mean pharmacokinetic parameters for carnosine in the thoroughbred horse 
following a single intra-venous bolus dose at 20 mg kg-1 BW (n = 6). 
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Mean SD CV 
C', (16M) 688.2 96.4 14.0 
A (jiM) 567.4 125.7 22.2 
B (FIM) 120.8 41.1 34.0 
a (min-1) 0.0205 0.0021 10.0 
B (min-1) 0.0045 0.0010 22.4 
k21(min -') 0.0073 0.0019 26.0 
klo (min-1) 0.0128 0.0016 12.9 
k12 (min-') 0.0050 0.0008 16.0 
Vc (1 kä 1) 0.1308 0.0205 15.6 
Vd(ss) (1 kg I) 0.2235 0.0234 10.5 
Vd(arca) (1 kä-1) 0.3819 0.0858 22.5 
CL (1 min-' kg-') 0.0017 0.0001 5.2 
AUC (µmol min 1-1) 53797 2850 5.3 
AUMC (fcmol min21-1) 7369167 1426627 19.4 
MRT (min) 136.3 19.6 14.4 
t112(a) (min) 34.0 3.6 10.7 
t, /2 (ß) (min) 161.9 43.3 26.7 
Figure 6.5 Cumulative percentage recovery of the administered carnosine dose in the urine 
of individual thoroughbred horses (n = 4) following a single intra-venous bolus 
injection at 20 mg kä-1 BW. 
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6.3 STUDY B: DETERMINATION OF CHANGES IN PLASMA CARNOSINE 
CONCENTRATION FOLLOWING ORAL ADMINISTRATION BY NASO-GASTRIC 
INTUBATION IN THE THOROUGHBRED HORSE. 
6.3.1 Objectives 
The aims of this study were to measure changes in plasma and urine carnosine concentrations 
following oral administration of carnosine by naso-gastric intubation in the thoroughbred horse. 
This was done in order to examine aspects of carnosine metabolism in vivo by measuring 
changes in the plasma and urine concentrations of its metabolites, histidine and ß-alanine, and to 
calculate the bio-availability of carnosine from the GIT. Furthermore, it was intended to assess 
the potential efficacy of carnosine for use as a supplement by which endogenous muscle 
carnosine concentration may be increased. 
6.3.2 Experimental methodology 
Protocol and sampling procedures 
Nine experimental thoroughbred horses (6 geldings, 3 fillies) aged from 4-9 years were used in 
two groups of 5. All horses were fasted overnight, for a minimum period of 12 h, prior to 
undertaking the study and received no feed during the course of the experiment. Water was, 
however, provided ad libitum . 
Furthermore, the horses undertook no exercise on the day of the 
study. Horses were weighed on the morning of the study to enable doses of carnosine to be 
administered on a body weight basis. Carnosine was dissolved in distilled water (500 ml) and 
administered by naso-gastric intubation. The container and naso-gastric tube was then flushed 
through with a further 250 ml of distilled water. Heparinized blood samples (5 ml) were 
collected via a 14 gauge catheter inserted into the left jugular vein. Catheterization was 
performed at least lh prior to administration. 
Carnosine was administered at three different doses. On the first occasion it was administered at 
50 mg kg -I BW (approximately 25 g total dose) to six horses, on the second occasion at 100 mg 
kg-1 BW (approximately 50 g total dose) to five horses of which 4 were the same as those used in 
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the first session, and on the final session at 200 mg kg-1 BW (approximately 100 ä total dose) to 
six horses. Pre-administration blood samples were collected immediately prior to the carnosine 
administration, and subsequent blood samples were collected at 30,60,90 120,180,240,360 
and 480 min during the first two sessions, and additionally at 15,45,75,105 and 300 min on the 
final (higher dose) session. Urine samples were collected from geldings only over a 12 h period 
and a 20 ml aliquot retained, as described in Chapter 2 (Harris and Snow 1988). 
Analytical methods 
Plasma and urine carnosine and histidine concentrations were determined by the HPLC method 
described in Chapter 3 (Dunnett and Harris 1992). Plasma and urine ß-alanine concentrations 
were determined as described in Chapter 2. 
Pharmacokinetic and statistical analysis 
Pre-administration plasma concentrations were subtracted from all post-administration 
concentrations prior to calculating pharmacokinetic parameters. The area under the plasma 
carnosine concentration, Cp vs. time curve (AUC) from 0- 480 min, following oral carnosine 
administration, was estimated using the Trapezoidal rule: 
AUCO-. w, omin =I [1/2(CO+C151t0-15' [1/2(C15+C30)]t15-30, ....... 
[1/2(C360 +C-180}t360-4130 
The bioavailability (F) of carnosine following oral administration, i. e. the percentage of the total 
administered dose which is absorbed and which enters the central compartment, was calculated 
according to: 
F= 1OO(AUCoj . Dose ;,. /AUC;,.. Dose,, ) 
where AUC; V and Dosei, " values were taken from the preceding study. Both AUC and F were 
estimated for each individual horse using its corresponding AUC;, as determined in the 
preceding study, prior to calculating the mean value (± SD). 
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6.3.3 Results 
Oral administration of carnosine by naso-gastric intubation, following overnight fasting, at doses 
of 50,100 and 200 mg kg-' BW resulted in significant increases in plasma carnosine 
concentrations, with mean (± SD) peak concentrations (Cmax) of 20.6 ± 10.6,54.7 ± 14.6 and 
133.2 ± 40.1 jiM, respectively. Peak concentrations occurred between 60 and 120 min after 
administration. Following administration at the highest dose, the plasma carnosine concentration 
at 480 min was still higher than the pre-administration value. Changes in plasma carnosine 
concentrations in individual horses following oral carnosine administration at doses of 50,100 
and 200 mg kä-1 BW are shown in Figure 6.6. Mean peak plasma carnosine concentrations 
increased proportionally with the increase in dose. A comparison of the changes in the mean (± 
SD) plasma carnosine concentrations following oral carnosine administration at the three doses 
are shown in Figure 6.7. 
Increases in plasma histidine concentrations were also observed following oral carnosine 
administration. Peak plasma histidine concentration occurred at a similar time to the peak 
plasma carnosine concentration. Mean (± SD) plasma carnosine and histidine concentrations 
following oral administration at a dose of 200 mg kg-' BW are shown in Figure 6.8. The mean (± 
SD) plasma C., ac, t,,.,, AUC and F for carnosine and histidine following oral carnosine 
administration at the 3 doses are given in Table 6.2. There was a decrease in the proportion of 
the administered carnosine which was metabolized to histidine as the size of the dose was 
increased. ß-alanine was not detected in plasma or urine either before or after carnosine 
administration at any dose. No significant increases in urinary carnosine or histidine excretion 
were observed over 12 h following oral carnosine administration. The changes in urine plasma 
carnosine and histidine concentrations are shown in Figure 6.9. 
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Figure 6.6 Changes in plasma carnosine concentrations in individual horses following 
oral carnosine administration at doses of 50,100 and 200 mg kg-' BW. 
(n =5 at 100 mg kg-' Bw, n=6 at the other doses) 
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Figure 6.7 Comparison of the changes in mean (± SD) plasma carnosine concentrations with 
time following oral carnosine administration at 50,100 and 200 mg kg-' BW. 
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Figure 6.8 Comparison of the changes in mean (± SD) plasma carnosine and histidine 
concentrations following oral carnosine administration at 200 mg kg-1 BW. 
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Table 6.2 Plasma Cmax, t,,, ax, AUC and bioavailability (F) of carnosine and histidine in the 
thoroughbred horse following oral camosine administration at doses of 50,100 
and 200 mg ka-I 13w. 
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Figure 6.9 Comparison of histidine excretion in the urine of the thoroughbred horse 
following intra-venous and oral carnosine administration at 20 mg kg -I BW and 
200 mg kb I BW, respectively 
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6.4 STUDY C: COMPARATIVE MEASUREMENTS OF CHANGES IN PLASMA N-a- 
ACETYLCARNOSINE CONCENTRATIONS IN THE THOROUGHBRED HORSE 
FOLLOWING BOTH ORAL AND INTRA-VENOUS ADMINISTRATION. 
6.4.1 Objectives 
The aim of this study was to determine the effect of N-a-acetylation of carnosine on bio- 
availability from the GIT of the thoroughbred horse. 
6.4.2 Experimental methodology 
Protocol and sampling procedures 
Only one experimental thoroughbred horse (DS), aged 9 years, was used owing to the limited 
availability of N-a-acetylcarnosine. The horse was fasted overnight for 12 h prior to undertaking 
each part of the study and received no feed on each experimental day. Water was, however, 
provided ad libitum . Furthermore, the horse undertook no exercise on the day of the study. The 
horse was weighed on the morning of the study to enable doses of to be administered on a body 
weight basis. 
During the first session N-a-acetylcarnosine dissolved in physiological saline (50 ml) was 
sterilized and administered by intra-venous bolus injection through a MillexT, \t GS 0.22 Jim 
sterile Teflon 1'\I filter (Millipore UK Ltd., Watford, UK) and 16 gauge catheter inserted into the 
right jugular vein. Heparinized blood samples (5 ml) were collected via a 14 gauge catheter 
inserted into the left jugular vein. Catheterization was performed at least Ih prior to 
administration. Pre-administration blood samples were collected immediately prior to the N-a- 
acetylcarnosine injection, and subsequent blood samples were collected at 5,10,20,40,60,120, 
180,240,300,360 and 480 min. Urine samples were collected over a 12 hr period and a 20 ml 
aliquot retained, as described in Chapter 2 (Harris and Snow 1988). N-a-acetylcarnosine was 
administered at a dose of 10 mg kg-1 BW (approximately 5g total dose). 
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During the second session N-a-acetylcarnosine was dissolved in distilled water (500 ml) and 
administered by naso-gastric intubation. The container and naso-gastric tube were flushed 
through with a further 250 ml of distilled water. Heparinized blood samples (5 ml) were 
collected via a 14 gauge catheter inserted into the left jugular vein. Catheterization was 
performed at least Ih prior to administration. Pre-administration blood samples were collected 
immediately prior to the N-a-acetylcarnosine administration, and subsequent blood samples were 
collected at 30,60,90 120,180,240,300,360 and 480 min. Urine samples were collected over 
a 12 h period and a 20 ml aliquot retained, as described in Chapter 2 (Harris and Snow 1988). N- 
a-acetylcarnosine was administered at a dose of 50 mg kä-' BW (approximately 30 ä total dose). 
Analytical methods 
Plasma N-a-acetylcarnosine concentration was determined by the HPLC method described in 
Chapter 3. Plasma and urine carnosine and histidine concentrations were determined by the 
HPLC method described in Chapter 3 (Dunnett and Harris 1992). Plasma and urine ß-alanine 
concentrations were determined, as described in Chapter 2. 
Pharmacokinetic analysis 
The determination of the mathematical equation describing the plasma N-a-acetylcarnosine 
concentration vs. time curve and the subsequent estimation of the conventional pharmacokinetic 
parameters were performed as described in Study A. 
6.4.3 Results 
Intra-venous bolus injection of N-a-acetylcarnosine produced a rapid increase in plasma N-a- 
acetylcarnosine to 296 pM 5 min after administration. This was followed by a rapid decline in 
the plasma N-a-acetylcarnosine concentration which reached the pre-administration value (1.9 
QCM) within 360 min. There was subsequently, only a very small increase in plasma carnosine 
concentration from a pre-administration value of 13.8 pM to a peak value of 20.4 µM at 20 min, 
but no increase in plasma histidine concentration. No ß-alanine was detected in the plasma 
following the injection of N-a-acetylcarnosine. The clearance of N-a-acetylcarnosine from 
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equine plasma following bolus intra-venous injection was described mathematically by the 
biexponential equation: 
Cl, = 165.4e-o. (M26t + 170.5e-o. t)01)2t 
Pharmacokinetic parameters associated with a single bolus intra-venous injection of N-a- 
acetylcarnosine in the thoroughbred horse are given in Table 6.3. 
Following oral administration of N-a-acetylcarnosine by naso-gastric intubation, no increase in 
plasma N-a-acetylcarnosine was observed, nor were there any increases in either plasma 
carnosine, histidine or ß-alanine concentrations over the subsequent 480 min. The urinary 
excretion of N-ct-acetylcarnosine was not determined. 
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Table 6.3 Pharmacokinetic parameters for N-a-acetylcarnosine following a single 
intra-venous bolus injection at a dose 20 mg kg-' BW. 
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Parameter Value 
C', (jiM) 335.9 
A (Jim) 165.4 
B (JiM) 170.5 
a (min-1) 0.0426 
ß (min-1) 0.0092 
k21 (min-1) 0.0261 
k10 (min-1) 0.0149 
U2 (min-1) 0.0107 
VC (1 kg-1) 0.2220 
Vd(SS) (I kg-1) 0.3127 
Vd(area) (1 kg-1) 0.3617 
CL (1 min-1 kg-') 0.0033 
AUC ({cmol min 1-1) 22485 
AUMC (ycmol min21-1) 2119844 
MRT (min) 94.3 
t[2(a) (min) 16.3 
t1.2 (B) (min) 75.6 
6.5 DISCUSSION 
No previous studies of carnosine transport and metabolism have been conducted following 
carnosine administration by intra-venous injection in any species. Following bolus intra-venous 
injection the change in plasma carnosine concentration (C!, ) with time (t) in the thoroughbred 
horse was described adequately by the general biexponetial equation: 
Cl, = Ae-ut + Be4 
where A and B are the zero time concentrations for the component distribution and elimination 
phases, and a and ß are the distribution and elimination rate constants, respectively. Therefore, 
data describing the change in plasma concentration following intra-venous bolus injection 
conformed to a two compartment model. 
The mean Vd(ss) value of 0.2235 1 kg-' for carnosine determined in Study A is equivalent to a 
total volume of approximately 1121 in a typical 500 kg horse, in contrast to an approximate total 
blood volume of 45 1. If an administered substance is extensively bound within the tissues then 
the Vd(ss) will be greater than the volume of the total body water which in man is approximately 
42 1 or 0.6 1 kg-1 (Hladky 1990). Assuming a similar volume of total body, water expressed per 
kg body weight in the horse then a Vd(SS) of approximately 0.2 1 kä-1 suggests that a significant 
amount of the administered carnosine is distributed to the extra-cellular fluid, but that little if any 
is bound within the tissues. 
The fate of carnosine following intra-venous administration therefore appears to involve both 
direct excretion of the unmetabolized compound in the urine, which accounts for a mean of 11.76 
± 4.48 mmol or 24.4 ± 10.0% of the total administered dose, and catabolism to histidine 
catalysed by carnosinase and non-specific dipeptidase. There was however, a large between- 
horse variability in the amount of carnosine excreted in the urine. The proportion of the 
administered carnosine dose which is catabolized to histidine is difficult to quantify accurately in 
the absence of pharmacokinetic data describing both the distribution of histidine to the tissues 
and the elimination of histidine from the central compartment (including the plasma) following 
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intra-venous administration. If it is assumed that the overall distribution and elimination rate 
constants, a and ß, for histidine are very similar to those of carnosine, then for a given dose the 
AUC for histidine and carnosine would be the same. Significant increases in plasma histidine 
concentration following the intra-venous administration of carnosine at a dose of 20 mg kg-' BW 
were seen, although there was considerable between-horse variation. Using the trapezoidal rule 
it was estimated that the mean AUC0t - Ott min 
for histidine was 17950 jimol min ml-' which 
would be equivalent to approximately 14.7 mmol, or 33% of the total carnosine dose 
administered. Over the same time period the mean total amount of histidine excreted in the urine 
was negligible, although it is possible that some of the histidine may have been deaminated via 
histidase and excreted in the urine as urocanic acid, or metabolized by other pathways (see 
Figures 1.3 and 1.4). In total urinary carnosine excretion and measured plasma histidine up to 
480 min accounted for approximately 57% of the administered dose. The remaining portion of 
the administered dose was probably accounted for partly by elevated plasma histidine 
concentration beyond 480 min and histidine uptake by tissues. This data when considered 
together with the moderate value for the apparent Vd(SS) suggests therefore, that there is minimal 41 
uptake, either by passive diffusion or active transport, of carnosine by low blood-flow equine 
tissues, such as skeletal muscle, in vivo. Nutzenadel et al. (1984) reported that there was no 
active uptake of carnosine in rabbit skeletal muscle in vitro , although the opposite was found in 
kidney. The rate of in vivo metabolism of carnosine to histidine in the thoroughbred horse 
following intra-venous administration was also highly variable between horses, which suggests a 
large between-horse variability in the activities of tissue carnosinase and non-specific 
dipeptidase, as described earlier in Chapter 4. 
Although the bioavailability of carnosine following oral administration increased proportionally 
with increasing dose it was still very low, with only 4.5% of the total administered dose being 
absorbed at the highest dosage. The low bioavailability is probably due to the zwitterionic nature 
of carnosine, and hence an inability to penetrate lipid membranes. The fact that some increase in 
plasma carnosine occurs may be evidence for the existence of a specific, but low capacity, 
carnosine transporter in the equine GIT, as reported in other mammalian species, such as the 
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hamster (Matthews et al. 1974), rat (Nutzenadel and Scriver 1976), rabbit (Ganapathy and 
Leibach 1983), mouse (Rajendran et al. 1984) and guinea pig (Himuki 1985). This would 
however, seem to be unlikely given the absence of carnosine from the normal equine diet. More 
probably, some carnosine may be taken up via another amino acid or peptide transporter. 
A portion of the carnosine dose is catabolized and appears in the plasma as histidine. At the 
highest dose level, where blood sampling was more frequent, the peak plasma carnosine and 
histidine concentrations occurred at the same time. This suggests that there is an initial phase of 
carnosine degradation in the GIT. Although a first pass effect through the liver cannot be 
excluded, data in Chapter 4 indicates a much higher carnosinase and non-specific dipeptidase 
activity in the GIT in comparison with the liver. From a comparison of the AUC for plasma 
carnosine and histidine it is probable that histidine accounts for a further 2- 3% of the total dose 
absorbed at the highest dosage. The ratio of histidine to carnosine in the plasma decreases as the 
size of the dose increases, suggesting saturation of camosinase and non-specific dipeptidase. 
This is consistent with the results from oral carnosine administration in the rat (Tamaki et al. 
1985). Negligible excretion of carnosine and histidine was observed following oral carnosine 
administration in the horse, unlike that seen in humans (Gardner et at. 1991). This probably 
reflects the small quantities which enter the systemic circulation and the longer interval over 
which this takes place, in contrast to intra-venous administration. 
The absence of N-a-acetylcarnosine in plasma following its oral administration suggests that the 
free terminal amine moiety of carnosine is essential for its uptake from the GIT, although 
carnosine uptake is low normally. 
Increased plasma activities of cytosolic muscle enzymes, such as AST and CK, are associated 
with changes in skeletal muscle cell membrane permeability, or cell damage (Janssen et al. 
1989). This can occur as a result of intra-muscular injection in humans (Metzler et al. 1970) and 
dogs (Aktas et al. 1995), exercise in humans (Noakes 1987; Janssen et al. 1989) and horses 
(Anderson 1975; Rose et al. 1983) and ERS in horses (Cardinet et al. 1963; Harris 1989). The 
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increase in plasma AST and CK activity has been used to estimate the mass of muscle damaged 
during trauma (Lefebvre er al. 1994) or following exercise in humans (Appel and Rhodes 1988: 
Janssen et at. 1989) and horses (Volfinger et al. 1994). However, AST and CK are not specific 
to skeletal muscle. Significant amounts of AST are present in the liver and heart, and CK in the 
heart and brain. Other factors cause an increase in plasma CK activity, such as cardiac muscle 
damage associated with rhabdomyolysis (Fujii et al. 1983), myocardial infarction (Klein et at. 
1973), and incorrect venepuncture technique (Fayolle et al. 1992) can lead to the erroneous 
diagnosis of skeletal muscle damage, or to an over-estimation of the mass of muscle damaged. 
Furthermore, examination of skeletal muscle by electron microscopy indicates less extensive 
damage than is suggested by parallel measurement of plasma enzyme activity (van-der-Meulen et 
a!. 1991). Carnosine is almost exclusively distributed within the skeletal muscles, with 
concentrations in other tissues, such as the heart and GIT being 50 to 100-fold lower than that in 
skeletal muscle. Consequently, a large increase in plasma carnosine concentration would provide 
a much more specific indicator of skeletal muscle damage than AST or CK. 
The controlled intra-venous bolus injection of carnosine in the horse could be used as a simple 
model to represent the changes in plasma carnosine concentrations following the onset of muscle 
damage during episodes of ERS, as described in the preceding chapter. The area under the 
concentration-time curve (AUC) following an intra-venous bolus injection is proportional to the 
total dose administered. Therefore the AUC calculated from the change in plasma carnosine 
concentration following release from damaged muscle would be proportional to the total amount 
released. Hence, the AUC from a known intra-venous dose could be used to calculate the mass 
of carnosine released into the circulation from damaged skeletal muscle, and hence an estimate 
of the mass of muscle damaged. 
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CHAPTER 7 
EFFECT OF DIETARY SUPPLEMENTATION WITH L-HISTIDINE AND Ji-ALANINE ON 
CARNOSINE CONCENTRATIONS IN TYPE I, IIA AND JIB MUSCLE FIBRES OF THE 
MIDDLE GL UTEAL OF THE THOROUGHBRED HORSE 
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7.1 INTRODUCTION 
Dietary availability of histidine plays an important role in the regulation of the biosynthesis and 
accumulation of carnosine in vertebrate skeletal muscle. The effects of both histidine deficient 
diets and histidine supplemented diets have been investigated in several species. Reduced 
skeletal muscle carnosine concentrations were found in experimental adult rats (Fuller et at. 
1947; Quinn and Fisher 1977), eels (Abe and Ohmama 1987) and salmon (Luckton 1958) 
maintained on a histidine deficient diet in contrast to controls. A similar reduction in the 
concentration of carnosine and anserine in the breast and leg muscles of adult roosters 
maintained on a histidine-free diet for a two week period has also been reported (Leveille et al. 
1960). Amend et at. (1979) reported that pectoral and leg muscle carnosine and anserine 
concentrations in adult cockerels, depleted by 12 weeks maintenance on histidine deficient diets, 
were subsequently restored to normal levels after 4 weeks on a histidine supplemented diet. 
Dietary histidine deficiency causes a more rapid decline in muscle carnosine concentration in 
younger animals. A decline in chick pectoral muscle carnosine concentration to 4% of its initial 
concentration following 5 weeks of histidine deprivation has been reported (Ousterhout 1960; 
Ousterhout and Luckton 1960). Histidine deprivation also causes a more rapid decline in skeletal 
muscle carnosine concentration in younger rats (Barbaro et at. 1978) than in older rats (Barbaro 
et al. 1977; Tamaki et al. 1977). Furthermore, other studies indicate that histidine is an essential 
dietary amino acid during the growing phase in other species including the human infant 
(Snyderman et at. 1963; Strecker 1970), although 24 days of histidine deprivation in young 
pregnant sows caused no significant reduction in muscle carnosine concentrations (Easter and 
Baker 1977). 
It has been shown by providing increasing levels of histidine in the diet, that increases in the 
skeletal muscle carnosine concentration occur once the histidine requirements for optimum 
growth have been fulfilled (Robbins et al. 1977). Rats fed a diet supplemented with histidine at a 
level of 5% w/w showed a two-fold greater camosine concentration in the gastrocnemius muscle 
in contrast to rats on a control diet with a histidine content of 0.76% w/w (Tamaki et at. 1977). 
In the mature Quarterhorse, supplementation of a basal diet with histidine, at levels of 0.4% w/w 
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over a period of two weeks in one study and up to 0.56% w/w twice per day in a further study, 
produced small but statistically non-significant increases in the carnosine concentration of the 
middle gluteal muscle (Powell et at. 1991; Miller-Graber and Seyers 1993). 
In contrast to the extensive investigations of the influence of dietary histidine on skeletal muscle 
carnosine concentration, the effect of dietary ß-alanine supplementation on muscle carnosine 
content has not been investigated. However, Margolis (1981) demonstrated an increase in 
olfactory bulb carnosine concentration in adult mice following ß-alanine administration. 
Furthermore, twice-daily intra-peritoneal injections of very large doses of ß-alanine (22 mmol 
kg-t BW, 2000 mg kä-1 BW) in adult mice over a5 day period produced a ten-fold increase in 
skeletal muscle carnosine concentration in contrast to controls (Margolis et al. 1985). 
The results of earlier investigations in other species suggest that substrate availability may be a 
limiting factor to the regulation of carnosine biosynthesis and accumulation within skeletal 
muscle. Thus increasing the endogenous concentrations of both histidine and ß-alanine may 
result in an increase in muscle carnosine content. Histidine and ß-alanine required for carnosine 
synthesis in the skeletal muscles are probably obtained via active transport from the blood. 
Earlier results show a normal plasma histidine concentration in the mature horse of 
approximately 50 - 60 jM (Chapter 5). ß-alanine was however, not detected in normal plasma 
indicating a concentration of less than 3 liM, which was the lower limit of quantification for the 
analysis (Chapter 5). The low plasma ß-alanine concentration may be due to the absence of 
significant quantities of ß-alanine from the normal equine diet and/or inadequate ß-amino acid 
membrane transport mechanisms in the gastro-intestinal tract (GIT). It is therefore possible that 
a large and sustained increase in plasma ß-alanine concentration in conjunction with a moderate 
increase in plasma histidine concentration in the horse, via dietary supplementation, may have a 
more significant effect on muscle carnosine biosynthesis than that previously achieved via 
histidine alone (Powell et at. 1991; Miller-Graber and Seyers 1993). This approach does not 
appear to have been adopted in earlier supplementation studies. 
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Increasing the carnosine concentration within the skeletal muscles of the horse will produce an 
increase in the total intra-cellular physico-chemical buffering capacity of the muscles and thus 
may attenuate the rate of decline in intra-muscular pH during anaerobic exercise such as 
sprinting and prolong the time to fatigue. 
7.2 EFFECT OF DIETARY SUPPLEMENTATION WITH L-HISTIDINE AND ß- 
ALANINE ON CARNOSINE CONCENTRATIONS IN TYPE I, IIA AND IIB MUSCLE 
FIBRES OF THE MIDDLE GLUTEAL OF THE THOROUGHBRED HORSE. 
7.2.1 Objectives 
The aim of the study was to investigate whether chronic supplementation of the normal diet with 
multiple daily doses of L-histidine and ß-alanine would increase the carnosine content of type I, 
IIA and LIB skeletal muscle fibres. 
7.2.2 Experimental methodology 
Protocol and sampling procedure 
Three experimental thoroughbred horses (DS, JS, GT) (2 fillies and one gelding) aged 4,5 and 9 
years, respectively, underwent one month of dietary conditioning (pre-supplementation period) 
prior to the commencement of the supplementation period. During the dietary conditioning 
phase each horse was fed a diet comprising l kg of pelleted feed (Spillers racehorse cubes ) and 1 
kg of soaked sugar beet pulp, three times per day, at 08.30 h, 12.30 h and 16.30 h, respectively. 
Soaked hay (3 kg dry weight) was also provided twice daily at 09.00 h and 17.00 h. Water was 
provided ad libitum . 
During the supplementation period an identical feeding regime was implemented. However, 
each hard feed meal was supplemented with L-histidine (free base) and ß-alanine. Histidine and 
ß-alanine were administered as dry powders mixed directly into the normal feed. Individual 
doses of histidine and ß-alanine were calculated according to body weiht. ß-alanine was 
administered at 100 mg kg-1 BW and histidine at 12.5 mg kg-t BW. Dietary supplementation was 
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begun on day I of the protocol and discontinued at the end of day 30. From day 3I to day 60 the 
horses were returned to the non-supplemented diet used during the conditioning phase. 
Heparinized blood samples (5 ml) were collected on days 1,6,12,18,24 and 30. On days 1 and 
30 blood samples were collected prior to the first feed and at hourly intervals thereafter up to 12 
h. On the four intervening sampling days blood was collected prior to the first feed and 2h after 
each subsequent feed. On day 0, pre-supplementation muscle samples were collected from the 
right middle gluteal muscle of each horse using the percutaneous needle biopsy technique 
described in Chapter 2. Subsequent muscle biopsies were collected immediately after the end of 
the supplementation period (day 3 1) and thirty days after returning to the non-supplemented diet 
(day 60). A diagrammatic representation of the experimental protocol and sampling intervals is 
shown in Figure 7.1. Clinical monitoring of the horses was performed daily over all three 
experimental periods. Clinical monitoring comprised a visual examination and measurement of 
body weight on a daily basis, twice-daily measurement of rectal temperature, and weekly blood 
sampling for clinical biochemistry and haematology. During the course of the study the horses 
received no formal training or exercise, although they were allowed one hour of free exercise 
each day. 
Histochemistrv 
Fragments of individual muscle fibres were characterized as either type [, IIA or [IB by 
histochemical staining for myosin ATPase activity at pH 9.6 following pre-incubation at pH 4.50 
as described in Chapter 2. 
Plasma and individual muscle fibre analysis 
Heparinized plasma samples were extracted and analysed for carnosine and histidine, and ß- 
alanine concentrations by the HPLC methods described in Chapter 3 (Dunnett and Harris 1992) 
and Chapter 2, respectively. Weighed individual muscle fibres were extracted and analysed for 
carnosine and taurine concentrations by the method described in Chapter 3 (Dunnett and Harris 
1995b). 
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Statistical analysis 
Owing to the small number of horses used in this study no between-horse statistical comparisons 
were made. Differences in carnosine and taurine concentrations within fibre types before and 
after supplementation were established within horses using 1-way ANOVA. In instances where 
differences were detected, significance was determined using a multiple comparison test (Fisher's 
PLSD). 
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Figure 7.1 Diagrammatic representation of the experimental protocol and sampling intervals. 
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7.3 Results 
All three horses were clinically normal prior to commencing the supplementation. No 
palatability problems with the histidine and ß-alanine supplemented diet were encountered and 
complete feeds were consumed on every occasion. No adverse physiological or behavioural 
effects of the supplemented diet were observed in any of the horses either during the thirty days 
of supplementation or during the subsequent withdrawal period. No significant changes in body 
weight were recorded and rectal temperatures remained within the normal range. No acute or 
chronic changes in clinical biochemistry or haematology were observed. 
Plasma concentrations 
Plasma histidine concentrations in DS, JS and GT prior to supplementation on day I of the study 
were 43.8,37.1 and 37.9 µM , respectively. The values were within the 
lower end of the normal 
range (see Chapter 5). ß-alanine was not detected in the plasma of any of the horses prior to the 
beginning of supplementation. The lower limit of quantitation for ß-alanine in plasma by the 
method used was 3 jiM. Changes in plasma histidine and ß-alanine concentrations for all horses 
prior to the first feed of the day and 2h after each subsequent feed on every sixth day are shown 
in Figures 7.2 and 7.3, respectively. As the supplementation period progressed there was a trend 
towards an increase in both plasma histidine and ß-alanine concentrations prior to the first feed 
of each day. Over the 30 day supplementation period large increases in the within-day peak 
plasma histidine and ß-alanine concentrations were also evident. No sustained increase in 
plasma carnosine concentration over the thirty day supplementation period was evident in any of 
the horses and both within-day and between-day changes appeared to be random. Comparisons 
of changes in plasma histidine and ß-alanine concentrations prior to the first feed of the day and 
hourly thereafter between the first and final days of the supplementation period, for the 
individual horses, are shown in Figures 7.4 - 7.6. Plasma histidine, ß-alanine and carnosine 
concentrations prior to the first feed of the day and within-day maximum values on day I and 
day 30 of the supplementation period, for the individual horses, are given in Table 7.1. 
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Figure 7.2 Changes in pre-feeding and 2h post-feeding plasma histidine concentrations for 
the individual horses. 
200 
400 
,., 3O 
3 
vF", 20C 
ID 
96 IN 
c 
DS 
is 
GT 
öc xzý öc sxx öc ýxx äc x ýy = öc ýý= öc zýz 
p" N ýO ON ýO ONN ýO ON ND O a" N ýO O ýti' N ýD O 
ÄAOAAO 
Figure 7.3 Changes in pre-feeding and 2h post-feeding plasma ß-alanine concentrations for 
the individual horses. 
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Figure 7.4 Comparison of within-day changes in plasma histidine and ß-alanine 
concentrations between day 1 and day 30 for horse DS. 
(Feeding times are indicated by vertical dotted lines. ) 
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Figure 7.5 Comparison of within-day changes in plasma histidine and ß-alanine 
concentrations between day I and day 30 for horse JS. 
(Feeding times are indicated by vertical dotted lines. ) 
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Figure 7.6 C onip. trison of within-day changes in plasma histicline and ß-alanine 
concentrations between day 1 and day 30 for horse GT. 
(Feeding times are indicated by vertical dotted lines. ) 
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Table 7.1 Values for pre-feeding and within-day maximum plasma histidine, ß-alanine and 
carnosine concentrations on day 1 and day 30 in individual horses. 
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Individual muscle fibre concentrations 
A total of 207 individual muscle fibres (101 pre-supplementation, 106 post-supplementation) 
from the three horses were dissected, characterized and analysed for carnosine and taurine 
concentrations. Mean (± SD) carnosine and taurine concentrations in pre- and post- 
supplementation type I, IIA and IIB muscle fibres from the individual horses are given in Tables 
7.2 and 7.3, respectively. Free histidine and ß-alanine were not detected in pre- or post- 
supplementation individual muscle fibres. The lower limits of quantitation for histidine and ß- 
alanine in individual muscle fibres by the method used were 1.0 and 0.4 mmol kg-' DW. Mean 
carnosine and taurine concentrations in pre-supplementation type I, IIA and IIB individual 
muscle fibres from the three horses were in good agreement with values reported previously in 
Chapter 4. Following 30 days of histidine and ß-alanine supplementation the mean carnosine 
concentration increased in type IIA and LIB fibres in all three horses compared with pre- 
supplementation values. These increases reached statistical significance in three instances. In 
type IIA and IIB fibres from horse GT mean carnosine concentrations increased significantly by 
31.2 and 43.8 mmol kg-1 DW (p < 0.01 and p<0.05) or by 49% and 40% above the pre- 
supplementation contents, respectively. Mean camosine concentration in type IIB fibres from 
horse JS also increased significantly by 22.1 mmol k; -1 DW (p < 0.01) or 17% above the pre- 
supplementation value. Owing to the presence of so few type I fibres it was difficult to make a 
realistic assessment of the significance of changes in carnosine concentration in type I muscle 
fibres. Distribution plots of carnosine concentrations in pre- and post-supplementation type I, 
IIA and 1113 fibres for the individual horses are shown in Figures 7.7 - 7.9. 
There was no statistically significant difference in the taurine concentrations of type I, IIA and 
LIB before and after supplementation in any of the horses. However, for type I fibres the 
previously mentioned proviso applies. 
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Table 7.2 Mean (± SD) carnosine concentrations in pre- and post-supplementation type I, 
IIA and 1113 fibres from individual horses. 
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Horse Treatment Carnosine, mmol kg-' DW (number of fibres) 
Type I Type IIA 
DS Pre 32.3 ± 14.5 (3) 72.1 ± 47.7 (11) 
Post - 76.2 ± 20.9 (17) 
JS Pre 59.5 ± 3.9 (2) 102.6 ± 12.7 (12) 
Post 55.5 (1) 112.2 ± 17.1 (18) 
GT Pre 44.8 ± 6.6 (4) 63.6 ± 20.9 (10) 
Post 37.0 ± 9.3 (2) 94.8 ± 30.2; (15) 
= significantly different to pre, p<0.05 
= significantly different to pre, p<0.01 
Type IIB 
111.8±22.8 (14) 
117.7±38.7 (12) 
131.2±26.6 (26) 
153.3 ± 28. O (22) 
108.6±41.5 (19) 
152.4±65. Ot (19) 
Table 7.3 Mean (± SD) taurine concentrations in pre- and post-supplementation type I, IIA 
and 1113 fibres from individual horses. 
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Horse Treatment Taurine, mmol kä-1 DW (number of fibres) 
DS 
is 
GT 
Type I Type IIA 
Pre 23.7± 4.2 (3) 3.1 ±3.3 (11) 
Post - 1.8 ± 1.6 (17) 
Pre 63.1 ± 16.1 (2) 1.7 ± 3.2 (12) 
Post 54.0 (1) 3.4±3.7 (18) 
Pre 55.1 ± 52.7 (4) 5.8 ± 4.6 (10) 
Post 23.0 ± 16.7 (2) 5.0: i- 5.8 (15) 
Type IIB 
3.0 ± 2.1 (14) 
1.8 ±3.2 (12) 
3.7 ± 4.6 (26) 
4.2 ±3.1 (22) 
9.8 ± 8.3 (19) 
7.1 ± 9.5 (19) 
Figure 7.7 Distribution plots of carnosine concentrations in pre- and post-supplementation 
type I, IIA and IIB fibres for horse DS. 
209 
6 
W 
4 
w 
w 
O 
W 
z 
6 
4 
2 
z 
PRE-SUPPLEMENTATION 
POST-SUPPLEMENTATION 
40 80 120 160 200 240 280 320 360 
CARNOSINE (mmol kg-' DW) 
40 80 120 160 200 240 280 320 360 
CARNOSINE (mmol kg-1 DW) 
Figure 7.8 Distribution plots of carnosine concentrations in pre- and post-supplementation 
type I, IIA and IIB fibres for horse JS. 
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Figure 7.9 Distribution plots of carnosine concentrations in pre- and post-supplementation 
type I, IIA and IIB fibres for horse GT. 
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7.4 DISCUSSION 
The horse has evolved as a herbivore. As such, carnosine is absent from its natural diet and must 
therefore be obtained via endogenous biosynthesis from its constituent amino acids, histidine and 
ß-alanine. Histidine is readily available in the equine diet as it is a common component of many 
plant proteins. ß-alanine is however, a non-protein amino acid which has a very low abundance 
in plant tissues. In the horse, as evident in other species, ß-alanine may be predominantly 
synthesised in the liver, as a final metabolite in the biosynthesis of uracil and thymine (Fink et at. 
1953; Fink et al. 1956). Skeletal muscle lacks the necessary mechanisms for ß-alanine synthesis 
(Matthews and Traut 1987). The normal skeletal muscle concentration of histidine in the horse is 
between 0.25 ± 0.05 mmol kg -1 DW (Chapter 4) and 0.85 ± 0.05 mmol kg-1 DW (Miller-Graber et 
al. 1990), or approximately 80 - 280 ; imol 1-1 intra-cellular water (ICW ). Carnosine synthetase is 
reported to have an apparent Kul value for histidine of 16.8 1iM (Horinishi et al. 1978) and 
therefore, normal muscle histidine concentrations are sufficient to saturate the enzyme. 
However, the normal physiological concentration of free ß-alanine in equine skeletal muscle is 
0.58 ± 0.17 mmol kg-1 DW or approximately 190 jimol 1-1 ICW (Miller-Graber et al. 1990). This 
concentration is much lower than the K\[ value of 1.0 - 2.3 mM ß-alanine previously reported for 
carnosine synthetase (Kish et al. 1978; Ng and Marshall 1978; Skaper et al. 1973). It is therefore 
possible that ß-alanine availability may be a limiting factor in the regulation of carnosine 
biosynthesis and skeletal muscle carnosine concentration. 
Preliminary single dose oral administrations of histidine and ß-alanine indicated that the 
bioavailabilities were approximately 100% and 25%, respectively. This information was used in 
conjunction with data on the normal endogenous plasma concentration of histidine and ß-alanine 
to calculate the doses which were used for the supplementation. The resulting doses of 12.5 and 
100 mg kg-' BW were intended to produce approximately equal plasma concentrations of these 
two amino acids during supplementation. Added to the feed the doses of histidine and ß-alanine 
represented 0.31% and 2.44% of the total diet on a weight per weight basis, respectively. This 
histidine dose was lower than that employed previously in the horse, 0.40% and up to 0.56%, 
(Powell et at. 1991; Miller-Graber and Seyers 1993), and much lower than those employed in 
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other species, and the ß-alanine dose was twenty-fold lower that employed previously in mice 
Margolis et at. 1985). 
Plasma histidine concentrations on day I of the supplementation period were similar between 
horses DS and JS. The response in horse GT was somewhat lower. In contrast, horse GT 
displayed the greatest increase in plasma ß-alanine concentration during supplementation on day 
I than the other two horses. During the course of the 30 day supplementation period there was a 
progressive increase in both pre- and post-feeding histidine concentrations in all three horses and 
a convergence in the values between horses. By day 30 plasma histidine concentrations before 
and after feeding in horse GT were similar to the other horses. Post-feeding peak plasma 
histidine concentrations increased by up to 140%. Miller-Graber and Seyers (1993) reported an 
80% increase in mean plasma histidine concentration in Quarterhorses during dietary histidine 
supplementation. A similar change in plasma histidine concentration has also been described in 
pigs during histidine supplementation (Izquierdo et at. 1988). Plasma ß-alanine concentrations 
showed much greater changes over the supplementation period. By day 30 ß-alanine was 
detectable in pre-feeding plasma and post-feeding peak plasma concentrations had increased by 
300 - 400%. These changes in plasma histidine and 
ß-alanine concentrations throughout the 
supplementation period indicate an adaptive response to the prolonged administration of these 
amino acids which is more pronounced for ß-alanine than for histidine. Differences in the 
magnitude of the adaptive responses for histidine and ß-alanine probably arose as a consequence 
of the existence of different membrane transport mechanisms for a-amino acids and ß-amino 
acids. Distinct highly specific but low capacity transport mechanisms for the ß-amino acids, ß- 
alanine, taurine and y-aminobutyric acid, have been demonstrated in the GIT of several species 
(Munck and Munck 1992; Munck and Munck 1994; Navab et at. 1984) and in chick pectoral 
muscle cells in primary culture (Bakardjiev and Bauer 1994). 
Increases in the carnosine concentrations in type I, IIA and 1113 fibres as a result of histidine and 
ß-alanine supplementation differed markedly between horses and on visual inspection of the data 
appeared to be correlated to adaptive increases in plasma ß-alanine concentration over the 30 day 
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supplementation period rather than to changes in plasma histidine concentration. This is 
consistent with the results of Powell et al. (1991) and Miller-Graber and Seyers (1993) where 
despite larger histidine doses no significant increase in middle gluteal muscle carnosine 
concentration was detected during histidine supplementation alone. The greatest increase, which 
was evident in both type 1IA and IIB fibres, was found in horse GT. This correlates with the 
greater adaptive response to ß-alanine supplementation found in this horse as shown by changes 
in plasma ß-alanine concentration. Horse JS also showed a significant increase in the carnosine 
concentration in type IIB fibres which correlates with the lesser though sustained increase in 
plasma ß-alanine concentration. No significant change in the carnosine concentrations in type 
IIA and IIB fibres in horse DS is supported by the fact that a significant increase in plasma ß- 
alanine concentration was only recorded on day 30, which suggests a slower adaptation to ß- 
alanine supplementation. 
The increase in the carnosine content of equine skeletal muscle, resulting from increased 
biosynthesis during dietary supplementation would therefore result in a corresponding increase in 
the total intra-cellular physico-chemical buffering capacity of the muscle (ßrntotai). An increase 
in ßrntotal arising from an increase in the muscle carnosine concentration (ßm, amosine) can be 
determined by using the Henderson-Hasselbach equation to calculate the increase in the 
protonated from of carnosine (pKa 6.83) over the pH range 7.1 - 6.5, which represents the typical 
change in intra-cellular pH during high-intensity (fatiguing) exercise: 
pH = pKa + loglo ([Salti/[Acid]) 
Hence, for a muscle carnosine concentration of 100 mmol kg-' DW the quantities of carnosine in 
the protonated form at pH 7.1 and 6.5, respectively are: 
pH 7.1 [Acid] = 100/[ 1+ antilog, o (7.1 - 6.83) 
= 34.9 mmol kg-' DW 
pH 6.5 [Acid] = 100/[ 1+ antilogl0 (6.5 - 6.83)1 
= 68.1 mmol kä'1 DW 
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A1 Acid) pH 7.1 - 6.5 = 33.2 mmol H+ kg-1 DW 
The increase in the protonated from of carnosine represents the amount of H+ ions buffered by an 
intra-muscular carnosine concentration of 100 mmol kg-1 DW. For example, in horse GT the 
mean carnosine concentrations in the type LIB fibres before and after supplementation were 108 
and 152 mmol kg-' DW, respectively. 
For the pre-supplementation type 1113 fibre carnosine concentration of 108 mmol kg-' DW : 
A [Acid] ={ 108/11 + antiloglO (6.5 - 6.83)1} -{ 108/[1 + antiloglO (7.1 - 6.83)1} 
ßrncarnosinc = 35.9 mmol H+ kg-1 DW 
For the post-supplementation type LIB fibre carnosine concentration of 152 mmol kg-' DW: 
A [Acid] _ {152/[1 + antilogl0 (6.5 - 6.83)]} - {152/[1 + antilogl0 (7.1 - 6.83)]} 
ßrncarnosine = 50.5 mmol H+ kg '1 DW 
The increase in the mean carnosine concentration in type LIB fibres as a result of 
supplementation would produce an increase in 
ßmcarnosine of 14.6 mmol H+ kg-' DW or 41 %. 
The same calculation performed using the carnosine concentration in type IIA fibres from horse 
GT before and after supplementation gives an increase in ßmcamosine of 10.4 mmol H+ kä-ß DW, 
or 49% as a result of supplementation. 
Titremetric measurements previously used have estimated the total intra-cellular physico- 
chemical buffering capacity of skeletal muscle (ßmt,, t) in the thoroughbred horse to be 117 ± 
8.5 mmol H+ kg-1 DW over the pH range 7.1 - 6.5 (Harris et al. 1990). Subtraction of the 
buffering capacity directly attributable to carnosine (ßmcarnosine), as calculated from the 
carnosine concentration using the Henderson-Hasselbach equation, indicated the residual 
buffering capacity from the effects of protein and phosphates (ßmresidual) to be 81.8 ± 9.7 mmol 
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H+ kg-t DW (Harris et al. 1990). The use of multiple linear regression analysis enabled estimates 
to be made of the residual buffering capacity to be made in type 1, IIA and lIB fibres. ßrnresidual 
was shown to be relatively constant in the three fibre types with a value between 68 and 72 mmol 
H+ kg-t DW (Sewell et at. 1990). Assuming a mean value of 70 mmol H+ kg-t DW for residual 
buffering capacity in type IIB fibres it can be calculated from the example of the horse (GT) 
above that ßrnt,, taj in type IIB fibres as a result of supplementation would have increased by 14%. 
The same approach indicates that ßin1etaj in type IIA fibres from this horse as a result of 
supplementation would have increased by 11%. Estimated values of ßmtotal and ßincarnosinc 
before and after supplementation and the increase in ßintctal (%) in type I, IIA and LIB fibres for 
the individual horses are given in Table 7.4. 
During high-intensity exercise, such as that encountered during Thoroughbred flat-racing, a high 
rate of ATP production is maintained through anaerobic glycolysis. However, this incurs a rapid 
production and accumulation of lactic acid within the skeletal muscles. Dissociation of the lactic 
acid into lactate ions and H+ ions results in a progressive increase in H+ ion concentration and 
subsequent fall in intra-cellular pH. In turn, this reduction in intra-cellular pH can impair the 
integrity of the various mechanisms involved in muscle contraction, such as ATP resynthesis, 
which may result in localized muscle fatigue. An increase in the intra-cellular physico-chemical 
buffering capacity of equine skeletal muscle, through an increase in skeletal muscle carnosine 
concentration, should attenuate the rate of decline in intra-cellular pH during high-intensity 
exercise thus enabling the maximal speed attained to be sustained for a longer period prior to the 
onset of fatigue. 
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Table 7.4 Estimates of ßfntot and ßmearnosine before and after supplementation and the 
increase in ßmt,, tal (%) in type I, IIA and IIB fibres for the individual horses. 
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Fibre type Buffering capacity DS JS GT 
rre rost rre rost rre cost 
Type I ßmcarnosinc 10.7 - 19.8 18.4 14.9 12.3 
ßmtotal 80.7 - 89.8 88.4 84.9 82.3 
A ßmtotal (%) - 1.6 -3.1 
Type IIA ßrncarnosine 23.9 25.3 34.1 37.2 21.1 31.5 
ßmtota( 93.9 95.3 104.1 107.2 91.1 101.5 
0 ßmtotal (%) 1.5 3.0 11.4 
Type IIB ßmcarnosine 37.1 39.1 43.6 50.9 36.1 50.6 
ßm total 107.1 109.1 113.6 120.9 106.1 120.6 
0 ßmtoti (%) 1.9 6.4 13.7 
CHAPTER 8 
GENERAL DISCUSSION 
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The imidazole dipeptide carnosine (ß-alanyl-L-histidine) and its methylated derivatives anserine 
(ß-alanyl-L-l-methylhistidine) and balenine (ß-alanyl-L-3-methylhistidine), are found 
predominantly in vertebrates and occur almost exclusively in the skeletal muscles (Crush 1970; 
Suyama et at. 1970; Carnegie et al. 1983; Plowman and Close 1988). Although they can all be 
found in varying proportions in a given species carnosine is usually dominant in terrestrial 
mammals, anserine in birds and balenine in aquatic mammals and reptiles. The carnosine 
concentration in the skeletal muscle of the horse is the highest found in any terrestrial mammal. 
In the eighty or so other species of animals studied only a very few such as the Tuna, sea snakes 
and some deep-diving whales have greater skeletal muscle imidazole dipeptide contents, 
predominantly balenine (Crush 1970; Suyama et al. 1970). The typical carnosine concentration 
in equine skeletal muscle is generally in excess of 100 mmol kg-1 DW, a concentration which 
easily exceeds that exhibited by other small molecules including phosphocreatine, creatine, ATP 
and taurine. This probably makes carnosine the most abundant low molecular mass compound 
present in mammalian skeletal muscle. The occurrence of such high intra-muscular carnosine 
concentrations in the horse is inextricably linked to its evolutionary adaptation to high speed 
running wherein muscle contraction is reliant upon anaerobic glycolysis to provide a rapid 
turnover of ATP. As a consequence of this energy producing pathway, there is a high rate of 
production and subsequent accumulation of lactic acid which dissociates into lactate and H+ ions 
within the working muscles. Muscle lactate concentrations as high as 200 mmol kä'' DW have 
been observed in the horse following racing (Valberg 1987) and experimental exercise studies 
(Snow et at. 1985). In the absence of an effective mechanism to counter this large accumulation 
of H+ ions (acidosis) the intra-muscular pH would theoretically fall to a value of approximately 
pH 1.0; a value well below that which is physiologically tolerable. In practice, however, during 
high-intensity exercise intra-cellular pH can decline from a normal resting level of pH 7.1 to a 
post-exercise value of pH 6.5 or slightly less (Harris et al. 1987). Even such a relatively high 
post-exercise pH can impair the contractile process and result in localized muscle fatigue and 
loss of performance. Therefore the maintenance of intra-muscular pH homeostasis may be as 
important to athletic performance as the ability to transport oxygen via the cardio-vascular 
system. 
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The horse, like many species, has evolved a system for the intra-cellular physico-chemical 
buffering of H+ ions in skeletal muscle comprising several different components, such as protein 
histidine residues, inorganic and organic phosphates, and the imidazole dipeptides including 
carnosine, which act in concert to provide the overall buffering capacity. Carnosine has a pl'y';, 
value of 6.83 (Tanokura et at. 1976) which enables it to function as an effective H+ ion buffer 
over the physiological pH range and it has been calculated that carnosine accounts for 
approximately 30% of the total intra-cellular physico-chemical buffering capacity in equine 
skeletal muscle (Sewell et al. 1991). The concentrations in skeletal muscle of the 
aforementioned buffering constituents, protein histidine residues, organic and inorganic 
phosphate are constrained within narrow physiological limits which allows limited scope for an 
increase in their muscle content in response to evolutionary demands for greater H+ buffering 
capacity. Much greater flexibility exists for increases to the imidazole dipeptide concentration in 
skeletal muscle in order to enhance total buffering. This adaptive response to the need for 
greater buffering is exemplified by differences between three athletic species, namely horses, 
dogs and humans. The total physico-chemical buffering capacity is higher in horses than in dogs 
and lowest in humans (Harris et al. 1990). However, the residual buffering capacity attributable 
to the histidine residues in the muscle structural proteins actin and myosin, and also phosphates 
is almost identical in each species. The differences between total buffering and residual 
buffering between species is attributable to the different concentrations of the imidazole 
dipeptides (Harris et al. 1990). This potential is visibly exploited in equine skeletal muscle 
where its high anaerobic, capacity and therefore considerable capacity for H+ ion production, is 
compensated for by an equally large carnosine concentration. 
There is considerable experimental evidence which clearly demonstrates the importance of 
carnosine towards intra-cellular physico-chemical H+ ion buffering capacity. The middle gluteal 
muscle is a principal locomotory muscle in the horse. The mean carnosine concentration in this 
muscle (107.8 mmol kö i DW), as determined in Chapter 4, is in agreement with previously 
established values (Marlin et al. 1989; Harris et a!. 1990), but is significantly higher than 
concentrations found in 'non-locomotory' skeletal muscles, such as the internal intercostal (63.7 
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mmol kä-' DW), and in the diaphragm (38.6 mmol kg-' DW) both of which can be considered to 
be 'non-skeletal' muscle. These latter two muscles have no direct role in the mechanics of 
locomotion, in contrast to the middle gluteal. As such they are likely to have a low glycolytic 
capacity and low potential for H+ ion production, and consequently a lower buffering 
requirement. The same argument can be used to explain the very low carnosine concentrations 
found in cardiac muscle (2.2 mmol kg-' DW) and the smooth muscle of the GIT (0.6 - 2.4 mmol 
ký-' DW) in the horse. Furthermore, carnosine concentrations in non-muscle tissues including the 
liver and kidney are approximately twenty-fold lower than the cardiac muscle values. 
Comparative measurements of carnosine concentrations and the relative proportions of type 1, 
IIA and IIB fibres present, in muscle samples from different regions of the middle gluteal 
muscle, indicated that the carnosine content was positively correlated to type 11 % FSA and 
negatively correlated with type I% FSA (Sewell et al. 1991). From this it was estimated that the 
carnosine concentrations in type 1, IIA and LIB fibres from horses of various ages and states of 
training were 21,86 and 116 mmol kg-' DW, respectively (Sewell et at. 1991). The development 
of the analytical methodology described in Chapter 3 (Dunnett and Harris 1995b) enabled the 
direct measurement of carnosine concentrations in individual type I, IIA and LIB muscle fibres 
from the middle gluteal of the thoroughbred horse, as described in Chapter 4. The measured 
carnosine concentrations in type I, IIA and IIB fibres were 21,95 and 104 mmol kg -t DW, 
respectively (Dunnett and Harris 1995a). The higher concentration in type II fibres in contrast to 
type I fibres is consistent with the physiological and metabolic differences between them (Snow 
1983) and the recruitment of type 11 fibres during high-intensity exercise (Lindholm et at. 1974; 
Snow et at. 1982). This provides further evidence for the importance of carnosine to H+ 
buffering in the horse. The lower concentration of carnosine found in type I fibres is, however, 
relatively high in comparison with other muscle metabolites, and may be explained partly 
through the necessity to buffer H+ ions diffusing from adjacent type II fibres, and partly through 
its proposed antioxidant function which provides protection to membrane lipids against damage 
from reactive oxygen species, such as OH' radicals, HOCI, H202 and singlet oxygen, (Boldyrev 
eta!. 1988; Kohen eta!. 1988) which can be generated in this highly oxidative tissue. 
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Higher muscle carnosine contents have been observed in horses selectively bred for higher 
intensity exercise. American Quarterhorses have mean middle gluteal muscle carnosine 
concentrations of approximately 159 mmol kg-' DW. in comparison to values of 125 mmol kg-' 
DW in Thoroughbreds and 111 mmol kb' DW in Standardbreds (Bump et al. 1990). Although 
carnosine undoubtedly makes an important contribution to total intra-cellular H+ ion buffering in 
skeletal muscle and, therefore in all probability, to the capacity for sprint exercise in the horse, 
there has been no previous direct experimental evidence demonstrating an increase in muscle 
carnosine concentration as a consequence of training. However, estimates of the carnosine 
contents in the different muscle fibre types were generally higher in exclusively highly trained 
thoroughbred horses in contrast to horses of mixed training (Sewell et al. 1992). Data from 
Chapter 4 suggests that long-term intensive training with a significant sprint exercise component 
can result in higher carnosine concentrations in all three fibre types in the middle gluteal muscle 
of young thoroughbred horses in contrast to non-trained horses of the same age. Although the 
difference in carnosine concentration in the type I and type IIB fibres between the trained and 
untrained groups did not reach statistical significance, a large increase was observed in the 
carnosine content of the type IIA fibres. The mean carnosine concentration in type [IA fibres 
from the trained horses was 92 mmol kä-1 DW in contrast to a value of only 68 mmol kg-' DW in 
the untrained horses. It is possible that this increase in the type [IA fibres rather than the type I[B 
fibres reflects a greater 'trainability' of the oxidative-glycolytic type IIA fibres in the horse. 
Carnosine is present in the plasma of the normal resting thoroughbred horse at concentrations 
ranging from approximately 5 to 20 pM . Furthermore, the plasma concentration in a given 
horse is relatively constant during a 24 h period and is unaffected by fasting. The constancy of 
the plasma carnosine concentration may in part be due to the minimal influence of the diet. The 
horse is an herbivorous animal and as such carnosine is not a normal constituent of the diet. The 
mean within-horse variance in plasma carnosine concentration (± 1.6 }im) over of the second 
half of a 24 h period during a triple feed regime was almost identical to that found during the 
same period during a 24 h fast (± 1.5 pM ). Other factors however, such as age, exercise and 
muscle damage may exert a variable influence on the plasma carnosine concentration both in the 
222 
short and the long term. In foals and yearlings, the concentration of carnosine in the plasma is 
significantly lower than that found in older horses. In other mammals carnosine is synthesized 
almost exclusively in skeletal muscle. As the animal matures the muscle carnosine content, 
increases (Christman 1976: Johnson and Hammer 1992), probably due to an increased 
biosynthetic capacity. Therefore, the age dependent increase in equine plasma carnosine 
concentration most probably arises from increased 'leakage' of carnosine from skeletal muscle 
associated with a higher rate of carnosine turnover in mature horses. Furthermore, plasma 
carnosinase activity present in humans and other primates is completely absent in equine plasma. 
Short duration high-intensity exercise can also cause a small, up to two-fold, elevation in plasma 
carnosine concentration, possibly due to minor muscle damage. Still larger increases in 
circulating levels of carnosine of as much as 700 ttiýt , can occur during episodes of ERS and 
probably arise from the occurrence of extensive muscle damage or changes in sarcolemmal 
permeability. This is suggested also by correspondingly large increases in the plasma activities 
of the muscle enzymes AST and CK. 
Carnosine administration to the horse via the intra-venous route produces a large but short term 
increase in the plasma carnosine concentration. Pharmacokinetic calculations indicate that the 
elimination half-life of carnosine from the central compartment, which includes the systemic 
circulation, is approximately 2 h, and that plasma carnosine concentrations have almost returned 
to normal within 8 h. This data in conjunction with a low value for the apparent volume of 
distribution at steady-state suggests that carnosine uptake into the peripheral compartment, which 
includes the skeletal muscle, is minimal. Although urinary excretion of unmetabolized carnosine 
can account for as much as 36% of the administered dose following intra-venous injection, there 
is a large between-horse variance in the proportion of the dose eliminated from the body in this 
manner. The fate of the remainder of the administered carnosine dose can probably be accounted 
for through carnosinase and non-specific dipeptidase catalysed degradation to histidine, with 
subsequent re-uptake of the amino acid by various tissues as evinced by a delayed and sustained 
increase in the plasma histidine concentration observed after intra-venous carnosine 
administration and the absence of increased urinary histidine excretion. 
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Orally administered carnosine is absorbed from the GIT of the thoroughbred horse and 
subsequently produces an increase in the plasma carnosine concentration. A large part of the 
dose is metabolized to histidine at an initial rate similar to the rate of absorption of carnosine 
resulting in an increase in the plasma histidine concentration. The coincidence of the peak 
plasma histidine and carnosine concentrations suggests that the majority of the carnosine 
hydrolysis occurs within the GIT, although a first-pass effect in the liver may also contribute. 
The greater carnosinase and non-specific dipeptidase activity observed in the equine GIT 
compared with the liver supports this. The proportion of the absorbed carnosine dose which 
appears as histidine in the plasma decreases as the size of the dose is increased suggesting that 
the enzymatic hydrolysis is becoming saturated. The bioavailability of carnosine via the oral 
route increases proportionally with the size of the dose. However, the bioavailability is very low 
with only 4% of the total administered dose entering the systemic circulation at the highest dose 
used. The low bioavailability of carnosine from the GIT is probably due in part to its extremely 
lipophobic nature which prevents diffusion across the membranes, and to the absence or low 
capacity of a specific membrane transporter. Owing to its low bioavailability, oral carnosine 
supplementation as a means to enhance the endogenous muscle concentration in the 
thoroughbred horse would be ineffective. Furthermore, the low Vd(ss) of 0.22 1 kg-1 and short t 12 
of 162 min suggest that carnosine does not penetrate extensively into the intra-cellular space 
of low blood-flow tissues, such as skeletal muscle. 
Dietary supplementation with the amino acid precursors of carnosine, histidine and ß-alanine, has 
the potential to increase the endogenous muscle carnosine concentration. Studies in other 
mammalian species have indicated that carnosine biosynthesis occurs within the skeletal 
muscles. However, the endogenous ß-alanine concentration of 0.58 mmol kg-t DW in equine 
skeletal muscle (Miller-Graber et al. 1990) is lower than its reported Kit for carnosine synthetase 
(Skaper et al. 1973; Kish et al. 1978; Ng and Marshall 1978), and therefore ß-alanine availability 
may be a limiting factor to carnosine biosynthesis in vivo . In Chapter 7, sustained dietary 
supplementation with histidine and ß-alanine in the thoroughbred horse produced increases in 
skeletal muscle carnosine concentrations in all horses. However, there was considerable 
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variability in the extent of this increase both between horses and between the different fibre 
types. Statistically significant increases were observed in only two of the three horses. Both of 
these demonstrated a significant increase in the type IIB fibre carnosine concentration, whereas 
only one showed a significant increase in the type 11A fibre carnosine concentration. It was not 
possible to assess the effect of supplementation on the carnosine concentration in type I fibres 
owing to the small number of these fibres obtained from the biopsy samples. 
In general, sustained ß-alanine supplementation resulted in a progressive day-to-day increase in 
plasma ß-alanine concentration, although this parameter also showed a large between-horse 
variability. This progressive response to continued ß-alanine supplementation was probably due 
to an adaptive increase in the gastro-intestinal bioavailability of ß-alanine. Changes in plasma 
histidine concentrations over the same period were much less marked. The extent of the increase 
in skeletal muscle carnosine content in a given individual appeared to be related to the magnitude 
of the adaptive increase in plasma ß-alanine concentration within that individual. This supports 
the earlier hypothesis that ß-alanine availability is a limiting factor to in vivo carnosine 
biosynthesis. 
The higher carnosine concentrations present in type [IA and IIB fibres in contrast to type [ fibres 
suggests a greater capacity for carnosine biosynthesis in the former. This could be established by 
an investigation of the distribution of carnosine synthetase activity in the different fibre types. 
Following the observation of an increase in the carnosine concentration in type IIA fibres with 
training, it would be of interest to determine whether this was accompanied by an adaptive 
increase in the activity of carnosine synthetase in these fibres, and whether previously observed 
increases in muscle buffering capacity during high-intensity training (McCutcheon et al. 1987; 
Sinha et al. 1991) can be accounted for by increases in the muscle carnosine content. Further 
work could investigate whether an increased skeletal muscle carnosine concentration, following 
long-term dietary supplementation with ß-alanine and histidine, influences the metabolic 
responses to maximal exercise, such as a delayed onset of metabolic acidosis, and a reduction in 
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muscle ATP depletion and IMP accumulation at the single fibre level, and plasma ammonia 
production. 
Several practical applications of the information gained from the current research may be 
envisaged. The release of carnosine into the systemic circulation can occur tinder various 
conditions, such as during training and racing, episodes of ERS, or as a result of trauma, and is 
indicative of muscle damage. The principal advantage of using equine plasma carnosine 
concentration as a clinical indicator of skeletal muscle damage is that owing to the extremely low 
carnosine concentrations in other tissues it is essentially a specific indicator of skeletal muscle 
damage. This is in contrast to AST and CK. If sufficient serial blood samples were collected the 
total amount of carnosine released and hence the mass of tissue affected could be estimated from 
comparison of the AUC data with that calculated from a known intra-venous bolus dose, or more 
accurately from an intra-muscular bolus injection. 
It has been reported that during episodes of ERS there appears to be selective damage to type II 
skeletal muscle fibres (Valberg et al. 1993). Then on this basis, since the distribution of 
carnosine is compartmentalized mostly into type IIA and IIB fibres, and taurine into type I fibres, 
during an episode of ERS a significant increase in plasma carnosine concentration only should be 
observed. However, this is contradicted by the plasma data in Chapter 4 from two of the horses 
which were presented with episodes of ERS. A significant increase in plasma taurine 
concentration was also observed in each case. Because of their heterogeneous distribution 
increases in the plasma concentration of carnosine or taurine may in theory be used as indicators 
of selective type II or type I muscle fibre damage, respectively. 
The compartmentalization of carnosine into type II fibres and taurine into type I fibres may 
enable them to be used as physico-chemical markers of the respective fibre types. This could be 
exploited by nuclear magnetic resonance imaging techniques to map the regional distribution of 
type I and type II fibres in the skeletal muscles and the relative proportions of each fibre type in 
the whole tissue. In principal it would be possible to extrapolate the technique to estimate these 
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relative proportions in all the locomotory muscles, and therefore to make an assessment of the 
athletic potential of an individual for endurance or sprint type exercise. 
Experimentally, sustained oral administration of ß-alanine and histidine appears to be an 
effective method for increasing the endogenous skeletal muscle carnosine concentration in the 
thoroughbred horse. An increased skeletal muscle carnosine concentration would result in a 
greater H+ ion buffering capacity which is likely to reduce the rate of metabolic acidosis during 
high-intensity exercise and subsequently may delay the onset of local muscle fatigue. It is 
therefore possible that a dietary supplement comprising these two amino acids could be used as 
an ergogenic aid to enhanced performance during sprint exercise. 
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